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Metabolism of chronic lymphocytic leukemia (CLL), a disease characterized by the relentless 
accumulation of mature B cells has been little explored. Bone marrow stromal cells provide a 
survival benefit to CLL cells, in part through PI3K/AKT pathway. Compared with 
proliferative B-cell lines, metabolic fluxes of oxygen and lactate were low in quiescent 
malignant B lymphocytes from CLL patients.  Glycolysis (extracellular acidification rate, 
ECAR) was consistently low in CLL samples, but oxygen consumption (OCR) varied 
considerably. Higher OCR was associated with poor prognostic factors such as ZAP 70 
positivity, unmutated IgVH, high β2M levels, and higher Rai stage.  Co-culture with the NK-
tert stromal line increased basal OCR and maximum respiratory capacity of CLL at 2 or 24 
hours of interaction, without significant changes in glycolysis.  Two other stromal lines 
displayed similar induction of OCR in CLL. The levels of ribonucleotide triphosphate pools 
in CLL cells were augmented with stromal interaction.  PI3K inhibitors, duvelisib (IPI-145) 
and idelalisib (GS1101), and the AKT inhibitor MK-2206, dramatically reduced OCR, 
ECAR, and ribonucleotide pools in CLL cells.  In concert, genetic ablation of PI3K in a 
malignant B cell line also diminished OCR and ECAR. Collectively, these data suggest that 
stroma affects metabolomics in quiescent CLL cells, driven in part by the PI3K/AKT 
pathway. 
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CHAPTER 1. INTRODUCTION 
Chronic lymphocytic leukemia 
Chronic lymphocytic leukemia (CLL) is a frequently occurring indolent malignancy 
characterized by the relentless accumulation of quiescent, immunologically dysfunctional 
mature B cells that fail to undergo apoptosis. Although different compartments such as bone 
marrow, spleen, lymph nodes, and peripheral blood provide diverse microenvironments, 
which affect the characteristics of CLL cells in general, the population is either slowly 
proliferating or quiescent with the majority of cells being in G0 phase of the cell cycle 
(Chiorazzi et al. 2005). However, these cells are transcriptionally and translationally active, 
suggesting that CLL cells are not inert and should have an active metabolomics profile 
(Balakrishnan et al. 2014).  
Mature CLL cells are CD5 and CD19 positive (Marti et al. 1989, Matutes et al. 1994) 
and overexpress anti-apoptotic proteins of BCL-2 family including like BCL-2, MCL-1, 
BCL-XL (Kitada et al. 1998). Pro-apoptotic proteins like BAX and BCL-XS are under 
expressed (Caligaris-Cappio and Hamblin 1999). 
Prognostic factors 
CLL is the most common leukemia in the western world. According to NCI’s SEER 
(Surveillance, Epidemiology and End Results Program), the incidence of CLL is 4.5 per 
100,000 individuals, making it the most common leukemia in the Western world (Rozman 
and Montserrat 1995). It mostly affects adults above the age of 60. Risk of contracting CLL 
for first degree relatives of patients is higher, almost three times likely to those with no CLL 
history in the family (Cuttner 1992).  
 
 
2 
 
CLL has a heterogenous disease course as some patient have an indolent disease and 
a long clinical course, whereas others have a rapid progression of the disease. The clinical 
course of CLL can be predicted by the following prognostic factors: Rai and Binet are two 
staging systems which are widely used to categorize CLL patients based on clinical 
characteristics i.e., lymphocyte counts (lymphocytosis) and lymph node enlargement. Rai 
staging is widely used in North America and is based on lymphocyte counts (Rai et al. 1975). 
Patients with early Rai stage disease (0, 1) have a greater than 10 year life expectancy 
(Brown 2011).  
In addition to the patients’ clinical stage, there are several cellular markers that 
strongly correlate with prognosis. The expression levels of ZAP 70 (zeta chain (TCR) 
associated protein kinase 70 kDa) is one such marker. ZAP 70 is a receptor tyrosine kinase 
expressed on the surface of CLL B cells (Orchard et al. 2004, Rassenti et al. 2004). It is 
closely related to SRC kinase and is one of the membrane components associated with early 
activation of T lymphocytes and natural killer (NK) cells (Mustelin and Tasken 2003). 
Usually higher expression of this protein is found in CLL in the lymph node as compared to 
peripheral blood CLL B cells. A study reported that ZAP 70 positive CLL cells have stronger 
adherence capacity to stromal cells and enhanced signaling with the microenvironment as 
compared to their counterparts (Stamatopoulos 2009, Lafarge et al. 2014, Lafarge et al. 
2015).  
Somatic mutation in the immunoglobulin variable region heavy chain (IgVH) divides 
CLL disease into two subsets. The one in which IgVH is mutated is responsive to therapy as 
compared to the subset where the gene remains unmutated. Presence of somatic mutations in 
IgVH indicates that the cells have encountered an antigen and thus are indicative of a more 
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mature B-cell. A telomere analysis has revealed that UM CLL has a more active disease in 
terms of cell proliferation; and as a result acquire more genetic lesions, whereas, MU-CLL 
tend to undergo less number of cell divisions (Damle et al. 2004). IgVH unmutated (UM) 
cells also respond better to B cell stimulation than the ones with IgVH mutated (MU) gene 
(Lanham et al. 2003). Patients with UM-CLL tended to have high-risk genomic aberrations 
such as del17p and del11q, whereas favorable aberrations such as del13q were 
overrepresented in the MU-CLL group (Krober et al. 2002). There is also a correlation 
between expression of both ZAP 70 positivity and IgVH unmutated status (Crespo et al. 
2003). ZAP 70 positive and IgVH unmutated patient cohort usually do not respond well to 
treatment. 
CD38 is another marker, whose expression on the cell surface signifies a cell 
population that has recently left the lymph node, indicating cell activation that is associated 
with a proliferative nature (Damle et al. 2007). CD38 is necessary for cell to cell interactions 
during B cell development (Malavasi et al. 1994). If the expression is ≤20%, it is categorized 
negative for CD38 and >20% as positive.  
Serum levels of both β2 microglobulin (β2M) and lactate dehydrogenase (LDH) are 
also prognostic marker for this disease. CLL cells are known to secrete β2 microglobulin 
(β2M). High serum levels of β2M have been associated with shorter survival. Similarly, high 
serum lactate dehydrogenase (LDH) levels are also indicative of poor clinical outcome to 
therapy. Additional risk factors include cytogenetics of the CLL cells (discussed in detail in 
the next section), age of the patients and gender; patients 60 years and above have a higher 
risk of contracting the disease and progression and in terms of gender, males are affected 
more than females. 
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Cytogenetics 
Genomic aberrations like 17p, 11q, 13q deletions, Trisomy (12+) are common in the 
landscape of CLL. The most frequent among these is 13q deletion. miR-15a and mir-16-1 
coding genes present on chromosome 13q  have found to be frequently deleted (55% of CLL 
cases) and therefore are implicated in pathogenesis (Dohner et al. 2000). Anti-apoptotic 
proteins, BCL-2 and MCL-1 are downstream targets of miR-15a and miR-16-1. 
Subsequently, these oncogenes (BCL-2, MCL-1) are expressed at higher levels after deletion 
of these microRNAs. Patients with isolated 13q deletions have a favorable clinical course and 
overall survival.  
11q deletion occurs in 10-20% of CLL patients leading to poor prognosis. 11q 
chromosome encompasses the ATM gene which is required for double stranded DNA repair. 
In a study by Dohner et al, incidence of 11q deletion second most in CLL after 13q deletion 
(Dohner et al. 2000)  
Tumor suppressor, TP53 is located on chromosome 17p. Previous studies 
demonstrated 17p13 locus deletion corresponded to shorter median survival compared to 
their counterparts with normal karyotype (Dohner et al. 2000) and high incidence observed in 
fludarabine refractory CLL. The frequency of the chromosome 17p deletion in CLL is 10% 
(Dohner et al. 2000). A recent study reported that this deletion occurs 25-40% in refractory 
disease (Fink et al. 2006). 
Trisomy 12 (extra copy of chromosome 12) is another common chromosomal 
anomaly in CLL with a frequency of 10-20%. Despite its frequency, little is known regarding 
genes associated with trisomy 12 or the mechanism of disease progression. 
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Treatment 
Standard treatment of care for CLL is chemo-immunotherapy including fludarabine (a 
purine nucleotide analogue), cyclophosphamide (an alkylating agent) and rituximab 
(monoclonal antibody against CD20) (FCR). The only curative therapy for refractory CLL is 
allogenic bone marrow transplantation (Dreger et al. 2014). Median overall survival for 
patients with CLL is 8 to 12 years (Wierda et al. 2007). In recent years, several agents that 
target B- cell receptor pathway have been used in the clinic that include, Bruton’s tyrosine 
kinase (BTK) inhibitor, ibrutinib and Phosphosphotidylinositide 3- kinase delta (PI3K δ) 
inhibitor, idelalisib. Also, several antibodies have shown promising response to CLL, that 
target CD 20 obinutuzumab and ofatumumab; targeting CD52, alemtuzumab and many other 
antibodies against CLL antigens are currently in testing in clinical trials, as they are better 
tolerated than chemotherapeutic agents. 
Microenvironment  
The literature is replete with data demonstrating that the supporting 
microenvironment (generally evaluated as bone marrow stromal cells) provides a survival 
advantage to CLL cells (Kurtova et al. 2009). CLL cells, in contact with stroma, showed 
increased expression of BCL-2 family of anti-apoptotic proteins (Patel et al. 2014). In this 
way they derive protection from both spontaneous as well as drug-induced apoptosis. 
Previous investigations from our group established that short-term (24 hours or less) 
interaction of CLL cells with stromal cells increased the transcription and translation rate of 
the CLL cells, including the transcription of early response genes such as MCL-1 
(Balakrishnan et al. 2014). This expansion in macromolecule synthesis was without an 
increase in CLL cell replication, which remained inert. 
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CLL cells respond to the surrounding microenvironment in vivo by the activation of 
specific signaling pathways in the tumor cells mediated by direct cell to cell contact or 
secretion of soluble factors. The B-cell receptor (BCR) and CD19 pathways in parallel, are 
pivotal for survival and maintenance of CLL B cells, and are activated by 
microenvironmental factors (Herman et al. 2011, Cui et al. 2014). Cells in the 
microenvironment can be broadly classified into macrophages, fibroblasts, T cells, nurse-like 
cells (modified dendritic cells). Crosstalk between these cells promotes CLL cell trafficking, 
survival and proliferation (Herishanu et al. 2011).  
SDF-1 (Stroma derived factor-1), BAFF (B cell activating factor), APRIL and CD40 
are some cytokines secreted by the microenvironment that promote CLL cell survival and 
protect against spontaneous and drug induced apoptosis. The SDF-1 –CXCR-4 axis has been 
widely studied and is linked to prolonged survival of CLL B-cells (Burger et al. 1999, 
Barretina et al. 2003). SDF-1 is important for tissue relocalization and is necessary for the 
cross talk between stromal cells and CLL cells. BAFF and APRIL are necessary for B cell 
survival (Nishio et al. 2005). 
Topographic interactions of CLL cells are dynamic as they shuttle amidst bone 
marrow, lymph node and blood. They come in contact with stroma cells in the first two 
compartments. CLL-stroma interactions can potentially rewire the metabolic pathways in 
these cells. CLL cells have strong binding affinity to stroma cells. In fact, some of the CLL 
cells migrate beneath the stromal cells, a process known as ‘pseudoemperipolesis’(Burger et 
al. 1999). In this way they derive protection from both spontaneous as well as drug-induced 
apoptosis. NK.Tert, HS-5 (human bone marrow derived stromal cells) and M2-10B4 cells 
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(derived from mouse) are well established cell lines that have been used to mimic the stromal 
microenvironment in vivo. 
ATP generating pathways 
There is overall increase in energy demand in malignant cells including CLL cells for 
survival and sustenance of homeostatic processes (Vander Heiden et al. 2009). The efficient 
pathway for generating cellular ATP is mitochondrial oxidative phosphorylation (OxPhos) in 
a normal functional cell, whereas, glycolysis is used to generate ATP under hypoxic 
conditions. However, in most solid cancers, cells exhibit increased glycolysis with 
production of lactate, even in normoxic condition a phenomenon termed ‘aerobic glycolysis 
or ‘Warburg effect’. This rewiring was initially thought to be a result of mitochondrial 
dysfunction in cancer cells. However, studies show that mitochondria are still functional in 
cancer cells and generate ATP (DeBerardinis et al. 2008, Ward and Thompson 2012). Recent 
studies demonstrate that cells rely on glycolysis even when the mitochondria in the cells are 
functional (Hsu and Sabatini 2008, Koppenol et al. 2011, Lim et al. 2011). Certain cancer 
cells get addicted to a particular substrate to fuel metabolic pathways (Glycolysis, OxPhos, 
TCA cycle and Pentose Phosphate Pathway). Flux from the metabolic pathways also 
provides biosynthetic precursors other than ATP. Therefore, understanding how these 
metabolic flux changes as CLL cells come in contact with the microenvironment is of 
primary importance. 
Under normal conditions, glucose is converted to pyruvate via a multistep process 
and the latter is fed into tricarboxylic acid cycle (TCA). This process is termed as glycolysis 
(Figure 1). In the absence of oxygen, pyruvate gets converted to lactate and produces only 2  
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Cantor JR, Sabatini DM, Cancer cell metabolism: one hallmark, many faces. Cancer 
Discovery 2012. Used with permission. Copyright License Number 3762030060159 
Figure 1. Schematic of the interconnection between metabolic pathways and byproducts 
in the cell. 
Glucose taken up by the cell undergoes a series of reactions to produce pyruvate which enters 
the Tricarboxylic acid cycle (TCA) cycle as Acetyl CoA. Pyruvate can also be converted to 
lactic acid. This process is termed glycolysis. As an end product, glycolysis yields 2 
molecules of ATP. The intermediate products from glycolysis are utilized in macromolecule 
biosynthesis. Glutamine taken up by the cell is converted to α-ketoglutarate in the TCA 
cycle. TCA cycle intermediates are also utilized in nucleotide, amino acid and lipid 
biosynthesis.  The TCA cycle occurs in the mitochondrial matrix and provides the precursor 
NADH for the electron transport chain. Through a series of oxidation and reduction reactions 
in the electron transport chain, ADP is phosphorylated to form ATP. This process is termed 
‘Oxidative Phosphorylation’. G6P- glucose 6 phosphate, F6P- fructose 6 phosphate, GADP- 
glyceraldehyde 3-phosphate dehydrogenase, 3PG- 1,3 bisphosphoglycerate, OAA- 
oxaloacetate, α-KG- α-ketoglutarate. 
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ATP molecules per glucose utilized. In cancer, due to hypoxic conditions, cells produce 
increasing amounts of lactic acid via glycolysis. The rate of glycolysis within a cell can be 
measured using lactic acid production via pH measurement. The intermediates from 
glycolysis are utilized by pentose phosphate pathway, nucleotide synthesis and TCA cycle. 
The NADH generated by the TCA cycle feeds into Oxidative Phosphorylation (OxPhos) 
pathway.  
The electron transport chain (ETC) consists of five complexes that reside in the 
mitochondrial membrane (Figure 2). ETC maintains the proton gradient and contributes to 
ATP synthesis (Mitchell 1961). NADH is an electron donor and oxygen is an acceptor. 
Complex I oxidizes NADH to NAD, and complex II oxidizes FADH to FAD and the 
electrons are accepted by oxygen at complex IV, which is then reduced to water. In this way, 
through a series of oxidation and reduction reactions, an electrochemical gradient is 
maintained as the electrons are pumped out of the intermembrane space to the cytoplasm. At 
complex V (F1F0 ATP synthase), the protons (H
+
) are allowed to flow back from 
mitochondrial matrix to the cytosol energetically favoring ADP and phosphate reaction to 
form ATP. OxPhos can be measured by the amount of oxygen consumed by the ETC to 
generate 36 moles of ATP.  
Glucose provides the source of carbons for bioenergetics and biosynthesis of 
macromolecules. Similarly, glutamine is the most abundant amino acid. Not only is it 
essential for protein translation, it acts as a nitrogen donor for nucleotide and amino acid 
synthesis, and for protein translation (Wise and Thompson 2010). Glutamine also supplies 
carbon for biosynthesis. Cancer cells often get addicted and become heavily dependent on 
one of these sources beyond the extent of meeting the energy demands.  
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Taken from Wikimedia Commons 
Figure 2. Schematic of mitochondrial electron transport chain.  
There are five complexes embedded in the inner mitochondrial membrane of the electron 
transport chain. Electrons are transported from nicotinamide adenine dinucleotide (NADH) 
to complex I, while NADH is oxidized to NAD
+
. Similarly, electrons are transferred from 
flavin adenine nicotinamide (FADH) to complex II. This electron transfer creates an 
electrochemical gradient by causing efflux of protons. These protons enter the mitochondrial 
matrix via complex V or ATP synthase, by causing changes in configuration of the proton 
pump, leading to phosphorylation of ADP to ATP.  
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The dynamic nature of CLL makes it more difficult to determine its metabolic 
phenotype as it changes with the context. My study explores the metabolic phenotype of CLL 
in suspension and in contact with stromal microenvironment.  
B cell Receptor Pathway (BCR) 
 The BCR pathway activation is directly linked to CLL pathogenesis (Ghia et al. 
2008). BCR has an immunoglobulin (IgM) bound to a heterodimer CD79 (α, β). When an 
extrinsic signal/antigen stimulates the dimerization of IgM and CD79 (α, β), the dimerized 
complex is  phosphorylated by the SRC kinases, LYN and SYK, which in turn activates a 
signalosome including second messengers, non-receptor tyrosine kinase, BTK, adaptor 
protein, GRB2, and guanine nucleotide exchange factor, VAV.  Along with co-stimulatory 
molecules such as CD19, the signal gets amplified and activates several downstream 
effectors including phosphoinositide 3-kinase (PI3K) (Woyach et al. 2012) (Figure 3). When 
PI3K is activated, the p85 subunit forms a complex with CD19 which further activates the 
p110 subunit, resulting in phosphorylation of phosphatidylinositol 4, 5-bisphosphate (PIP2) 
to PIP3. Upon formation of PIP3, AKT is activated (Vanhaesebroeck et al. 2001, Cantley 
2002, Foster et al. 2003).  BCR also activates mitogen activated protein kinase (MAPK) 
which controls cell survival and proliferation. By sequential phosphorylation of messengers, 
BCR activates transcription factors, MYC, NF-κB and NFAT. 
The B cell receptor also mediates cell adhesion by ‘inside out’ signaling via integrins. 
Due to intrinsic signals BCR activates integrins leading to a conformational change in the 
structure of the latter, resulting in adhesion or migration. Activation of LYN, PI3K, BTK,  
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Figure 3: B cell receptor pathway in chronic lymphocytic leukemia. 
B cell receptor upon encountering an antigen, gets activated.  CD79 (α, β) gets 
phosphorylated by SRC kinases, LYN and SYK, which in turn activates a signalosome 
including BTK, GRB2, VAV etc.,  Along with CD19, BCR recruits PI3K to the membrane, 
where the latter phosphorylates PIP2 to PIP3, that activates AKT. AKT signals to its 
downstream effectors, GSK3β (cell cycle, glucose metabolism), mTOR (translation, 
metabolism and proliferation), BAD (apoptosis, cell survival) and FOXO (cell death, 
metabolism). 
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and PLC-γ are responsible for ‘inside out’ signaling through integrins (Spaargaren et al. 
2003). 
In spite of its prominence in regulating various signaling pathways, the surface 
expression of BCR relatively low in CLL for unknown reasons (Vuillier et al. 2005). 
PI3K/AKT axis 
 
A primary node in the BCR pathway is the PI3K/AKT pathway, which promotes 
downstream activation of survival factors in CLL cells (Figure 3). An additional survival axis 
is initiated from the CD19 receptor, which also cascades through PI3K. PI3K serves a myriad 
of functions including cell survival, proliferation, differentiation, chemotaxis, metabolism, 
apoptosis and cytoskeletal reorganization. As mentioned previously, PI3K converts PIP2 to 
PIP3 and this reaction can be reversed by a phosphatase, PTEN, dephosphorylates and 
converts PIP3 back to PIP2. SRC  homology 2- containing inositol 5' phosphatase (SHIP) has 
a similar role and decreases PIP3 levels upon engagement with FcγRIIB1 (Ono et al. 1996). 
There are 4 class I isoforms of PI3K, α, β, γ and δ. While the α and β isoforms of 
PI3K are ubiquitously expressed, the δ and γ isoforms are majorly found in leukocytes 
(Vanhaesebroeck et al. 1997, Sawyer et al. 2003). PI3K α has been shown to regulate cellular 
metabolism, insulin signaling and angiogenesis in solid tumors, whereas the β isoform has 
been found to be active in platelets (Hamada et al. 2005, Zhao et al. 2006, Yuan et al. 2008, 
Kim et al. 2009). 
The PI3K α and β are essential in mice. Their deletion in mice leads to embryonic 
lethality (Bi et al. 1999, Bi et al. 2002).  
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PI3K γ knockout mice are viable; however, they display a decreased number of 
splenic T cells and impaired T cell function along with decrease in cytokine production 
(Hirsch et al. 2000, Li et al. 2000, Sasaki et al. 2000). Immune cells that lack δ isoform (in 
knockout mice), display impaired immune responses and chemotaxis and reduced 
immunoglobulin production (Clayton et al. 2002). 
The PI3K γ and δ isoforms are overexpressed in CLL and have non-overlapping 
functions. The gamma isoform signaling confers immune tolerance and cell migration 
capacity to CLL cells and is also necessary for eliciting responses from T cells (Alcazar et al. 
2007), whereas the delta isoform mediates cell proliferation and differentiation. The 
expression levels of the delta isoform increases upon contact with the microenvironment.  
Based on the structure of the PI3K class I molecule, they are divided into two 
subtypes, class IA and class IB. The class IA consists of one of the catalytic subunits 
isoforms, p110α, β or δ which pairs with regulatory subunit of PI3K, p85. Class IB uniquely 
is made up of a catalytic subunit p110γ that associates with regulatory subunit p101 and p84  
(Stephens et al. 1997) (Figure 4).  
p110 α is commonly mutated in solid cancers and harbors hotspots, whereas, the 
mutation frequency in other isoforms it is still not clear. However, overexpression of δ and γ 
isoforms was reported in hematological malignancies, brain and colorectal cancers (Skorski 
et al. 1997, Benistant et al. 2000, Mizoguchi et al. 2004, Sujobert et al. 2005, Hickey and 
Cotter 2006). PI3K delta becomes activated by binding of ligands to tyrosine kinase receptors 
or BCR crosslinking.  
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Figure 4. PI3K class I isoforms and their characteristics 
  
Class IA                               Class IA                                 Class IA                              Class IB                                      
Coded by PIK3CA             Coded by PIK3CB               Coded by PIK3CD             Coded by PIK3CG                   
Ubiquitously expressed      Ubiquitously expressed       Leukocytes                          Leukocytes                                 
Proliferation, metabolism   Platelet activation                Survival, chemotaxis,        Immune response                     
                                                                                                   proliferation  
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Classically, PI3K signaling is associated with AKT activation. AKT is activated upon 
translocation to the plasma membrane when it is recruited by PIP3 (via PH domain) and 
phosphorylated at Thr308 by PDK1 (phosphoinositide-dependent protein kinase-1). AKT 
promotes cell survival by phosphorylating and inactivating BAD, a member of pro-apoptotic 
machinery. BAD otherwise dimerizes with BCL-XL, an anti-apoptotic protein and renders it 
non-functional (Datta et al. 1997). Similarly, it phosphorylates and inactivates FOXO 
preventing its nuclear translocation (Brunet et al. 1999). Several FOXO target genes are 
members of pro-apoptotic machinery (BIM, FAS) and cell cycle inhibitors (p21, p27). 
Therefore AKT consequently inhibits their transcription. AKT also promotes cell 
proliferation by phosphorylating GSK3β, hampering its kinase activity, which in turn cannot 
phosphorylate cyclin D1 and renders it functional (Diehl et al. 1998). 
AKT has three different isoforms, encoded by the genes AKT1, AKT2 and AKT3. 
AKT 1 and 2 isoforms are ubiquitously expressed and AKT 3 is expressed predominantly in 
brain and testes (Yang et al. 2003).  AKT 1 is vital for CLL cell survival (Hofbauer et al. 
2015). AKT is also used as a surrogate marker for response to treatment in CLL . Phospho-
AKT levels decline with various targeted therapies including with PI3K inhibitors. 
PI3K/AKT downstream metabolic effectors 
 Several investigations have established that the PI3K alpha–mediated signaling 
cascade influences cellular metabolomics, including glycolysis and energy production 
(Engelman et al. 2006). Recent studies further demonstrated a role for AKT in this pathway. 
AKT-independent signaling is also involved in activation of cellular metabolomics (Hahn-
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Windgassen et al. 2005, Arvisais et al. 2006). However, the role of PI3K delta/gamma in 
regulating metabolomics has not been elucidated. 
Activation of AKT is linked to increased glycolysis in cancer cells. Phosphorylation 
of AKT at Ser473 promotes glucose uptake by mobilizing glucose transporters (GLUT4) to 
the cell membrane (via AS160 activation) (Jiang et al. 2003, Sano et al. 2003) as well as its 
utilization (Kohn et al. 1996). Insulin mediated glucose uptake is largely mediated by AKT2 
(Whiteman et al. 2002). AKT also regulates hexokinase and phosphofructokinase activity, 
two of the ten enzymes critical in the glycolysis pathway (Deprez et al. 1997, Gottlob et al. 
2001, Rathmell et al. 2003). Recently, PI3K was implicated in regulating Aldolase 
mobilization from the cytoskeleton and enhance glycolysis, in an AKT independent manner 
(Hu et al. 2016). Aldolase is a key enzyme in glycolysis that converts Fructose 1,6 
bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. 
Although the mechanism remains unknown, mitigation of PI3K activities lead to 
decrease in mitochondrial respiration in cancer cells leading to hypoxia (Kelly et al. 2014). 
Another study demonstrated that inhibition of PI3K/AKT pathway diminished oxygen 
consumption in head and neck cancers by phosphorylation and subsequent inhibition of 
pyruvate dehydrogenase activity (Cerniglia et al. 2015). Active AKT was also reported to 
translocate to mitochondria and phosphorylate ATP synthase along with other mitochondrial 
resident proteins, thereby resulting in upregulation of mitochondrial respiration in 
immortalized hepatocytes (Li et al. 2013). 
The PI3K/AKT pathway cross talks with mTOR (mammalian target of rapamycin), a 
master regulator of cellular metabolism. mTOR activity is highly augmented in cancer cells 
 
 
18 
 
(Laplante and Sabatini 2012). mTOR has been shown to mediate mitochondrial oxidative 
phosphorylation by hexokinase inhibition in epithelial cancers (Lu et al. 2015). 
Targeted therapy in CLL 
 The microenvironment in CLL simulates constitutive activation of BCR and PI3K 
pathways (Cuni et al. 2004, Burger and Chiorazzi 2013) Therefore, inhibiting these pathways 
might be an effective anti-cancer strategy for CLL patients. Recently, two targeted agents 
were approved for CLL. Ibrutinib, which targets BTK, was approved in 2014 by the FDA. 
The second drug that was approved for CLL treatment was idelalisib, a PI3K δ isoform 
specific inhibitor. Selective targeting of PI3K pathway is essential because pan-PI3K 
inhibition using Wortmannin and LY294002 results in adverse effects, as α and β isoforms 
are expressed in all cells. 
Duvelisib (IPI-145)  
Duvelisib is an orally available PI3K class I δ/γ inhibitor that is in Phase III clinical 
trials for CLL as a monotherapy. It is also being tested in combination with rituximab and 
bendamustine as for follicular and non-Hodgkin’s lymphomas (NCT02576275, 
www.clinicaltrials.gov).  It prevents the activation of PI3K δ/γ isoforms by binding 
competitively and reversibly to the p110 ATP binding site of the isoforms. It inhibits the δ/γ 
isoforms with an IC50 of 1/50 nM and Ki value is 23/243 pM. It inhibits adaptive and innate 
immune responses (Winkler et al. 2013). Therefore, it is used for the treatment of 
autoimmune and inflammatory diseases. Studies have demonstrated that duvelisib diminishes 
PI3K signal transduction via blocking the AKT pathway. However, its effect on cellular 
metabolism has not been investigated. Inhibition of both δ/γ isoforms is much more effective 
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than inhibition of delta alone (Subramaniam et al. 2012). Both duvelisib and idelalisib are 
very similar in structure (Figure 5). 
Duvelisib treatment in vitro has been shown to inhibit CCL3, CCL4 secretion from 
CLL cells and prevent migration of CLL cells beneath the stroma cells. It was also shown to 
inhibit CLL proliferation induced by CD40-IL2-IL-10. Importantly, this drug also overcomes 
acquired resistance to ibrutinib that occurs after monotherapy due to acquired BTK missense 
mutation at cysteine to serine 481 residue located in the catalytic domain. Duvelisib also 
inhibits IL2, TNF-α and IFN-γ secretion by T cells (Dong et al. 2014). 
Idelalisib (GS 1101)   
Idelalisib is a selective inhibitor of PI3K p110 δ used to treat refractory/relapsed CLL 
and follicular lymphoma treatment. Idelalisib was first approved for clinical use as first line 
treatment for CLL by the FDA in 2014. It was highly successful in clinical trials for CLL and 
indolent lymphomas (Fruman and Cantley 2014, Gopal et al. 2014). The IC50 of idelalisib for 
the δ isoform is 19 nM and the Ki value is 1pM; for the α, β, γ isoforms, the IC50 is 8600, 
4000, 2100 and the Ki value is 453, 211 and 110pM. Idelalisib treatment results in inhibition 
of PI3K downstream signaling cascade. It also forces the CLL cells out of the lymph node 
into blood circulation leading to lymphocytosis (Herman et al. 2010). Similar to duvelisib, 
idelalisib also alters cytokine production from T cells and NK cells. It also induced apoptosis 
in the presence of protective microenvironmental factors like BAFF, TNF-α, and fibronectin 
(Herman et al. 2010). Idelalisib was used along with bendamustine and rituximab in a phase 
III clinical trial on 416 patients with relapsed CLL and lead to prolonged progression free 
survival of 23 months compared with 11 months on bendamustine and rituximab 
 
 
20 
 
combination only. Therefore, the combination of these drugs emerged as a new treatment 
option for patient with relapsed or refractory CLL. 
MK2206  
MK2206 is an allosteric pan AKT inhibitor (Hirai et al. 2010). It binds to AKT in a 
non-ATP competitive manner.MK2206 is used in combination therapy for treating advanced 
solid tumors. Its IC50 values for isoforms AKT1, AKT2 and AKT3 are 8, 12 and 65 nM 
respectively.MK2206 is currently in Phase I and II clinical trials as a combination therapy 
agent for CLL along with bendamustine and rituximab for CLL and small B cell lymphocytic 
leukemia and for non-small cell lung and pancreatic cancers (www.clinicaltrials.gov). 
MK2206 achieved promising results when tested in combination with erlotinib, lapatinib as 
well as docitaxel and carboplatin against human cancer cell lines (Hirai et al. 2010). 
MK2206, when used in combination with bendamustine, in clinical trials evoked a 
positive response from patients. Single dosage of MK2206 decreased cytokine production, 
mobilized lymphocytes out of the lymph nodes, and lead to an inhibition of AKT activity by 
decreasing phosphorylation at Ser473 residue (Ding et al. 2014). It induces caspase mediated 
apoptosis. It also decreases MCL-1 protein levels and increased PARP cleavage indicating 
apoptosis. 
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Figure 5. Chemical structure of PI3K and AKT inhibitors. 
  
                     Duvelisib                        Idelalisib 
                               MK2206 
Chemical name: 5-fluoro-3-phenyl-2-[(S)-
1-(9H-purin-6-ylamino)-propyl]-3H-
quinazolin-4-one 
Chemical name: 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-
[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one 
Chemical name: 8-chloro-2-phenyl-3-[(1S)-1-  
(7H-purin-6-ylamino)ethyl]isoquinolin-1-one 
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Hypothesis & Aims 
Although CLL cells are quiescent, transcription and translation processes are active in 
these cells. Microenvironment provides survival advantage to CLL cells. Stroma cell lines 
derived from human bone marrow mimic the microenvironment. Interaction with stroma 
activates B cell receptor pathway, where PI3K is an active node. PI3K is an important 
regulator of cellular metabolism. Global RNA synthesis and protein synthesis increase in 
CLL upon interaction with stroma. 
Based on this background, and existing knowledge of CLL-stroma interactions, I 
hypothesize that stroma interaction upregulates metabolism in CLL lymphocytes through a 
mechanism involving PI3K pathway. CLL lymphocytes are metabolically active and may 
show different metabolic profiles that are in line with the aggressiveness of the disease based 
on prognostic markers. Changes in metabolomics should enhance the nucleotide biosynthesis 
needed for increased gene transcription. In accordance with these expectations, 
pharmacological intervention in this pathway is expected to inhibit metabolic changes and 
reduce the survival of CLL cells.  
Aim 1: Elucidate the bioenergetics profile of primary CLL cells peripheral blood 
lymphocytes, encompassing two major energy (ATP) generating pathways, glycolysis and 
mitochondrial oxidative phosphorylation (OxPhos) and determine the relationship to CLL 
prognostic factors.  
Aim 2. Determine the impact of stroma on energy generating pathways, oxidative 
phosphorylation and glycolysis in primary CLL cells.  
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Aim 3.  Delineate the role of PI3K pathway in induction of glycolysis and OxPhos in CLL 
cells.  
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CHAPTER 2. Materials and Methods 
Patient sample collection 
Peripheral blood samples were collected from 107 CLL patients.  All patients had 
given written informed consent in accordance with the Declaration of Helsinki and under a 
protocol approved by the Institutional Review Board of The University of Texas MD 
Anderson Cancer Center. All experiments were performed using freshly-isolated CLL cells 
from peripheral blood samples.  Purity of B cell population is 95% or higher determined by 
CD19 and CD5 double positive staining.  Patient characteristics are summarized in Table 1. 
Isolation of CLL cells 
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Hypaque 
density gradient centrifugation method (Atlanta Biologicals, Norcross, GA). Blood collected 
in 20 mL heparinized tubes was centrifuged for 10 min at 20ºC. The top layer of plasma was 
removed and the blood was diluted at a ratio of 1:3 with 1X phosphate-buffered saline (PBS) 
and carefully layered over 10 mL of Ficoll in a 50mL conical tube. The tube was centrifuged 
at 1500rpm for 20 min at 20ºC. The mononuclear cells at the interphase were gently removed 
and washed twice with 1X PBS. Cell counts were taken using Beckham Coulter counter and 
cells were resuspended in RPMI 1640 supplemented with L-glutamine and 10% Human 
Serum. Cells were cultured at a density of 1x10
7 
cells/mL. All experiments were performed 
using freshly isolated CLL cells from peripheral blood samples; purity of this cell population 
was ≥95%.   
PBMCs from healthy donors were isolated using the Ficoll technique as described 
above. 
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Pt # Ag
e 
Se
x 
# 
Prio
r Rx 
WB
C 
% 
LY
M 
β2M LD
H 
RAI ZAP IgVH CD38 Cytogenetics 
3 58 F 0 114.
8 
94 3.6 876 4 Pos UN 86 2011: 46,XX[20] 
4 61 M 0 183.
1 
97 3.1 516 1 Neg MU 1.3 53,XY,+6,+7,+11,+15,+18,+19,+20[1]/46,XY[19] 
5 72 M 0 50.5 89 2.8 515 1 np MU NA not performed 
6 46 M 3 172.
6 
89 np 956 4 Pos UN 43 not performed 
7 89 F 0 14.8 91 3.1 387 3 np MU NA not performed 
8 55 F 0 71.8 92 1.7 562 1 Pos NR NA not performed 
9 51 M 0 132 83 2.6 563 1 Pos UN 26 45,X,add(Y)(q12),t(1;3)(p36.3;q21),-19[1]/48,XY,+X,-
2,+3,+5,+6,+11,+12,-15,-16,-22[1]/46,XY[18] 
10 53 F 0 124.
9 
85 1.4 512 1 Pos UN NA 46,XX[20] 
11 62 M 0 92.7 90 2.7 591 1 Pos UN 58 46,XY,add(18)(q23)[8]/46,XY[12] 
12 62 F 0 160.
3 
93 2.2 511 0 Neg MU Neg not performed 
13 50 F 0 21.8 70 1 426 1 Pos MU NA not performed 
14 77 M 1 70 95 4.4 429 1 Neg NR NA 2005: 46,XY[20] 
15 51 F 1 76.7 97 4.2 123
8 
4 Pos UN 19.3 46,XX,del(20)(q11.2q13.1)[8]/47,XX,del(11)(q13q22),+12[2]/47,XX,del
(11)(q13q22),+12,-
17,+mar[1]/47,XX,del(9)(q22q34),del(11)(q13q22),+12,add(13)(q34),-
17,+mar[2]/46,X,add(X)(p22.1) 
,t(1;5)(p13;q13),-4,-11,+12,-17,-22,+3mar[2]/46,XX[5] 
16 53 F 0 34.4 93 2.5 383 0 Pos MU NA 46,XX,del(13)(q12q14)[3]/46,XX[17] 
17 72 M 1 74.6 96 3.9 521 4 Pos MU NA 46,XY[20] 
18 71 M 0 12.2 41 2.7 498 1 Pos np NA 45,X,-Y[8]/46,XY,del(11)(q22)[1]/46,XY[11] 
19 54 M 0 27.7 56 1.9 289 3 Pos UN 18.8 46,XY[20] 
20 54 F 0 102.
6 
94 1.9 605 0 Pos UN 5.4 No mitotic cells recovered 
21 60 M 0 76.2 88 1.5 771 4 Neg NR 15 46,XY[20] 
22 64 F 0 281. 92 2.6 746 1 Neg MU NA 2002:  46,XX[20] 
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5 
23 69 F 2 24 95 3.1 553 0 NR Neg NA not performed 
24 61 M 0 70.9 83 7 975 4 Pos UN 21 42~46,X,-
Y,del(2)(q32),del(11)(q23),del(17)(p13.1),+0~2mar[cp10]/46,XY[8] 
25 65 M 0 33.7 84 2.5 512 1 np np NA not performed 
27 53 M 0 57.4 84 1.7 525 1 Pos MU NA not performed 
28 76 F 3 200.
5 
87 4.9 691 3 Pos UN NA not performed 
29 44 F 0 92 76 2 141
7 
0 Neg UN NA not performed 
30 51 F 1 26.3 83 4.4 886 2 Pos UN 19.5 46,XX,del(20)(q11.2q13.1)[9]/47~48,XX,del(11)(q13q22),+12,-
17,+1~2mar[cp3]/ 
31 79 F 0 104.
5 
90 2.9 609 2 Pos UN 0.2 45,XX,del(13)(q12q14),-19[1]/45,X,-
X,t(10;20;12)(q21;q13.3;q13)[1]/46,XX[18] 
32 70 M 3 89.3 93 2.5 495 1 Neg UN 23.4 46,XY,der(1;10)(p10;p10)[1]/46,XY,del(11)(q13q23)[1]/46,XY[18] 
33 59 M 1 131.
4 
98 3.1 636 1 np UN NA not performed 
34 77 M 3 49.5 86 2.4 578 0 Neg MU NA not performed 
35 68 M 2 112.
8 
87 3.3 571 2 np UN NA not performed 
36 61 F 0 25 74 2.2 483 1 Pos MU NA 46,XX[20] 
37 56 M 1 39.1 89 4.3 440 2 Pos UN 62.3 45,XY,t(1;8)(q31;q21),-2[1]/46,XY[19] 
38 91 M 1 224.
9 
84 20.8 823 3 Pos UN 83.9 not performed 
39 68 M 1 241.
5 
94 4.1 953 1 Pos NR 17.8 45,X,-
Y[5]/46,XY,del(11)(q21q23)[2]/45~47,XY,del(11)(q21q23),del(13)(q12
q32), 
der(19)t(4;19)(q21;q13.3)[cp7]/46,XY[8] 
40 70 M 3 96.1 95 3 550 1 Neg UN NA 46,XY,der(1;10)(p10;p10)[1]/46,XY,del(11)(q13q23)[1]/46,XY[18] 
41 62 F 0 15.6 84 7.4 845 4 Pos UN 84.2 44,XX,add(7)(q36),-9,del(13)(q12q32),der(17;18)(q10;q10)[3]/44,idem, 
add(15)(p11.2)[2]/44,idem,add(22)(p11.2)[3]/46,XX[12] 
42 66 M 0 45 87 2.8 554 1 Neg NR NA 46,XY[20] 
43 83 M 0 20.7 70 2 434 0 Neg MU NA not performed 
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44 70 F 0 95.9 78 2.8 467 0 Neg MU NA No analyzable metaphases recovered 
45 64 F 6 64.9 90 1.6 770 4 Pos NR NA not performed 
46 62 F 0 31.2 89 2.1 538 0 np MU NA No mitotic cells recovered 
47 61 M 0 30 52 2.1 501 0 Neg MU NA 46,XY[20] 
48 66 F 1 75.5 85 5.7 554 4 Pos UN 0.7 39,X,-X,-7,add(8)(p23),-9,-20,-21,-21,-22,-
22,+mar[1]/44,XX,add(1)(p36.1),del(2)(p13), 
-16,add(17)(p13),-18[1]/45,XX,t(5;17)(q31;p13),del(6)(q21),-
20[1]/46,XX,add(6)(p21), 
add(14)(q32)[1]/46,XX[16] 
49 83 F 4 52.9 85 3.7 206
7 
0 Pos UN 47 47,XX,+12[19]/46,XX[1] 
51 68 F 1 34.6 90 1.8   np 0 Neg MU 1.5 not performed 
52 59 F 0 72.3 88 2 741 1 Pos UN 1.7 47,XX,i(7)(q10),+12[16]/46,XX,i(7)(q10)[cp2]/46,XX[2] 
54 49 M 1 43.4 89 2.2   np 4 Neg UN 3.5 not performed 
55 54 M 0 43.9 73 2.1 448 1 Pos UN NA not performed 
56 71 M 0 32.4 72 2.2 518 1 Neg MU NA not performed 
57 53 M 0 32.9 75 2 387 1 Neg MU NA No mitotic cells recovered 
59 61 F 0 62.3 91 2.4 660 1 Neg MU NA 46,XX[20] 
60 67 F 0 36.8 89 1.6 479 1 Pos NR 69 46,XX[20] 
61 76 F 2 107.
2 
83 3.9 ND 1 ND UM 3 not performed 
63 53 M 1 42.5 85 1.4 578 4 Neg UN 3.5 46,XY[20] 
64 74 F 1 125 92 3 462 2 Neg UN 0.2 not performed 
65 56 F 0 113.
3 
86 3.4 430 2 Neg MU NA not performed 
67 65 M 1 123.
8 
91 3.7 687 4 Pos NR NA not performed 
69 84 M 1 36.6 92   np 367 1 np NR NA not performed 
70 65 F 1 140.
2 
95 3.3 514 1 Neg MU NA 46,XX[20] 
73 57 M 0 82 89 4.1 712 4 Pos UN 85.6 45,XY,-
9,der(15)t(13;15)(q22;p11.2),add(17)(p11.2),+mar[1]/45,idem,t(8;9)(q24;
q22), 
 
 
28 
 
t(12;16)(q13;q24)[6]/46,XY,del(3)(q21)[1]/46,Y,-
X,add(9)(q22),+mar[1]/46,XY[11] 
74 78 M 0 27.6 89   np 436 4 Pos MU NA 46,XY[20] 
75 75 F 0 120.
5 
91 3.5 379 3 Pos MU 0.9 46,XX[11] 
76 83 F 4 77.1 87 3.9 208
7 
0 Pos UN NA not performed 
81 51 F 0 19.7 76 1.7 504 0 Pos MU NA not performed 
83 67 F 0 25.2 84 3.1 572 3 Neg UN NA 46,XX[23] 
84 69 F 0 127.
2 
97 3.7 547 1 Pos UN 1.5 46,XX,t(8;14)(q24.2;q32)[5]/46,XX,t(4;11)(q25;q23)[1]/46,XX[14] 
86 68 M 0 111.
9 
90 3.8 963 0 Pos UN NA 47,XY,+12[6]/46,XY[14] 
88 48 M 0 46.1 89 1.4 440 0 np MU NA not performed 
89 70 F 0 30.1 82 4.1 720 0 Neg MU NA not performed 
91 37 F 0 45.4 92 1.6 474 0 Neg MU NA not performed 
103 64 F 0 19.4 58 2.3 383 0 Neg MU NA 46,XX[20] 
104 57 M 0 66.5 92 1.9 498 1 Neg MU NA 46,XY[20] 
105 42 F 2 132.
8 
79 6.1 795 2 np UN NA not performed 
105
b 
58 M 1 56.6 88 4.3 615 1 Pos UN 91 45,X,-
Y[4]/45~46,XY,+2,i(17)(q10),del(20)(q11.2q13.3)[cp7]/46,XY,t(13;14)(
q21;q32)[1]/46,XY[8] 
106 65 M 0 32.6 88 2.2 623 0 Neg MU NA 47,XY,+12[5]/46,XY[15] 
107 47 F 0 23.6 82 2.2 529 0 Neg MU NA not performed 
108 56 M 0 32.4 80 1.3 533 0 Neg MU NA 46,XY[20] 
115 47 M 0 18.3 87 1.6 367 1 Neg MU NA No mitotic cells recovered 
112 72 M 0 55 89 4.3 715 0 Pos NR NA not performed 
110 78 M 2 41.9 79 3.8 414 1 Neg MU NA not performed 
116 83 F 0 42.8 80 3.2 550 3 np MU NA not performed 
118 67 M 1 27.6 81 3.8 481 0 Neg MU NA 46,XY[20] 
 
 
29 
 
119 43 F 0 23.3 69 2.1 392 0 Neg UN NA 46,XX,del(9)(q13),del(11)(q21),+2mar[cp4]/46,XX[16] 
117 67 F 0 97.4 97 1.5 556 0 Neg MU NA not performed 
120 69 M 2 38.3 91 3.4 558 0 Pos MU 0.2 48,XY,+12,+19[5]/48,idem,-13,-16,+2mar[1]/46,XY[14] 
121 54 M 0 51.3 83 2.7 511 0 Pos UN NA not performed 
122 62 M 0 48.5 92 1.8 483 0 Neg MU NA 46,XY[20] 
123 71 M 0 165.
3 
89 3.9 475 3 Pos MU 57 46,XY,del(11)(q13)[cp2]/46,XY[18] 
124 76 F 0 141 94 3.3 490 0 Neg NR NA not performed 
125 49 M 0 40.4 84 1.7 429 1 Pos UN 8.9 45,XY,t(2;14)(p12;q32),-11[1]/46,XY[19] 
126 66 M 0 16.2 83 4 506 1 Neg MU 0.6 Insufficient yield of analyzable 
metaphases/46,XY,t(4;10)(p16;q24)[1]/45,XY,-3,-14,+mar[1]/46,XY[8] 
127 71 F 0 49.1 94 2.4 527 2 Neg MU NA not performed 
128 56 F 0 106.
2 
95 3.1 519 4 Pos UN 54.5 45,XX,-17,der(20)t(17;20)(q21;p13))[5]/46,XX[15] 
130 62 M 0 16.9 52 1.7 417 1 Neg MU 1 46,XY[20] 
132 75 F 0 107.
4 
95 3.7 623 4 Neg UN NA not performed 
133 76 F 0 77.3 93 2 567 2 Neg NR NA not performed 
134 63 M 0 136.
3 
93 3.6 785 1 Pos UN NA not performed 
135 50 M 1 40.9 91 1.8 486 0 Neg MU NA 46,XY[20] 
136 63 M 0 55.3 81 2.5 530 0 Pos UN NA 46,XY,add(17)(p13)[4]/46,XY[16] 
 
 
 
Table 1.  List of CLL patients and their characteristics. 
MU=Mutated; np= not performed; NR= Not Reported; UN= Unmutated; NA= not available 
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B cell isolation  
Normal B cells were isolated by negative selection using Easy Sep
TM  
human B Cell 
Enrichment Kit (Stem Cell Technologies, Vancouver, CA). 
Cell lines 
Stromal cell lines and their culture conditions as well as conditions for Mino and 
JeKo-1 mantle cell lymphoma cell lines are in Table 2.  CLL cells were co-cultured with 
stromal cell lines in a ratio of 100:1.   All cell lines were periodically checked for 
Mycoplasma contamination using MycoTect kit (Invitrogen, Waltham, MA).   
Drugs 
Duvelisib (IPI-145) was obtained from Infinity Pharmaceuticals and used at 1 μM 
concentration to treat cells in all experiments. Idelalisib (GS1101) was obtained from Gilead 
Sciences and MK-2206 from Selleck Chemicals; 1 μM idelalisib and 2.5 μM MK-2206 were 
used in the experiments. All compounds were dissolved in 100% DMSO. DMSO-treated 
cells were used at the same time point as controls. 
Cytotoxicity assays 
Cells were stained with annexin V/propidium iodide and counted using flow 
cytometry. 5x10
5 
cells were collected in 5 mL tubes and resuspended in 100 µL of 1X 
Annexin binding buffer with 5 µL of Annexin –FITC. Samples were incubated in the dark 
for 15 min at room temperature and 300µL 1X Propidiumiodide buffer (with 1X PBS and 50 
µg/mL of PI) was added to the reaction and analyzed by Flow Cytometry (BD Accuri, 
Franklin Lanes, NJ). 10,000 events per sample were recorded.  
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Stroma cell line  Origin  Source Culture conditions 
NK-Tert Human Dr. Jan Burger, MD 
Anderson Cancer Center 
MEM +10% human serum, 
10%FBS, 0.4μg/mL hydrocortisone, 
0.1µg/mL 2-
Mercaptoethanol(Manshouri et al. 
2011) 
M2-10B4 Mouse Dr. Jan Burger, MD 
Anderson Cancer Center 
DMEM +10% FBS 
HS-5 Human ATCC® DMEM +10% FBS 
MCL cell line  Origin  Source Culture conditions 
JeKo-1 Human Dr. Hesham Amin, MD 
Anderson Cancer Center 
RPMI 1640, 10%FBS  
Sp53 Human Dr. Hesham Amin, MD 
Anderson Cancer Center 
RPMI 1640, 10%FBS  
Mino Human Dr. Hesham Amin, MD 
Anderson Cancer Center 
ATCC® RPMI 1640, 20%FBS 
 
Table 2. Source of cell lines and culture conditions 
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Extracellular flux assays 
Extracellular flux assays (Seahorse Bioscience, Chicopee, MA) were used to measure 
the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of CLL 
cells. XF96 wells were coated with Cell Tak solution diluted in sodium bicarbonate buffer 
and water to enhance adsorption (20.5 µL Cell Tak + 1610 µL 1M sodium bicarbonate + 62 
µL distilled molecular biology grade water). Cell Tak solution (17 µL) was used to coat the 
plate and incubated for 20 min for adsorption to take place at room temperature. Excess Cell 
Tak was drained and the plate was washed twice with 1X PBS and allowed to dry for 1hr in a 
laminar flow cabinet. Stromal cells (5 × 10
3
) were first plated on Cell-Tak–coated XF 
microplates and were allowed to adhere for 4-6 hours. CLL cells (5 × 10
5
) were plated onto 
the stromal cells in RPMI-1640 + 10% human serum.  CLL cells were cultured on 6-well 
plates, with or without duvelisib for 24 hours. The day before extracellular flux analysis, the 
assay cartridge was hydrated with 200 µL of XF calibrant overnight at 37ºC in a non-CO2 
incubator. Cells were counted and plated onto XF microplates.  RPMI-1640 medium was 
replaced with XF base (OCR) or glycolysis base (ECAR) media as recommended by 
Seahorse Bioscience. All the compounds used in the flux assays are listed (Table 3). Five 
technical replicates for each condition were plated. The plate was centrifuged at 100 g for 5 
min at 20ºC and checked under microscope to make sure the CLL cell adhered to the Cell-
Tak /stroma cells. The plate was pre-incubated at 37ºC non-CO2 incubator for 30 minutes. 
The drugs were loaded into drug injection ports in the assay cartridge for cell mitochondrial 
stress test A: Oligomycin (1.25 µM), B: Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone or FCCP (1 µM), C: Antimycin A (0.75 µM) + Rotenone  
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(1 µM) (Figure 6). Glycolysis stress test A: Glucose (10 mM), B: Oligomycin (1.5 µM), C: 2-
Deoxy-D-Glucose (100 mM). Glycolysis and cell mitochondrial stress tests using standard 
mixing and measuring times recommended by Seahorse. 
Oligomycin is mitochondrial uncoupler. It disrupts the ATP synthase activity by 
binding to the F0 component of the complex. Once oligomycin is added, oxygen consumption 
required for ATP synthesis declines, whereas the oxygen required for maintaining the 
electron transport chain remains (Figure 7). If the mitochondria is defective or is targeted by a 
drug then the proton leak increases as well. The consumption of oxygen is coupled to the 
electron transport towards the production of ATP. The proton current generated by basal 
respiration supplies the ATP synthase and the proton leak. An approximate measure of the 
mitochondrial ATP synthesis in the basal state can be obtained from the decrease in 
respiration by inhibiting the ATP synthase with oligomycin. Therefore, to calculate the 
coupling efficiency, we can deduct the oxygen consumed after addition of oligomycin, from 
the basal state. FCCP is an ionophore that disrupts the mitochondrial membrane gradient, 
causing the cell to consume oxygen to rescue the membrane potential for the ETC activity. 
The oxygen consumption capacity of the cell in response to the stress induced by FCCP is 
termed ‘Maximal Respiration’. The quantitative difference between the basal respiration and 
maximal respiration is termed ‘Spare respiratory capacity’ of the cell. To ensure the oxygen 
consumed is mitochondrial, Antimycin A and Rotenone, (inhibitors of mitochondrial 
complexes III and I activities respectively) are injected together. After their addition, the 
oxygen consumption must decline steeply and rapidly indicating that the oxygen consumed 
was indeed used by the ETC. However, non-mitochondrial respiration does get recorded and 
those values get deducted from the basal and maximal reparation values.  
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Assay Cell type Compound/Injection Optimal 
Concentration 
OCR CLL/MCL/Stroma Glucose 17 mM 
OCR CLL/MCL/Stroma Sodium Pyruvate 2 mM 
OCR CLL Human Serum  1 % 
OCR CLL/MCL/Stroma Oligomycin 1.25 mM 
OCR CLL/MCL/Stroma FCCP 0.5-1 μM 
OCR CLL/MCL/Stroma Antimycin A 0.75 μM 
OCR CLL/MCL/Stroma Rotenone 1 μM 
ECAR CLL/MCL/Stroma L-Glutamine 2 mM 
ECAR CLL/MCL/Stroma D-Glucose 10 mM 
ECAR CLL/MCL/Stroma Oligomycin 1.5 μM 
ECAR CLL/MCL/Stroma 2-Deoxy-ᴅ-Glucose 100 mM 
 
 
Table 3. List of compounds and drugs used in the extracellular flux assays. 
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Figure 6: Graphical representation of cell mitochondrial stress profile. 
The two hour test measures different parameters of mitochondrial respiration, when subject 
to stress by addition of drugs – Oligomycin (ATP coupler), followed by FCCP (uncoupler) 
and Antimycin A and Rotenone (inhibitors of complex III and I activity). 
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Figure 7. Biological targets of the drugs used in the extracellular flux assays. 
2-Deoxy-ᴅ-glucose is a competitive inhibitor for hexokinase in the glycolysis pathway. 
Rotenone and Antimycin A target Complex I and III respectively. Oligomycin inhibits 
complex V activity and FCCP affects the inner mitochondrial membrane. 
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Similarly, for ECAR, glucose (10 mM) is injected, followed by oligomycin that 
disrupts ATP production as discussed before; therefore, the cell has to rely on glycolysis to 
meet its energy demands (Figure 8). The capacity of the cell to utilize glycolysis as a source 
of ATP determines its glycolytic capacity. A final injection of 2-Deoxy-D-Glucose ensures 
the readout (mPH) is due to lactic acid production (end step of glycolysis). 
Optimization of cell numbers and drug concentrations for the XF assay: 
For optimal read outs from the mitochondrial and glycolysis stress tests, it is critical 
to plate sufficient number of cells in a monolayer to minimize variations. Optimization 
assays were run before starting the experiments for each cell type to determine the 
concentrations for each drug and the number cells to be used. NK.Tert cells were plated in 
5000, 7500, 10,000 (Figure 9A). 5000 stroma cell gave an optimal readout for ECAR/OCR. 
M2-10B4 and HS-5 cells were tested similarly (plated in 5000, 7500, 10000, 15000 cells 
counts) (Figure 9B). 
All drugs and substrates used in extracellular flux assays were titrated for optimal 
concentrations. Optimal concentration can be defined as the minimum amount of drug 
required to induce a response in OCR or ECAR. The protocol followed for the XF assays are 
as recommended by Seahorse Bioscience. Three minutes of mixing followed by four minutes 
of measurement of oxygen concentration or acidity of the medium. This cycle repeats after 
addition of each drug.  
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Figure 8: Graphical representation of glycolytic stress profile. 
This test measures glycolysis by the decrease in pH levels in the media. Glucose utilization 
by the cells is measured after addition of glucose, followed by addition of oligomycin (ATP 
synthase inhibitor) and injecting 2-Deoxy-ᴅ-glucose to cut off the non- glycolytic 
acidification. 
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Figure 9: Optimization of stroma and CLL cell numbers for extracellular flux analysis.  
A. NK.Tert cells cultured in MEM media were plated on XF96 plates at different cell 
numbers (2500, 5000, 10,000) and allowed to adhere for minimum of 6 hours.Five technical 
replicates were plated for each concentration.  The media was replaced with XF test media 
supplemented with fresh 17.5 mM Glucose and 2 mM sodium pyruvate. The pH was adjusted 
to 7.4-7.6. Oligomycin (1.25 μM), FCCP (1 μM) and Antimycin A + Rotenone (0.75 μM+1 
μM) were added in the order shown above. B. M2-10B4 cell numbers (2500, 5000, 7500, 
10,000, 15000) were optimized as described in (A)   
 
 
  
A B 
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Fibronectin coating  
CLL samples were assayed for OCR and ECAR using fibronectin (Sigma Aldrich, St. 
Louis, MO) as the adhesive at different concentrations (10, 15, 20μg/mL). XF96 plates were 
coated according to the manufacturer’s protocol. 
Cytokine stimulation assays 
CLL cells were incubated with stroma derived growth factor-1 (SDF-1, 250, 500 
ng/mL), B cell activating factor (BAFF 100 ng/mL), SDF-1 and BAFF in combination, IgM 
(10 μg) for 24hr and analyzed for ECAR and OCR. 
Conditioning media experiments 
CLL cells were cultured in conditioning media obtained from stroma cell culture. 
NK.Tert and M2-10B4 cells are grown in the media described in Table 2. Media is freshly 
added on day 1 to stroma cells. After 24hr culture, conditioning media from these cultures 
were obtained without disturbing the stroma layer (day 2) and added to CLL cells. CLL cells 
are then cultured in this media for 24hr before assaying for extracellular flux. 
Ribonucleotide pools extraction  
After 24 co-culture, CLL cells were carefully removed in 15 mL conical tubes, 
centrifuged at 1500 rpm at 4C for 5 min. The pellets were then washed with 10 mL of ice 
cold PBS and pelleted by centrifugation. After PBS was aspirated, 0.5 mL of ice-cold 0.4 N 
perchloric acid was added to the pellet, mixed well and incubated on ice for 5 min. The cells 
were repelleted by centrifugation and the supernatant was transferred to a clean Eppendorf 
tube. The 0.25 mL percloric acid was added to the pellet and extraction was repeated. The 
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supernatant was added to the first supernatant and its pH was adjusted with KOH to 6-7. The 
supernatant was spun down and the resultant supernatant was carefully removed with a glass 
syringe without disturbing the precipitate at the bottom. Intracellular nucleotide pools were 
separated using High Pressure Liquid Chromatography (HPLC). The extracts were applied to 
an anion-exchange Partisil-10 SAX column and eluted at a flow rate of 1.5 ml/min with a 50-
min concave gradient (curve 9; Waters Alliance 2695 separations module; Waters 2487 Dual 
λ absorbance detector) from 60% 0.005 M NH4H2PO4(pH 2.8) and 40% 0.75 M NH4H2PO4 
(pH 3.7) to 100% 0.75 M NH4H2PO4 (pH 3.7). The column eluate was monitored by UV 
absorption at 257 nm, and the nucleoside triphosphates were quantitated by electronic 
integration with reference to external standards. The intracellular concentration of 
nucleotides contained in the extract was quantitated using the number of cells and cell size 
(median). 
Immunoblotting 
Proteins from cell pellets were extracted using Cell lysis buffer (Cell Signaling 
Technology, Danvers, MA) supplemented with Protease inhibitor (EDTA free miniSTOP, 
Roche, Basel, Switzerland) and Phosphatase inhibitor (PhosSTOP, Roche), 25 mM boiled 
sodium orthovanadate and 10 µg/mL phenylmethanesulfonylfluoride (PMSF) in 1.5 mL 
Eppendorf tubes. Cells were incubated on ice for 30 min with occasional vortexing. The cells 
were centrifuged at 14000 rpm at 4ºC for 15 min. 
All steps were performed on ice. Supernatant was removed into a clean Eppendorf 
tube and protein was quantified using Bradford assay. 40-50 µg of protein was diluted with 
lysis buffer and ¼ 
th
 of sample buffer (Loading dye + 5% β-mercaptoethanol) was boiled at 
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95ºC for 5 min. The denatured protein was loaded onto 4-12% Bis-Tris gradient gel (BioRad, 
Hercules, CA) and the 1X XT MOPS (BioRad) was used as the electrolyte. The gel was 
transferred to a membrane using 1X Transfer Buffer (100 mL 1X Tris Glycine buffer + 200 
mL Methanol+ 700 mL milliQ water) at 400 mA for 1 hour at 4ºC. The membrane was 
probed with 1X blocking buffer for 1 hr at room temperature. The membrane was incubated 
overnight with 1:1000 dilution of the primary antibody (All antibodies used are listed in 
Table 4). The next day, after removing the primary antibody, the membrane was washed with 
1X wash buffer (1X PBS + 0.01 % Tween-20) twice for 5 min followed by 1 wash with 1X 
PBS. The membrane was incubated with 1:4000 dilution of the secondary antibody 
(Odyssey) for 1 hr at room temperature protected from light. The wash procedure mentioned 
above was repeated and the blot was scanned using an Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE). The protein expression was quantitated by utilizing Image 
Studio ™  Lite Ver 4 (LI-COR). For serum starvation experiments the cells in growth media 
were counted and washed twice with 1X PBS, before resuspending in RPMI 1640 media 
supplemented with 0.5% FBS for 2 hours. For IgM stimulation experiments, cells were 
serum starved as mention before and 10 μg of IgM was added to 1 mL of media containing 
cells (1×10
7
 CLL cells/ 3×10
6
 JeKo-1 cells). 
Glucose/glutamine uptake assays 
CLL cells were suspended in glucose free or glutamine-free media and either [
3
H]2-
deoxy-D-glucose (0.5 µl, specific activity 28 Ci/mmol)  for 60 min or [
3
H]L-glutamine (1 µl 
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Primary Antibody Company Species Dilution 
OXPHOS cocktail Abcam Rabbit 1:500 
p-STAT3 Tyr 705 Santa Cruz Bio Rabbit 1:250 
P-STAT3 Ser727 Cell Signaling Rabbit 1:1000 
STAT3 total Cell Signaling Mouse 1:1000 
p-AKT Thr308 Cell Signaling Rabbit 1:1000 
p-AKT Ser473 Cell Signaling Rabbit 1:1000 
AKT total Cell Signaling Mouse 1:1000 
UCP2 Novus Biologicals Rabbit 1:1000 
DNA pol γ Cell Signaling Rabbit 1:1000 
NRF1 Santa Cruz Rabbit 1:250 
p-S6 Ser235 Cell Signaling Rabbit 1:1000 
S6 Ribosomal protein Cell Signaling Mouse 1:1000 
p-ERK44/42 Ser Cell Signaling Rabbit 1:1000 
p-ERK 44/42 total Cell Signaling Mouse 1:1000 
GAPDH Genetex Rabbit; Mouse 1:20000 
p-ACC1 Ser79 Cell signaling Rabbit 1:1000 
GLUT4 Abcam Mouse 1:1000 
PI3K p110δ Santa Cruz Rabbit 1:1000 
 
Table 4. List of primary antibodies used in western blotting procedure. 
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specific activity 50.3 Ci/mmol) was added and incubated for 20 min (both reagents from 
Perkin Elmer, Waltham, Massachusetts) in a 12 well plate.  At the end of the incubation 
period the plate was placed on ice and 1 mL ice cold 1X PBS was added to each well to stop 
the uptake and collected into 15 mL conical tube and washed with 1X PBS to get rid of 
excess radioactive compound and the cells were quenched with 1 mL 1N sodium hydroxide 
and placed in a 37ºC water bath overnight. The next day 1 mL of quenched cells was added 
to 19 mL of counting liquid and radioactivity was quantified using the scintillation counter. 
The disintegrations per minute were quantified by the cell number. For control experiments, 
CLL cells were stimulated by addition of insulin 10 μg/mL (Sigma, St. Louis, MO) after 4 hr 
of incubation with the drug and 15 minutes before addition of either [
3
H] 2-deoxy-D-glucose 
for untreated/treated cells. CLL wells were also stimulated with anti-IgM (10μg/mL/107cells) 
to activate the B cell receptor pathway after 24hr of drug treatment and 15 minutes before 
addition of either [
3
H] 2-deoxy-D-glucose for untreated/treated cells. 
Flow cytometry analysis for measurement of mitochondrial reactive oxygen species, 
membrane potential, and mass 
CLL cells (5x10
6
) were washed and stained with 1:1000  Mito SOX Mitochondrial 
Superoxide Indicator in RPMI 1640 + 1% FBS for 10 min at 37ºC in a CO2 incubator and 
washed with 1X PBS and resuspended in 1X PBS to measure mitochondrial reactive oxygen 
species using Flow cytometry. This dye selectively targets mitochondria and is oxidized by 
generation of superoxide. Similarly, cells were simultaneously stained with 500 nM (working 
concentration) Mitotracker Deep Red FM to stain for live cell mitochondria and 
Tetramethylrhodamine, Ethyl Ester, Perchlorate to measure the mitochondrial outer 
membrane potential (MOMP) and incubated for at least 30 min and analyzed by Flow and 
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30,000 events were recorded per sample. All the three reagents are light sensitive and 
samples were protected from light throughout the assay. All reagents were obtained from 
Life Technologies Grand Island, NY.  Geometric means of histograms were quantified using 
FlowJo, LLC software (Ashland, OR). 
Metabolite Mass Spectrometry  
CLL cells were co-cultured with NK.Tert cells for 24hr, washed and cellular 
metabolites were extracted using 80% methanol by following the protocol provided by Mass 
spectroscopy facility at Beth Israel Deaconness Medical Center. The samples were sent for 
polar metabolite analysis. 
The changes in metabolites after co-culture were calculated by the ratio of values 
obtained for each metabolic after co-culture vs suspension culture. The metabolites were then 
grouped into pathways using Kyoto Encyclopedia of Genes and Genomes (KEGG) IDs. 
CRISPR-Cas9 gene editing 
BCR knockout 
(These experiments were conducted in collaboration with Dr. Richard E. Davis laboratory, 
Department of Lymphoma/Myeloma, UT MDACC) 
CRISPR Cas9 px330 plasmids with BCR target DNA sequence constructs were 
donated by Dr. Davis. JeKo-1 cells (6 x 10
6
) were transfected (10 μg of plasmid 
DNA/million cells) by electroporation (Neon® transfection system, Invitrogen) according to 
the manufacturer’s protocol. No DNA and non-specific plasmid were used as negative 
control. GFP only transfection was used as a positive control to measure transfection 
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efficiency. JeKo-1 cells in culture were harvested, washed with 1X PBS, cells were counted 
by tryphan blue exclusion. Cells were pelleted by centrifugation and supernatant was 
carefully removed. The pellet was resuspended in R buffer (100 μL/106 cells). Appropriate 
plasmid DNA was added to sterile Eppendorf tubes and 100 μL of cells were added to each 
tube. 100 μL electroporation tip was used to mix the cells with the DNA and placed in the 
electroporation Tip chamber contacting 3 mL of E2 electroporation buffer. JeKo-1 cells were 
then pulsed once at 1500 V, for 20 mS. The cells were then plated in 3 mL DMEM media 
supplemented with 10% FBS in a 6 well plate. The cells were stained and analyzed for BCR 
heavy chain (IgM) and light chain (κ) expression, by flow cytometry, 72 hr post transfection. 
The cells were resuspended in 100 μL of FACS buffer with IgM and the corresponding light 
chain Ab (JeKo-1 κ, Mino –λ). The cells were incubated on ice for 20 min in the dark. The 
cells were then washed with FACS buffer and resuspended in 200 μL FACS buffer 
containing Pacific blue (Thermo Fisher Scientific, Waltham, MA) / Propidium Iodide (BD 
Biosciences, San Jose, CA) to stain for dead cells.  
The knockout (KO) cells were stained and sorted by FACS on day 6 (Figure 10). 
After sorting, the cells were placed in DMEM media supplemented with 20% FBS +1 U 
Penicillin Streptomycin solution. Three KO clones were generated, where the Cas9 construct 
harbored DNA sequences complimentary to different regions of CH2 domain of BCR.  
Targeting CH2 IGHM constant region http://crispr.mit.edu/job/8849455957183642 
TS4: CCCCCGCAAGTCCAAGCTCATCT 
TS5: CAGGTGTCCTGGCTGCGCGAGGG 
TS6: ACCTGCCGCGTGGATCACAGGGG 
IGHMC_gRNA_04_F CACCGATGAGCTTGGACTTGCGG 
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IGHMC_gRNA_04_R GATGAGCTTGGACTTGCGGGTTT 
 
IGHMC_gRNA_05_F CACCGGTGTCCTGGCTGCGCGA 
IGHMC_gRNA_05_R GGTGTCCTGGCTGCGCGAGTTT 
 
IGHMC_gRNA_06_F CACCGACCTGCCGCGTGGATCACAG 
IGHMC_gRNA_06_R GACCTGCCGCGTGGATCACAGGTTT 
 
PIK3CD Knock in –Knock out  
The knock in – knock out approach enabled us to viably mark the PI3K δ KO cells by 
expressing the GFP instead of PI3K δ from its DNA locus and consequently use the cells for 
further studies. The general approach was to knock in (KI) the GFP-STOP-polyA cassette 
right after translation initiation site of the PI3Kδ leading to PI3Kδ promoter driven 
expression of GFP instead of PI3Kδ. We have used the CRISPR/Cas9 system to introduce 
DNA double strand breaks at the desired location and at the same time provided template 
plasmid for homologous recombination mediated KI. The px330 plasmid (Addgene plasmid 
#42230, PubMed 23287718) coding for Cas9 and gRNA targeting PI3K δ (target site 
sequence: 5’- CATCTGGGAAGTAACAACGCAGG-3’) was cloned according to the 
published protocol (PMID: 24157548). The target site was designed using CRISPR design 
tool at http://crispr.genome-engineering.org/ (PMID: 23873081). Electroporation was used 
(Neon Transfection System, Thermo Fisher Scientific) to deliver the px330 plasmid at the 
same time as the KI template plasmid (9 μg per 1e10 cells of each plasmid). The pSC-B-
amp/kan plasmid (Agilent Technologies, Santa Clara, CA) was used to carry the KI template 
sequence that consisted of (from 5’ to 3’): left homology arm (400 bp of PI3K δ DNA 
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sequence upstream of translation initiation site), kozak sequence (GCCACC), GFP with 
STOP codon, bGH PolyA signal sequence, and right homology arm (300bp of PI3Kδ 
sequence downstream of translation initiation site). The homology arms contained silent 
mutations preventing targeting of the template plasmid or PI3K δ locus after the KI. The 
PI3K δ KO GFP positive cells were identified and sorted to purity using FACS. As a control 
for KI specificity, px330 plasmids with non-specific target site were electroporated together 
with template plasmid. No GFP positive cells were detected in the specificity control.  
px330 and px 335 plasmids were cloned with two different target (beginning of exon 
3 for PI3KD gene) inserts. PI3KD homology arm sequence is used as the repair template 
with Green Fluorescent Protein insert.  
1. Annealing the oligo: The oligos (custom ordered from IDT) were reconstituted and 
diluted to 100 pmol/µl. 10 µl PCR buffer, 5 µl forward oligo, 5 µl reverse oligo, 80µl 
ddH2O were mixed and placed in a thermal cycler with slowly decreasing temperature 
as follows: 95°C 2 min, 90°C 2 min, 85°C 5 min, 70°C 5 min, 65°C 5 min to stop at 
20°C. The resulting product would be double stranded oligos at 5 pmol/µl. 
P110delta_gRNA_01_F CACCGCATCTGGGAAGTAACAACGC 
P110delta_gRNA_01_R AAACGCGTTGTTACTTCCCAGATGC 
P110delta_gRNA_02_F CACCGCAGGATGCCCCCTGGGG 
P110delta_gRNA_02_R AAACCCCCAGGGGGCATCCTGC 
P110delta_gRNA_03_F CACCGAGTTACCTCAGCTGAGC 
P110delta_gRNA_03_R AAACGCTCAGCTGAGGTAACTC 
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Figure 10. Sorting B cell receptor knockout cells from Cas9 transfected JeKo-1 cells. 
On day 4 after transfection of JeKo-1 (1×10
7
) cells with Cas9 plasmid containing BCR target 
sequence, the cells were stained with IgM-FITC and κ-PE (1:100 ratio) for 20 minutes on ice 
and sorted for IgM negative population as shown. 
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2. Phosphorylation of the oligos: 20 µl of previous reaction (200pmol of 5’ ends), 5 µl 
of 10 X T4 DNA Ligase Buffer,1 µl of T4 Polynucleotide Kinase (10 units), 24 µl 
ddH2O were taken together in an Eppendorf tube and incubated at 37°C(water bath) 
for 30 minutes. Resulting concentration of ds phosphorylated oligos: 2 pmol/µl. The 
oligos were then diluted to 0.1 pmol/µl by adding 19 µL of ddH2O to 1 µL of ds 
oligo. 
3. Ligation of the oligo with px330 or px335 plasmids: These plasmids were first cut 
with restriction enzyme BbsI and treated with CIP (Calf-intestinal alkaline 
phosphatase). 
10 µL of the ligation reaction is set upon ice in an Eppendorf as follows 
1 µL of opened plasmid (40 ng/ µL), 0.5 µL of ds phosphorylated diluted oligo (0.1 
pmol), Buffer 1 µL, Ligase 0.5 µL, ddH2O 7 µL. The reaction was gently mixed by 
pipetting up and down and incubated at 16°C overnight. 
The combination of the oligos with the px plasmids are as follows: 
px330- oligo 1, px330- oligo 2, px335- oligo 1, px335- oligo 3 
4. Transformation of bacteria: The reaction was then chilled on ice and 2 μl of the 
reaction was added to 100 μl of competent cells (StrataClone Blunt PCR Cloning Kit 
from Agilent Technologies). 20 µl of bacteria was spread on an agar plate with 
ampicillin. β-galactosidase was used for blue white colony screening and placed in 
37°C incubator overnight. The next day, 3 white colonies were picked and streaked 
on agar plate with ampicillin. After 6hrs of incubation at 37°C, the bacteria from the 
streaks were inoculated  
 
 
51 
 
In 2 mL of LB broth supplemented with 100 µg/mL ampicillin and incubated at 37ºC 
for another 6 hrs. This culture was used to prepare a mini prep using Qiagen mini 
prep kit. 
5. Sequencing: The DNA obtained from minipreps was sent for Sanger sequencing at 
the DNA sequencing core facility at MD Anderson Cancer Center. Sequences of 
interest were verified with  Finch TV (Geospiza Inc) and Lasergene SeqBuilder 
(DNASTAR™) 
6. After sequence verification, more DNA was obtaining by using Qiagen Maxiprep Kit 
(Valencia, CA). 
 Repair Template: PI3KCD homology arm gene block was ordered from Integrated DNA    
Technologies.  
1. The gBLOCK containing PIK3CD homology arms was captured into the Strataclone 
pSC plasmid. 
2.  The plasmid with p110delta_HA_1 was then opened with BbsI restriction enzyme to 
insert GFP-PolyA fragment to make final template for KI. 
3. Co-transfection of JeKo-1 cells were as follows: 
i. Px330-1 (9 µg) + PI3KCD_HA (9 µg) 
ii. px330-2 (9 µg)+ PI3KCD_HA (9 µg) 
iii. Px335-1 (6 µg)+ Px-335-3 (6 µg) + PI3KCD_HA (6 µg) 
The combination that gave the highest GFP + ve cells was used for further experiments. GFP 
expression was checked by Flow cytometry (Figure 11). Experimental set up consisted of no 
DNA control, non-specific control, GFP control and px330-1 plasmid transection. 
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Knock-in template sequence (with PI3K homology arms and GFP): 
GGTCTCAGGGCACCTGACCAGCTGTCCTGCCATCTCCCTTCTGTGCCAGCTGGTG
GCCATGACTGGCTTTCGTGGATGTGTATGTTCCTGAGGAAAGATGATTTGCTGTG
CGTGCTCCTGTGGGGAGGACATGCAGTGTCTGCCTGGGAGAAGAGGCAGCTGA
GGCCGTGGCCCGGAGTAGTAGGAGCCACAAGCCACCCTGGGCAGGACGAG
GCCCTGAGGGAGGTGAGCTTTTTGTACCCGCAGGTCGGGAACTCACTCCTGAGC
TTCCTGCTGTCCAAGGACCCCACTGTTTTCCAGGGAGTCCCTTCCAAAGGTCTCA
CTCAACTCAGCTGAGGTAACTCATTTTGCCATTTCTTCATTTTTAGGACAACTGT
CATCTGGGAAGTAACAAGCCACCATGGAACCCGTGAGCAAGGGCGAGGAGCTG
TTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCAC
AAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACC
CTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGA
CCACCTTCACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCA
GCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCAT
CTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG
CAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAGGTCTATAT
CACCGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGACCCGCCACA
ACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCA
TCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG
CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCG
TGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGATCAGC
CTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTT
CCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAAT
TGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAG
GACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGACATGCC
CCCTGGTGTGTACTGCCCCATGGAATTCTGGACCAAGGAGGAGAATCAGAG
CGTTGTGGTTGACTTCCTGCTGCCCACAGGGGTCTACCTGAACTTCCCTGTG
TCCCGCAATGCCAACCTCAGCACCATCAAGCAGGTATGGCCTCCATCCGGTCC
TCAGACCTTGGTGCTCAGAGAGAGAGAGAGAGAGAGAGACACAGATAGACAGA
CAGACAGACAGACAGATGGACAGGTGGACAGACGGACAGACAGATGGACAGAT
GCACTGCTTTTCAGACTTGGGATCCTCAGATGAGAATTTTAAAAGATAAATAATG
GTTTGTTTGTTTGTTTGTTTGTTTTGAGACGGAGTTTCGCTCTTATTGCCCAGGCT
GGTGTGCAATGGCGCAATCTCGGCTCC 
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Figure 11. Sorting PIK3CD knockout cells from Cas9 transfected JeKo-1 cells.  
On day 3, after co-transfection of JeKo-1 (1×10
7
) cells with Cas9 and GFP containing 
PIK3CD repair template, the cells were sorted for GFP positive cells that were knockout for 
PIK3CD as shown.  
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Fluorescence Activated Cell Sorting 
For BCR KO experiments, IgM-FITC conjugate and light chain antibodies (κ, λ) –PE 
conjugate obtained was from Life Technologies (Carlsbad, CA). The cells were counted by 
Trypan Blue staining and 2×10
7
 cells were stained at 1 μL of sterile Abs /million cells in 1 
mL of media and taken to the FACS facility. The KO cells were collected in RPMI 1640 
containing 20 % FBS and 1 % Penicillin and Streptomycin solution.  These cells were then 
centrifuged at 1500 rpm for 5 minutes and resuspended in RPMI 1640 + 10 % FBS + 1 % 
penicillin-streptromycin solution. 
PCR for mtDNA copy number 
QiaAMP DNA mini kit (Qiagen, Venlo, Limberg, Netherlands) was used and DNA 
was extracted from CLL samples according to manufacturer’s protocol. qPCR SYBR green 
master mix was used to amplify the mitochondrial DNA from 4 CLL patient samples. All 
samples were run in triplicate. These experiments were conducted in collaboration with Dr. 
Benny Kaiparettu’s laboratory, Baylor College of Medicine. 
Electron Chain Transport activity analysis 
Frozen cell lysates were lysed and then used for electron transport chain (ETC) 
enzyme assays. The enzymes were assayed at 30 °C using a temperature-controlled 
spectrophotometer; Ultraspec 6300 pro, Biochrom Ltd., (Cambridge, England). Each assay 
was performed in triplicate. The activities of the five enzymes were measured using 
appropriate electron acceptors/donors according to published procedures (Vu et al. 1998, 
Enns et al. 2005). These experiments were conducted in collaboration with Dr. Benny 
Kaiparettu’s laboratory, Baylor College of Medicine.   
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Citrate synthase (CS) was used as a marker for mitochondrial content. Enzyme activities are 
expressed relative to total protein as nmol/min/mg protein. 
Statistical analysis 
Student’s t-tests (two-tailed) and ANOVA were performed using Prism 6 software 
(GraphPad Software, San Diego, CA). 
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CHAPTER 3. RESULTS 
As discussed in the Introduction Section, although CLL cells are quiescent, they are 
active in transcription, translation, and metabolomics.  However, the metabolic activity of 
CLL cells has not been explored in detail in previous studies. To gain a deeper understanding 
of the bioenergetics of CLL cells in context of the microenvironment, and to test my 
hypotheses that stroma would modulate CLL metabolism and PI3K would play a crucial role 
regulating metabolism of these cells, I conducted the following three aims. 
Aim 1: Elucidate the bioenergetics profile of primary CLL peripheral blood lymphocytes, 
encompassing two major energy (ATP) generating pathways, glycolysis and mitochondrial 
oxidative phosphorylation (OxPhos) and their relationship to CLL prognostic factors. 
Aim 2. Determine the impact of stroma on energy generating pathways, Oxidative 
Phosphorylation and glycolysis in primary CLL cells. 
Aim 3.  Identify the role of PI3K pathway in induction of glycolysis and OxPhos in CLL 
cells. 
 
Aim 1.  Elucidate the bioenergetics profile of primary CLL peripheral blood 
lymphocytes 
Aim 1.1. Elucidate the bioenergetic profile of primary CLL cells in relation to glycolysis and 
mitochondrial OxPhos. 
Oxidative phosphorylation and glycolysis are the two major pathways leading to the 
production of ATP. Glycolysis is often upregulated in cancer cells to meet its energy 
demands (Warburg 1956).  Cancer cells are highly proliferative and require energy for DNA 
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replication- and cell division- associated processes.  However, the more prominent pathway 
that quiescent mature cells such as CLL rely on has not been well elucidated so far. 
CLL metabolic profile 
Glycolysis (measured as ECAR) and OxPhos (measured as OCR) profiles were 
analyzed in CLL patient samples using Seahorse extracellular flux analysis. The cells 
obtained from all of the CLL patients samples were cultured in RPMI 1640 +10% human 
serum before the analysis. Glycolysis and OxPhos were measured in 41 patient samples using 
cell mitochondrial stress test and glycolysis stress tests as described in Materials and 
Methods. Along with the CLL cells, peripheral blood mononuclear cells (mostly T cells) 
(5x10
5
) and quiescent mature B cells obtained from 4 healthy donors were also analyzed for 
ECAR and OCR as were mantle cell lymphoma cell lines, (another B cell malignancy), 
JeKo-1, Mino, Granta and Sp53 (40,000 cells).  These cell lines were actively proliferating, 
therefore, we expect their metabolism to be much higher than quiescent B cells.  
A phenogram depicting the metabolic phenotype of cells was plotted using the data 
from all the cell types assayed above. The phenogram can be divided into four quadrants.  
Abscissa is taken as ECAR and ordinate as OCR. Lower left quadrant depicts metabolically 
less active cells as both ECAR and OCR have low values; lower right quadrant depicts cells 
that are more glycolytic owing to high ECAR, but low OCR values; upper left quadrant 
depicts aerobically active cells as OCR is high compared to ECAR; upper right quadrant 
denotes cells that are metabolically highly active as both oxygen consumption as well as 
glycolysis rates are high. 
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 OCR and ECAR were lower in CLL lymphocytes (n=41) than in healthy mature B 
cells, PBMCs, or MCL cell lines, the latter were highly metabolic both aerobically and 
anaerobically (Figure 12).  Among the malignant lymphocyte samples, there was very little 
glycolytic disparity, whereas mitochondrial respiration varied.  The coefficient of variation 
for OCR was 57% versus ECAR at 42%. 
Aim 1.2.  Evaluate the metabolic profile of CLL patient samples in relation with the most-
prevalent prognostic factors and cytogenetic profiles.  
Impact of prognostic factors on CLL mitochondrial OxPhos and glycolysis 
To understand the basis for these differences in OCR, we compared basal OCR with 
prognostic markers of the disease. These are factors that have been associated with 
aggressiveness of disease, the outcome of treatment in the clinic, and relapse and disease 
progression. These prognostic factors were ZAP 70 status, IgVH mutational status, Rai 
staging, β2 microglobulin, LDH levels, lymphocyte counts, CD38 status, gender, age and 
cytogenetics. 
ZAP 70 is a tyrosine kinase receptor that is expressed on T cells and its expression in 
normal B lymphocytes is not known.  However, in CLL cells, ZAP 70 is expressed 
(Rosenwald et al. 2001). ZAP 70 expression on the surface of malignant B cells is correlated 
with aggressive CLL disease. ZAP 70 expression is measured by immunohistochemistry or 
by flow cytometry. The patient is considered negative for ZAP 70, if it is expressed on less 
than <20% of the monoclonal B cells and if the expression is found on ≥20% of B cells, 
he/she is ZAP70 positive. For OCR, CLL cells from 20 ZAP 70 negative patients and 29  
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Figure 12. Phenogram of CLL cells compared with healthy and other malignant 
lymphocytes.   
Bioenergetic profile of CLL cells(5x10
5
) from 41 patients (red circles) compared with 
peripheral blood mononuclear cells (PBMCs) from healthy donors (n = 3, blue triangles), B 
cells from healthy donors (n = 4, inverted green triangles), and proliferating B cell lymphoma 
cell lines (JeKo-1, Mino and Sp53, maroon squares). All cells were in suspension cultures. 
Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate (OCR) (n = 5 
technical replicates for all extracellular flux experiments conducted) were measured and 
normalized to 1x10
5 
cells 
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ZAP 70 positive were analyzed.  There is an overlap in the OCR values for the negative and 
positive samples which can be attributed to the variable levels of ZAP 70 in these cells as 
opposed to complete presence or absence.  Statistical analysis (unpaired t-test) suggested that 
ZAP 70-positive samples had higher OCR compared to their counterparts (Figure 13A). ZAP 
70 negative patients and 19 ZAP 70 positive were assayed for ECAR; however, these ECAR 
values were fairly similar and varied based on ZAP 70 expression (Figure 13B).   
 
ZAP 70 status generally correlated with IgVH mutational status (Crespo et al. 2003). 
Absence of somatic mutations in IgVH marks aggressive disease. Somatic mutation occurs in 
the gene segments VH, D, JH that code for immunoglobulin heavy chain variable region. 
CLL is classified into two subsets based on the germline mutations of IgVH. Mutational 
status is confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). 19 CLL 
samples with IgVH mutation and 27 samples with unmutated IgVH were analyzed for OCR. 
Basal OCR was significantly higher in IgVH unmutated cohort than in mutated cohort 
(Figure 13C). Similarly, glycolytic flux was assayed for 11 IgVH mutated and 18 unmutated 
CLL samples. However, they did not display any correlation with IgVH status (Figure 13D). 
 
Binet and Rai staging defines various stages of CLL disease.  Among these two, Rai 
staging is commonly used in the USA and is mainly based on lymphocytosis (>15,000 
lymphocytes/mm
3
) in blood and prevalence of disease in bone marrow, lymph nodes and 
other sites.   Staging is mainly used for treatment purposes and risk stratification. There are 
five stages- 0, 1, 2, 3 and 4; 0 and 1 being low risk for overall survival and 2-4 being high   
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Figure 13. Correlation of CLL OCR and ECAR with ZAP 70 expression and IgVH 
mutational status. 
CLL cells were assayed for OCR and ECAR, after isolation from peripheral blood. A. Basal 
OCR of CLL cells obtained from ZAP 70-negative (neg) (n=20) and ZAP 70-positive (pos) 
(n=29) patients were compared. B. Glycolytic flux from CLL cells of ZAP70-negative 
(neg)(n=9) and ZAP 70-positive (pos) (n=19) patients were compared. C. Similar to A, CLL 
cell basal OCR was compared based on the mutational status of IgVH in patients: mutated 
(M)(n=19) or unmutated (U)(n=27). D. Glycolytic flux from IgVH mutated (M)(n=11) and 
unmutated (U)(n=18) CLL cells were compared. Unpaired student’s t-test was used to 
calculate statistical significance. 
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risk. 34 patients with low grade CLL and low grade (stages 0-1), and 20 with high grade 
were analyzed for OCR. Higher basal OCR correlated with advanced disease stage (Figure 
14A). In contrast, when glycolytic flux from 25 low grade patients (stages 0-1), and 11 high 
grade CLL were compared, no significant difference was observed between the two groups 
(Figure 14B). 
 
β2 microglobulin (β2M) is a cell membrane protein associated with HLA-antigens 
and its levels are elevated in serum of CLL patients with advanced disease. The cut-off levels 
for β2M according to CLL International Prognostic Index in healthy individuals is 
≤3.5μg/mL. A value of >3.5 μg/mL is associated with high risk CLL disease. CLL patients 
with low serum (≤3.5μg/mL, n=39) β2M levels and with high levels (>3.5 μg/mL, n=15) 
were analyzed for OCR. High basal OCR marginally correlated with high β2M levels (Figure 
15A). Whereas, ECAR analyzed for 18 CLL patients with low β2M levels and 7 with high 
levels did not correlate (Figure 15B). 
 
Lactate dehydrogenase (LDH) is an enzyme that converts lactate into pyruvate. 
Elevated LDH levels are an indicator of tissue damage. In my study, patients are grouped 
according to their serum LDH levels- 8 patients had low levels (300-500 μg/mL) (L), 26 
patients have intermediate levels 501-700 μg/mL (M), and 17 patients with high level >700 
μg/mL (H, high). These samples were analyzed using a cell mitochondrial stress test (Figure 
15C). Similarly, glycolysis stress tests were performed on CLL cells from patients with low 
(n = 5), medium (n = 11), high (n = 9) LDH levels (Figure 15D). In general, LDH levels did 
not associate with either OCR or ECAR.    
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Figure 14. Correlation of CLL OCR and ECAR with Rai stage. 
CLL cells were assayed for OCR and ECAR, after isolation from peripheral blood. A. Basal 
OCR of CLL cells were compared for patients classified by Rai stage: low grade (stages 0-1, 
n = 34), high grade (stages 2-4, n = 20). B. Glycolytic flux from low grade (stages 0-1, n = 
25), high grade (stages 2-4, n = 11) CLL cells were compared. Statistical significance was 
calculated using unpaired student’s t-test. 
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Figure 15. Correlation of CLL OCR and ECAR with LDH and β2 microglobulin levels.  
A. Basal OCR from CLL cells were compared for patients classified according to β2M  cut-
off levels determined by CLL International Prognostic Index  ≤3.5 μg/mL (n=39), >3.5 
μg/mL (n=15), respectively. B. glycolytic flux of CLL cells were compared for patients with 
≤3.5μg/mL (n=18), >3.5μg/mL (n=7) levels. Statistical significance was calculated using 
unpaired student’s t-test for A and B. C. CLL OCR correlation with patient lactate 
dehydrogenase (LDH) levels. Basal OCR from CLL cells were compared for patients with 
different LDH levels: low (L) (300-500 μg/mL, n = 8), medium (M) (501-700 μg/mL, n = 
26), high (H) (>700 μg/mL, n = 17). D. glycolytic flux of CLL cells were compared for 
patients low (L) (300-500 μg/mL, n = 5), medium (M) (501-700 μg/mL, n = 11), high (H) 
(>700 μg/mL, n = 9) LDH levels. Statistical significance was calculated using one way 
ANOVA. 
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The incidence of CLL is higher in males than in females (Ries L.A.G. 2003). To determine if 
CLL lymphocytes from men had higher metabolic profile, cell mitochondrial stress tests 
were performed for OCR on cells obtained from 27 male and 27 female patients. There was 
no statistical variation between the two cohorts (Figure 16A). However, when these cells 
were compared for glycolytic flux ECAR varied significantly between the two groups, with 
males (n=14) displaying higher glycolysis rates than females (n=13) (Figure 16B).   
 
CLL onsets at a later stage in life and is most common in the elderly with adults 
above 60 years of age at a greater risk. Basal OCR of CLL cells were compared in patients of 
different age groups, 27 patients from ages 40-59, 14 patients from ages 60-69 and 13 
patients from ages 70 and greater (Berger et al. 1978)(Figure 16C). ECAR was assessed for 
12 patients from ages 40-59, 5 patients from ages and 8 patients from ages 70 and greater 
(Figure 16D). Both OCR and ECAR values did not correlate with age. 
 
CD38 is a type II transmembrane glycoprotein that is expressed on the surface of 
hematopoietic cells. Its functions involve signal transduction and mediating cell to cell 
adhesion (Deaglio et al. 2011). The cut-off value for CD38 positivity is ≥20%, whereas cells 
with less than 20% surface expression of the receptor are considered negative. CD38 positive 
patients respond poorly to therapy (Durig et al. 2002) and have short survival.  CD38 surface 
expression was measured by flow cytometry. 13 patients negative for CD38 and 7 patients 
positive for CD38 were assessed for OCR. Considering the sample size is relatively small, 
the difference between OCR of these two groups was not significant and thereby CD38 status 
did not impact OCR (Figure 17A).  
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Correlation of CLL OCR and ECAR with patient’s gender and age. 
A. Basal OCR of CLL cells were compared based on the gender of the patient, male (n=27) 
or female (n=27). B. Glycolytic flux of CLL cells were compared based on the gender of the 
patient, male (n=14) or female (n=13). Statistical significance was calculated using student’s 
unpaired t-test for A and B. C. Basal OCR of CLL cells were compared for patients of 
different age groups: 40-59, 60-69, ≥70 years (n = 54).D. Glycolytic flux of CLL cells were 
compared for patients of different age groups. Statistical significance was calculated using 
one way ANOVA. 
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Figure 17. Correlation of CLL OCR and ECAR with patient’s cytogenetic profile and 
CD38 status.  
A. Basal OCR of CLL cells from patients expressing CD38 ≥20% (positive), <20% 
(negative) were compared. Statistical significance was calculated using unpaired student’s t-
test p=0.14 B. Basal OCR of CLL cells were compared for patients with various 
chromosomal abnormalities by extracellular flux analysis: 11q deletion (n = 4), 13q deletion 
(n = 2), 17p deletion (n = 2), trisomy 12 (+12) (n = 2). C.K. (n = 7) indicates complex 
karyotype with 2 or more of these deletions, O (n = 16) indicates other chromosomal 
abnormalities and U (n = 21) indicates unknown karyotype. Statistical significance was 
calculated using ANOVA p=0.4. 
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Impact of CLL cytogenetics on metabolism 
The most common chromosomal aberrations that are identified in CLL are: 11q 
deletion, 13q deletion, 17p deletion and trisomy. These lesions are detected by fluorescence  
in situ hybridization (FISH) karyotyping. CLL patients were grouped based on the 
karyotyping results. 4 patients that are unique for 11q deletion without other major 
chromosomal anomalies mentioned before were grouped into 11q category. Similarly, 2 
patients for 13q, 2 for 17p and trisomy 12 (+12) (n = 2). If two or more of these aberrations 
occur together, then the patients are categorized into complex karyotype pool (C.K.) 16 
patients are classified into another cohort that exhibit other aberrations, but not these major 
ones listed. Karyotype for 21 patients were not done, therefore are unknown.  It is difficult to 
correlate OCR data with cytogenetics as the sample size for these chromosomal anomalies 
was very small with a large portion of samples falling into the unknown category (Figure 
17B). 
 
Aim 2. Elucidate the impact of stroma on CLL-bioenergetics 
Aim 2.1.  Elucidate the impact of stroma on CLL OxPhos and glycolysis pathways. 
CLL cells that are positive for ZAP 70 and have an IgVH unmutated status have an 
increased advantage for interaction with the microenvironment. Interaction with stromal cell 
in vivo and in vitro greatly enhances cell survival. Though a few studies touched upon the 
aspect of the metabolic advantaged conferred to CLL cells by interaction with stroma cells, 
there is still not much clarity of how stromal cells contribute to bioenergy or biosynthesis in 
CLL cells.  
  
 
 
69 
 
Metabolite analysis in CLL cells after stroma co-culture 
My study aims at delineating the metabolic pathways that get activated in CLL cells 
and the change in metabolic fluxes upon interaction with stroma.  
To study changes in metabolic pathways in CLL upon stromal interaction, CLL cells 
were obtained from 40 CLL samples and co-cultured with NK.Tert stromal cells and 
measured for cell death by Annexin-PI staining at the end of 24 hr. The stroma protected 
CLL cells from endogenous cell death (Figure 18). CLL cells were co-cultured with NK.Tert 
at a ratio of 100:1. CLL cells were carefully removed and harvested at the end of 24 hrs. 
Metabolites were extracted using 80% methanol and examined by the mass spectroscopy 
core for metabolite analysis. Metabolites in CLL varied in their concentrations post co-
culture, and were categorized into different pathways according to their KEGG IDs (Figure 
19). For this analysis, the top five hits that were identified included TCA cycle, 
gluconeogenesis, purine and pyrimidine synthesis, indicating that cellular metabolism is 
affected by co-culturing CLL cells with stroma. Some of the metabolites in the listed 
pathways were augmented upon co-culture. Both, bioenergy (TCA cycle) and biosynthesis 
(purine and pyrimidine synthesis) of CLL increased, contributing to the prolonged survival of 
these cells in the co-cultures. In addition, the top hit is degradation pathway of methionine, 
whose end products, succinyl coA and pyruvate feed into the TCA cycle  
Furthermore, the metabolite analysis revealed that lactic acid levels in CLL cells were 
significantly elevated upon co-culture with stroma; this is in contrast with the results 
obtained from extracellular flux assays. Metabolite analysis also saw an increase in pyruvate 
levels (although not statistically significant), which might mean that lactic acid is getting   
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Figure 18. Effect of NK-Tert stromal cell co-culture on CLL cell survival.  
CLL cells after isolation were either cultured in suspension (Ctrl) or co-cultured with NK.tert 
cells (NK) for 24hr. The cells were stained for Annexin-PI and the results were analyzed by 
flow cytometry. The results were analyzed by a paired student’s t –test (n=40, p<0.0001). 
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Figure 19. Effect of stroma on CLL metabolic pathways.  
CLL cells from 5 patient samples were co-cultured with or without NK.Tert cells for 24hr.  
Metabolites were extracted with 80% methanol were assessed bymass spectrometry.  
Metabolites were grouped into major biochemical pathways and were analyzed using 
Ingenuity Pathway Analysis (IPA). Change in metabolite concentrations are expressed as 
stroma/suspension culture ratios. 
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converted to pyruvate. The metabolites that are synthesized by mitochondrial enzymes were 
analyzed. Orotate levels saw an increase in CLL cells post co-culture with stroma marking 
the increase in dihydroorotaate dehydrogenase activity 
I further tested for changes in energy generating pathways, glycolysis and oxidative 
phosphorylation in the presence of stroma. Three stromal cell lines were employed in this 
study. Before CLL-stroma co-culture could be assayed for extracellular flux assays, the 
number of stroma cells necessary for a proper read out for OCR/ECAR needed to be 
optimized. NK.Tert cell line is derived from human bone marrow. These cells were marked 
by no spare respiratory capacity (SRC) for oxygen consumption, irrespective of cell numbers 
plated. HS-5, another cell line derived from bone marrow, was optimized for extracellular 
flux assays (See Materials and Methods). M2-10B4 cells obtained from mouse were tested 
similarly. These two cells lines displayed higher OCR as well as SRC when compared to 
NK.Tert. 
 
 Influence of stroma on CLL glycolysis 
I first assessed the effect of stroma on glycolysis. CLL cells were co-cultured with 
NK.Tert cells for 24 hrs. Cell viability was measured in both suspension and co-culture in 
parallel cultures. These cells were assayed for glycolysis stress test (Figure 20A).  Glycolytic 
flux represents the amount of glucose the cells can metabolize after injection with 10 mM 
glucose. The third value of OCR after glucose has been injected was recorded and non-
glycolytic acidification value (obtained after addition of 2-Deoxy ᴅ-glucose) was deducted to 
obtain the value of glycolytic flux. The glycolytic flux was calculated for 29 patient samples.    
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Glycolytic capacity represents the extent to which cells can rely on glycolysis when aerobic 
ATP synthesis is disrupted by oligomycin (1.25 µM). This value was obtained in a similar 
way to that of flux-in that the third value after addition of oligomycin (or 20 minutes of 
mixing and measuring) was noted and the non-glycolytic acidification value was deducted 
from it. For all 29 patients, glycolytic flux and capacity values were obtained for CLL 
suspension, CLL-NK.Tert co-cultures and NK.Tert culture (Figure 20B-C). ECAR values 
from NK.Tert cells were deducted from the co-cultures. It is to be noted that co-cultures did 
not impact glycolysis of NK.Tert cells as no change was found in ECAR of NK.Tert cells 
assayed alone or after co-culture with CLL cells (CLL cells were removed from stroma cells 
after 24 hr). 
CLL cells from 5 patient samples were assayed in presence of stroma, without any 
prior co-culture, to determine, if cell-to-cell contact causes an immediate change in metabolic 
flux (however, the experimental set up takes 2 hr). In CLL cells, the glycolytic flux and 
capacity were overall variable but did not induce statistically significant changes after co-
culture with the NK.Tert cell line (in dotted lines, Figure 20 B-C).  
 
Effect of stroma co-culture on CLL oxidative phosphorylation 
In contrast, co-culture had a positive effect on mitochondrial respiration in CLL 
lymphocytes (Figure 21A); the 28 samples tested, either had increased basal OCR (18/28) or 
maximum respiratory capacity (MRC) (26/28) (Figure 21B-C).Basal OCR reading was taken 
before the cells were subjected to stress by addition of drugs. Basal OCR is calculated by 
taking the 3
rd
 reading, which is 21 minutes after the start of the assay and after deducting the 
non-mitochondrial respiration value (12
th
 reading, 3
rd
 after the addition of Antimycin A and   
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Figure 20. Effect of stromal cells on CLL glycolysis.  
A. CLL cells were cultured in suspension (Ctrl) or co cultured with NK.Tert (NK) in XF96 
well plates and then assayed for glycolysis. A. A representative glycolysis stress test profile 
from from a CLL patient (#9) cells in suspension culture (red curve), CLL-NK.tert co-culture 
(green curve), and only NK.tert cells (blue curve) assayed after 24 hr in culture. B. Similarly 
cultures as in figure A were assayed for either 2 hours (n = 9, dashed lines) or 24 hours (n = 
20, solid lines) and glycolytic flux was measured. C. Glycolytic capacity of 29 CLL samples, 
20 minutes after addition of oligomycin was measured. Statistical significance was calculated 
using paired student’s t-test.  
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Figure 21. Effect of stromal cells on CLL oxidative phosphorylation.  
A.CLL cells were cultured in suspension or co cultured with NK.Tert in XF96 well plates for 
24hr and then assayed for oxygen consumption. Mitochondrial stress test profile of CLL 
patient sample (#30). CLL cells in suspension culture (red curve), co-culture on stroma 
(green curve), and only NK.tert cells (blue line) were assayed. B.CLL basal OCR was 
compared after 24 hours or 2 hours (n=12) in suspension (Ctrl) versus stromal co-cultures 
(NK).  C. Similarly, CLL maximum respiration capacity was also analyzed pre– and post–co-
culture for 24 hours (n = 28). Statistical significance was calculated using paired student’s t-
test.  
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Rotenone).  MRC is the cellular respiratory capacity of complex I/II when uncoupled from 
the rate-limiting complex V.  NK.Tert cells alone showed very low OCR, and this value was 
subtracted from the reading obtained in stromal co-culture CLL cells. Furthermore, CLL cell 
addition to stromal cell culture did not affect stromal OCR (Figure 22). 
 
 The basal OCR and MRC augmentation was also observed with 2 other stromal 
lines, HS-5 and M2-10B4. CLL cells from 8 patient samples were co-cultured with M2-10B4 
and assayed for OCR (Figure 23). Similarly, cells from 3 patient samples were co-cultured 
with HS-5 (Figure 24). Co-culture with HS-5 stromal cells increased CLL OCR as well. 
Stroma-mediated increase in OCR was not due to an increase in the proliferation index, as 
CLL cells on stroma stained negative for Ki67 (not shown). 
 
Correlation between CLL prognostic factors and stroma induced OCR 
It would be interesting to investigate if stroma co-culture differently impacts CLL 
OCR in relation with prognostic markers. To start with, markers that affected OCR based on 
their expression levels were assessed. CLL samples in suspension and co-culture that are 
ZAP 70 negative (n=11), and those that are positive for ZAP 70 were analyzed (n=21). Both 
of the groups demonstrated a statistically significant increase in OCR (Figure 25A).  
CLL samples in suspension versus co-culture that are IgVH mutated (n=11) and that 
unmutated (n=19) were compared for OCR and analyzed for statistical significance using 
paired student’s t-test (Figure 25B). Both the groups showed an increase in OCR upon co-
culture.  
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Figure 22. Effect of CLL co-culture on stroma OCR.  
NK.tert cells were cultured alone (Ctrl) or with CLL cells (Post CC) for 24hrs (n=3) and 
were assayed for OCR. Statistical significance was calculated using paired student’s t-test 
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Figure 23. Effect of M2-10B4 stromal cell co-culture on CLL oxidative phosphorylation.  
CLL cells were cultured in suspension or co-cultured with M2-10B4 in XF96 well plates for 
24hr and then assayed for oxygen consumption. A. Cell mitochondrial stress test profile of 
one patient sample (#45). CLL cells in suspension (red curve), CLL-M2-10B4 co-culture 
(green line), and M2-10B4 cells (blue line) were analyzed. B. Basal OCR of 8 patient 
samples in suspension (Ctrl) or with M2-10B4 co-cultures (Str) described in A was 
compared. Statistical significance was calculated using paired student’s t-test. 
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Figure 24. Effect of HS-5 stromal cell co-culture on CLL oxidative phosphorylation.  
A. CLL cells cultured in suspension or co cultured with HS-5 in XF96 well plates for 24hr 
and then assayed for oxygen consumption. CLL cells in suspension (red curve), CLL-HS-5 
co-culture (green line), and HS-5 cells (blue line) were analyzed. B. Basal OCR of 3 patient 
samples from suspension (Ctrl) versus HS-5 co-cultures (Str) described in A was compared. 
Statistical significance was calculated using paired student’s t-test. 
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Figure 25. Differential impact of stroma on CLL OCR based on ZAP 70 status and 
IgVH mutation.  
Basal OCR of CLL cells in suspension (Ctrl) or NK.Tert co-culture were compared for 
patients based on A. ZAP 70 expression; negative (n=11), positive (n=21) B. IgVH status, 
mutated (n=11), unmutated (n=19). Statistical significance was calculated using paired 
student’s t-test. 
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 Similarly, for CLL cells from patients with benign disease (Rai stage 0,1 (n=26)), 
displayed a statistical increase in OCR upon co-culture (Figure 26A). Whereas, patients with 
advanced disease did not show significant OCR induction. Similarly, in patients with low 
serum β2M levels (<3.5μg/mL (n=12)) and high β2M levels ≥3.5μg/mL (n=24)) -B), OCR 
was upregulated upon co-culture. Patients with intermediate LDH levels showed a significant 
increase in OCR on stroma (n=18), although stroma did not induce OCR in CLL patients 
with low or high LDH levels (Figure 26C).   
Stroma upregulated OCR in CLL cells obtained from patients irrespective of gender 
and those that belong to ages 40-59 and greater than 70 (Figure 27).   Basal OCR from 
patients that are CD38 negative showed a significant increase in basal OCR upon co-culture 
with stroma, whereas the positive cohort did not (Figure 28A). Stroma modulated CLL OCR 
did not correlate with patient chromosomal abnormalities (Figure 28B). 
 
Aim 2.2. Determine if stroma regulates mitochondrial metabolism via cell-to-cell contact or 
secretion of growth factors. 
The mechanism by which stroma upregulates CLL OxPhos is unknown. Growth 
factors secreted by stroma that promote cell survival, proliferation or chemotaxis may be 
responsible for changes in oxygen consumption. To test this possibility, the minimal essential 
medium in which NK.Tert cells were grown for 24hrs was added to freshly isolated CLL 
cells and assayed for OCR after 24hr. This did not increase CLL OxPhos in the two patient 
samples tested (Figure 29). Similarly, conditioned media in which M2-10B4 cells are 
cultured did not increase OCR in CLL cells.   
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Figure 26. Differential impact of stroma on CLL OCR based on Rai stage, β2M and 
LDH levels.  
Basal OCR of CLL cells assayed in suspension (Ctrl) vs NK.Tert co-culture were compared 
based on Rai stage, β2M and LDH levels of patients. A. benign Rai stage, 0,1 (n=26), 
advanced stage 2-4(n=16) B. β2 microglobulin levels <3.5μg/mL (n=12) and ≥3.5μg/mL 
(n=24) C.LDH levels Low, (301-500) (n=9); medium (501-700)(n=18) and high (≥700) 
(n=12). Statistical significance was calculated using paired student’s t-test.  
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Figure 27. Differential impact of stroma on CLL OCR based on gender and age.  
Basal OCR of CLL cells in suspension (Ctrl) versus NK.Tert co-culture were compared for 
patients based on gender and age A. Gender, male (n=21), female (n=18); B. Age (40-59) 
n=15, (60-69) n=12, (≥70) n=12; Statistical significance was calculated using paired 
student’s t-test. 
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Figure 28. Stroma modulated CLL OCR correlation with patient chromosomal 
abnormalities.  
A. Basal OCR of CLL cells in suspension (Ctrl) versus NK.Tert co-cultures from patients 
expressing CD38 ≥20% (positive), <20% (negative). Statistical significance was calculated 
using paired student’s t-test. B. Basal OCR of CLL cells after co-culture were compared for 
patients with various chromosomal abnormalities: 11q (n = 4), 13q (n = 2), 17p deletions (n = 
2), trisomy 12 (n = 2). C.K. (n = 6) indicates complex karyotype with 2 or more these 
deletions, O indicates other chromosomal abnormalities (n = 13), U indicates unknown 
karyotypes (n = 21) were compared. Statistical significance was calculated using one way 
ANOVA p=0.68 
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Figure 29. Effect of conditioned media culture on CLL OxPhos. 
A. Basal OCR of CLL cells in suspension culture (red curve) was compared with CLL cells 
cultured in conditioning media (CM; media from stroma cultures was removed 24hr after its 
addition) from NK.Tert (green curve) or M2-10B4 cells (blue curve). B. Basal OCR of CLL 
cells (n=2) in suspension culture were compared to the cells in conditioning media; five 
technical replicates were used. 
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The possibility of growth factors secreted by stroma cells into media that could regulate 
oxygen consumption of CLL cells can be excluded. 
Stroma derived factor-1 (SDF-1), is a chemokine that binds to the CXCR4 receptor 
on the CLL cell surface and helps the cells in chemotaxis towards the bone marrow. 
Exogenous SDF-1, which is secreted as a soluble protein that activates CLL cells and induces 
proliferation and differentiation, is incubated with CLL cells from (n=2). These cultures were 
then assayed for OCR (Figure 30A).   
BAFF on the other hand, resulted in a decrease in CLL OCR (Figure 30B). SDF-1 
and BAFF were added together to CLL suspension cultures to test if they complement in 
inducing oxygen consumption. But, both the cytokines taken together did not cause any 
effect on CLL oxygen consumption (Figure 30B).  
These experiments with conditioning media and cytokines suggest that contact with 
stroma cells may be necessary to induce OCR. To test the possibility of cell adhesion causing 
the augmentation in OCR, experiments using fibronectin in place of stroma were performed.  
Fibronectin is a glycoprotein that binds to integrins in the extracellular matrix 
(Pankov and Yamada 2002). It can also be secreted by stroma cells by which CLL cells 
adhere to bone marrow/lymph nodes in vivo. CLL cells were cultured on fibronectin coated 
XF96 plates in increasing concentrations (5, 10, 15, 20µg). After 24hr, these cells were 
assayed for OCR. Fibronectin decreased CLL OCR and therefore did not mimic stroma co-
culture (Figure 31).  Furthermore, CLL cells were incubated with IgM to activate the B-cell 
signaling pathway and assayed for OCR (n=5). IgM did not result in increase in oxygen 
consumption either (Figure 32A)  
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Figure 30. Effect of chemokines on CLL oxygen consumption.  
A. CLL cells were assayed for OCR after incubation with SDF-1 (250 ng/mL) B. CLL cells 
were assayed for OCR after incubation with BAFF (150 ng/mL) or SDF-1 + BAFF for 24hr. 
Paired student’s t-test was used to calculate statistical significance. 
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Figure 31. Impact of fibronectin culturing on CLL OxPhos. 
CLL cells cultured on fibronectin coated XF96 plates for 24 hrs were assayed for OCR. A. 
CLL OCR in suspension (on cell tak) versus culture on 10 µg fibronectin. B. CLL OCR in 
suspension (on cell tak) versus culture on 20 µg fibronectin.  
B 
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Figure 32. Effect of IgM stimulation or immediate stromal contact on CLL oxygen 
consumption.  
A.CLL cells were assayed for OCR after incubation with IgM (10μg/mL) for 24hr.  B. CLL 
basal OCR was compared after 2 hours of stromal co-cultures (NK) with corresponding 
suspension cultures (Ctrl) of 12 patient samples. Paired student’s t-test was used to calculate 
statistical significance. 
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This underpins that stromal cell contact is necessary for induction of OCR. To 
confirm this, CLL cells were plated on top of NK.Tert cells, just before the beginning of the 
assay without any prior co-culture. The experimental set up takes about two hours, therefore 
CLL-stroma cells were in contact for 2hr before the assay. Induction of stromal-mediated 
CLL cell OCR increase was an early event; 11 of 12 CLL samples showed a statistically 
significant increase in basal OCR but not MRC when plated on stroma for 2 hours (Figure 
32B). 
 
Aim 2.3 Evaluate the impact of stroma co-culture on substrate uptake, ATP pools and 
mitochondrial biology, by CLL cells.  
Effect of stroma co-culture on glucose and glutamine uptake by CLL cells  
The most important building blocks necessary for cellular bioenergy and biosynthesis 
are carbon and nitrogen. Glucose is a major source of carbon, whereas glutamine provides 
nitrogen to the cell. Glucose and glutamine are also the most important substrates for ATP 
production along with fatty acids. Since, stroma promotes oxidative phosphorylation in CLL, 
it would be necessary to test if glucose or glutamine consumption to fuel OxPhos/TCA cycle 
would be enhanced as well. 
In previous studies, it has been shown that stroma co-culture activates PI3K/AKT 
signaling pathway. Active AKT signaling is related to increase in glycolysis and glucose 
uptake. From experiments in Aim 2.1, it is clear that though AKT signaling is active (it was 
demonstrated in previous studies that stroma interaction promotes AKT activation in CLL), 
glycolysis in CLL cells was not promoted, atleast in terms of conversion of glucose to 
lactate. There is a possibility that glycolysis, is in fact upregulated in presence of stroma, 
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however, glucose is converted to pyruvate and fed into the TCA cycle, instead of getting 
converted to lactate. 
To determine whether stroma co-culture may induce CLL cells to take up more 
glucose, its uptake was measured in CLL cells, 24hrs after co-culture with NK.Tert cells. The 
procedure for uptake of [H
3
]-2-Deoxy-ᴅ-Glucose assay is described in materials and methods 
section. The results were quantitated based on cell number. It was surprising that glucose 
uptake was lower after stroma co-culture, in all 7 samples measured as compared to 
suspension culture (Figure 33A). In addition, I also tested the levels of glucose transporter 
GLUT4 (commonly expressed in CLL), in CLL cells after co-culture with stroma in 11 
patient samples. There was slight increase in expression of GLUT4 in 2 of 11 samples 
(Figure 33B). 
 
Many malignant cell types have been shown to increase the catabolism of glutamine 
to supplement their increased metabolic needs and also become addicted to it (Eagle 1955);  
It may be possible that CLL cells switch their carbon source preference upon interaction with 
stroma, and therefore an alternative carbon source could be utilized. Therefore, glutamine 
uptake in CLL cells with and without co-culture on stromal cells was measured. However, 
glutamine increase was heterogeneous, as cells obtained from only 3 of 7 samples, showed an 
increase on stromal interaction (Figure 33A). As controls, CLL samples were stimulated with 
insulin (obtained from bovine pancreas) or IgM half an hour before the glucose and 
glutamine experiments. This did not impact the outcome of the experiments significantly 
(data not shown).  
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Figure 33. Effect of NK.Tert on substrate uptake and glucose transporter levels in CLL. 
A. Effect of stroma on glucose (Glu) and glutamine (Gln) uptake in CLL cells. [
3
H] 2-
Deoxy-ᴅ-glucose was used to determine the cellular uptake of the substrate in CLL cells 
(n=7) in suspension (Ctrl) or with (NK) co-culture, and analyzed for statistical significance. 
Three technical replicates were performed for suspension and co-culture. Disintegrations per 
minute (DPM)/60 min were normalized to 10
6
 cells. Similarly, [
3
H] glutamine was used to 
compare cellular uptake of the substrate in CLL cells (n=7), before and after co-culture; 
DPM/15 min were normalized to 10
6
 cells. B. Immunoblot analysis of whole-cell extracts of 
control (C) and NK.tert co-culture (N) of CLL cells (n=5) and normal lymphocytes (NL). 
Proteins were extracted and analyzed using antibodies to detect protein levels of GLUT4. 
GAPDH serves as loading control.    
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Effect of stromal co-culture on ATP production in CLL 
As OxPhos and energy production feed into nucleotide biosynthesis, levels of 
intracellular ribonucleotide pools were measured. CLL cells after 24 hr (n=12) and 48hrs 
(n=6) of co-culture with NK.Tert cells were assayed for changes in NTP pools levels. Of the 
4 ribonucleotide triphosphates, ATP (adenosine triphosphate), GTP (Guanine 
triphosphosphate), and CTP (Cytosine triphosphate) pools showed 40% increase and the UTP 
(Uridine triphosphate) pool showed a 150% increase after interacting with NK.Tert cells at 
24 and 48 hours (Figure 34A).  Endogenous concentrations were normalized as 100%. In 6 
out of 12 samples assayed post 24hrs, a significant increase in all NTP pools was observed, 
and in the rest of the samples, only a modest increase was detected. Cell viability, number 
and size were taken into consideration while calculating the NTP pools. Additionally, CLL 
cells were also co-cultured with M2-10B4 cells for 24hr and were assayed changes in NTP 
pools (Figure 34B).  There was a significant increase in all NTP pools in 4 of 5 patient 
samples measured.  
Although, an overall increase in NTP pools was not anticipated, augmentation of ATP 
pools consolidated the increase in oxidative phosphorylation of CLL after co-culture.  
 
Effect of stromal co culture on mitochondrial functionalities of CLL 
Since mitochondrial respiration increased in CLL in presence of stroma, it is likely 
that mitochondrial functionalities like generation of reactive oxygen species (ROS) and 
mitochondrial outer membrane potential (MOMP) also get affected. Therefore, changes in 
ROS and MOMP in CLL cells were measured 24 hours after co-culture by flow cytometry. 
Of the 8 patients measured for ROS, only one of them showed a significant downregulation  
  
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Effect of stroma co-culture on CLL intracellular nucleoside triphosphate 
pools. 
A.NTP pools were extracted using perchloric acid from CLL cells after 24 (n=11) or 48(n=6) 
hours of co-culture with NK.Tert cells and analyzed using high performance liquid 
chromatography (HPLC). B. Similar to A, NTP pools were extracted from CLL cells in 
suspension and corresponding co-cultures with M2-10B4 cells (n=5) after 24hr. Statistical 
significance was analyzed by using one way ANOVA.   
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upon co-culture (Figure 35A); otherwise changes in ROS levels were sparing. Similarly, no 
significant changes were observed in MOMP in suspension version co-cultures (n= 3).  
 
To test for the possibility of mitochondrial fission, changes in mitochondrial mass and 
mtDNA copy number in CLL cells upon coculture, all three were analyzed by flow 
cytometry.  Mitochondrial mass was not affected after 24 hours after co-culture (n=3)  
(Figure 35A). Similarly, mtDNA copy number was analyzed in 4 patient samples (Figure 
35B). In one sample, the copy number decreased contrary to what was expected, and rest of 
the samples recorded no major change.  
 
Effect of stromal co-culture on CLL mitochondrial complexes function and activity. 
Electron transport chain is the major physical component of oxidative 
phosphorylation. It consists of five major complexes inclusive of the ATP pump. It is 
necessary to probe for changes in the expression and activity of these five complexes. Whole 
cell extracts from CLL samples (n=6) were probed for NADH dehydrogenase (CI), succinate 
dehydrogenase (CII), (cytochrome c reductase) CIII, (cytochrome c oxidase) CIV and ATP 
synthase (CV) by immunoblotting. No major change was observed in the expression levels of 
these proteins (Figure 36A). Therefore, we next tested changes in activity of each of these 
complexes. Akin to their expression levels, there was no major change  in the ETC complex 
activity in two patient samples analyzed (Figure 36B). 
 
Effect of stromal co culture on mitochondrial biogenesis markers and uncoupling protein in 
CLL 
Parallel to the measurement of mitochondrial functionalities, CLL cells in suspension   
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Figure 35. Effect of NK.Tert on CLL mitochondrial biology and functionalities. 
A. Geometric means (from flow cytometry data) of CLL cells from 8 patient samples were 
analyzed to compare mitochondrial reactive oxygen species (ROS) (on left y-axis) before and 
after NK.tert co-culture.  Similarly, 3 patient samples were analyzed for mitochondrial outer 
membrane potential (MOMP) and mitochondrial mass (on right y-axis), before and after co-
culture. B. DNA was extracted from CLL cells from 4 patient samples that were co-cultured 
with NK.tert. qPCR analysis for CLL mtDNA from suspension culture (black bar), CLL 
mtDNA post co-culture with stroma (green bar) was performed in triplicate. The results were 
analyzed by a paired student’s t –test p=0.192. 
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Figure 36. Effect of NK.Tert on CLL mitochondrial electron transport chain protein 
expression and function.  
 
A. Immunoblot analysis of whole-cell extracts of control (C) and NK.tert co-culture (N) of 
CLL cells (n=6). Proteins were extracted and analyzed using antibodies to detect protein 
levels of all 5 mitochondrial respiratory chain complexes (I, II, III, IV, and V). GAPDH 
serves as loading control.  B. Mitochondrial respiratory complexes activity comparison in 
suspension (Ctrl) and NK.Tert co-culture in two patient samples. 
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 and co-culture were assayed for changes in expression of mitochondrial biogenesis markers 
like DNA polymerase γ (POLG) necessary for mitochondrial DNA replication and nuclear 
respiratory factor 1 (NRF1), which is a transcription factor required for mt DNA transcription 
and replication. However, immunoblot of these proteins did not depict detectable changes 
post co-culture (Figure 37A).  
Since, oxygen consumption is enhanced, mitochondrial uncoupling protein 2 (UCP2) 
levels were also measured. Uncoupling proteins dissociate ATP synthesis from oxygen 
consumption in mitochondria (Andrews et al. 2005), therefore UCP2 (isoform majorly 
expressed in B cells) levels are expected to fluctuate after stroma co-culture, since OCR as 
well as ATP levels increased. However, there was no change in UCP2 protein levels (Figure 
37B). 
 
Effect of stromal co culture on PI3K, mTOR and STAT3 pathways in CLL 
PI3K and mTOR are major players in regulating cell metabolism. Recently, the 
STAT3 pathway was implicated in affecting mitochondrial metabolism (Gough et al. 2009, 
Demaria et al. 2010). Therefore, it is required to test if these pathways are activated upon 
interaction with stroma. It is already known that PI3K/AKT pathway is activated after co-
culture. CLL cells were co-cultured with NK.Tert cells for 24hrs and were harvested to 
perform immunoblot analysis to detect the phosphorylation of AKT on Ser473, phospho-S6 
(downstream effector of mTORC1) and phosphorylation of STAT3 on Ser727. Although the 
results were heterogeneous, p-S6 levels were elevated in 6 of 11 patient samples tested 
(Figure 38). 
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Figure 37. Effect of stroma on CLL mitochondrial biogenesis markers and uncoupling 
protein 2 expression.  
A. Changes in mitochondrial biogenesis markers in CLL were probed for after stroma co-
culture. CLL cells were cultured with NK.Tert (N) cells and were harvested indicated time 
points. Proteins lysates were extracted from cells and used for immunoblot analysis of 
control (C) and NK.Tert co-culture (N) to detect expression levels of DNA Pol γ and NRF1. 
B-C. CLL cells were cultured with NK.Tert cells (N) and were harvested at 24hr. Proteins 
lysates were extracted from cells and used for immunoblot analysis to detect expression 
levels of UCP2.    
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Figure 38. Effect of stroma on activation of mTOR pathway in CLL cells. 
A-B. Immunoblot analysis of whole-cell extracts of control (C) and NK.tert co-culture (N) 
(24hr) of CLL cells (n=11). Proteins were extracted and analyzed using antibodies to detect 
activation of mTOR pathway by checking for phosphorylation of ribosomal S6 protein at 
Ser235 residue. C. Densitometry plot showing relative protein levels of p-S6/S6 protein. 
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Similarly, in spite of heterogeneity, STAT3 was activated after NK.Tert or M2-10B4 
co-culture (Figure 39). This further implies that pathways regulating metabolism are indeed 
activated upon stroma co-culture. 
As hypothesized, stroma affected oxidative metabolism in CLL cells, without causing 
major changes in glycolysis. Cell-to cell contact was necessary for this stroma-induced 
metabolic change in CLL and this phenomenon could not recapitulated by addition of 
cytokines to CLL. CLL cells saw an increase in ATP levels along with other ribonucleotide 
triphosphates upon 24hr co-culture with stroma cells. Major changes in mitochondrial 
biology were not observed in spite of increase in oxygen consumption. 
 
Aim 3. Delineating the role of PI3K/AKT axis on CLL bioenergetics 
Aim 3.1. Determine the role of PI3K pathway in regulating glycolysis and mitochondrial 
oxidative phosphorylation in CLL by pharmacologic inhibition.  
Pharmacological inhibition of the PI3K/AKT pathway diminishes CLL mitochondrial 
OxPhos. 
Prior investigations have established stroma-mediated survival benefit to CLL cells 
and induction of PI3K/AKT signaling. The PI3K axis is constitutively active in CLL cells in 
presence of the microenvironment, and many PI3K inhibitors have been developed that 
abrogate this pathway. 
Effect of duvelisib on CLL metabolism 
PI3K δ/γ inhibitor, duvelisib, is in Phase III clinical trials for CLL. I examined its 
ability to alter the OxPhos pathway in CLL cells with or without stroma.    
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Figure 39. Effect of stroma on activation of AKT and STAT3 pathways in CLL cells. 
Immunoblot analysis of whole-cell extracts of control (C) and NK.tert co-culture (N) (24 hr) 
of CLL (n= 6). Proteins were extracted and analyzed using antibodies to detect activation of 
AKT pathway by probing for phosphorylation of AKT at Ser 473 residue and STAT3 by 
probing for phosphorylation of STAT3 at Ser 727 residue. Densitometry graph of p-
STAT3/STAT3 and p-AKT/AKT B. CLL sample # 501 was co-cultured with NK.Tert and 
harvested at the indicated time points. CLL samples # 127 and 82 were co-cultured with M2-
10B4 (M) cells for 24 hr.   
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CLL cells were incubated with duvelisib (1 µM) for 24hr and assayed for cell death 
using annexin –PI staining. Modest cell death was observed with duvelisib in 40 samples 
tested (Figure 40). Then, cells were counted and equal number of untreated and duvelisib 
treated cells were assayed for glycolysis and OxPhos. Duvelisib treatment mitigated both 
glycolysis and aerobic respiration (Figure 41-42). Although, there was heterogeneity in 
reduction of basal OCR, MRC was significantly reduced upon duvelisib treatment. Similar 
extents of decline in OCR were obtained, when CLL cells were co-cultured on stroma 
(Figure 43) in 3 of 5 samples tested. 
 
Effect of idelalisib and MK2206 on CLL metabolism 
Since, duvelisib inhibits both PI3K δ and ɣ, an inhibitor of single PI3K isoform or 
downstream AKT were employed to test if they can impact overall energy metabolism. 
Therefore the effects of a PI3K δ inhibitor, idelalisib was examined, whose signaling is more 
prominent in CLL cells, in context of microenvironment. Idelalisib is approved for CLL 
therapy by the FDA. To further test whether this inhibition of metabolic pathways is AKT 
dependent, an AKT inhibitor MK-2206, was used. 
CLL cells were treated with DMSO or one of the drugs, idelalisib (1 µM) or MK2206 
(2.5 µM). Both these drugs compromised glycolysis in all 5 samples tested, without being 
cytotoxic (Figure 44). Similarly they caused a significant decline in MRC, although their 
effect on basal OCR was heterogenous (Figure 45). This suggests that inhibition of the AKT 
pathway at least in part underlies the mitigation of glycolysis and OxPhos pathways.  
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Figure 40.Effect of duvelisib treatment on survival of CLL cells in vitro. 
CLL cells untreated (DMSO) and duvelisib treated (1 μM) were incubated for 24hr and 
stained with annexin- PI and analyzed by flow cytometry. The results were analyzed by a 
paired student’s t –test (n=23, p=0.0081). Duvelisib causes minimal cell death (5-15%) at 1 
μM concentration. 
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Figure 41.Effect of duvelisib on glycolysis in CLL. 
A.CLL cells were treated with 1 µM duvelisib for 24hr (n=5) and assayed for glycolytic flux 
along with untreated controls.   B. Duvelisib treated patient samples in A were analyzed for 
glycolytic capacity (n = 5). The results were analyzed by a paired student’s t –test p=0.98. 
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Figure 42. Effect of duvelisib on mitochondrial OxPhos in CLL cells in suspension 
culture. 
CLL cells were either DMSO treated (Ctrl) or treated with 1 µM duvelisib (IPI) for 24hr and 
were assayed for OxPhos. A. Basal OCR and B. maximum respiration capacity were 
compared in control versus duvelisib treated CLL cells (n = 9). The results were analyzed by 
a paired student’s t –test. 
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Figure 43. Effect of duvelisib treatment on CLL OxPhos in presence of stroma.   
CLL lymphocytes from five patients were isolated and were either DMSO treated (Ctrl) or 
treated with 1µM duvelisib in suspension or in stroma co-culture for 24 hours and compared 
for changes in basal OCR. The results were analyzed by a paired student’s t –test between 
Ctrl vs IPI-145 (p=0.15), NK.Tert vs NK.Tert + IPI-145 (p=0.48). 
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Figure 44.Effect of idelalisib and MK2206 on CLL glycolysis.  
CLL cells untreated or treated for 24 hours with PI3K δ inhibitor idelalisib (GS, n = 5) and 
were compared for changes in glycolytic flux (A) and glycolytic capacity (B).  CLL cells 
were treated with AKT inhibitor MK2206 (MK, n = 6) and compared with untreated controls 
for changes in glycolytic flux (C) and glycolytic capacity (D). The results were analyzed by a 
paired student’s t –test p=0.98.    
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Figure 45.Effect of idelalisib and MK2206 on CLL mitochondrial OxPhos. 
CLL cells untreated (Ctrl) or treated for 24 hours with PI3K δ inhibitor idelalisib (GS, n = 6) 
and were compared for changes in basal OCR (A) and maximum respiratory capacity (B) 
Similarly, CLL cells, untreated (Ctrl) or treated for 24 hours with AKT inhibitor MK-2206 
(MK, n = 6) compared for changes in basal OCR (C) and maximum respiratory capacity (D).  
The results were analyzed by a paired student’s t –test. 
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Aim 3.2. Determine the impact of PI3K/AKT inhibition on substrate uptake, ATP 
ribonucleotide pools and mitochondrial biology in CLL.  
 
Effect of duvelisib on glucose and glutamine uptake by CLL cells  
Because glycolysis is hampered by inhibition of AKT, whose role in glucose uptake 
and utilization is well established, we hypothesized that duvelisib treatment would inhibit 
glucose uptake. Surprisingly, an assessment of the uptake of [
3
H] 2-deoxy-D-glucose 
demonstrated that glucose uptake was not significantly impacted by duvelisib treatment 
(Figure 46), which might mean, although, glucose uptake did not change, there is a 
possibility that its utilization maybe encumbered. Furthermore, glutamine uptake was not 
affected as well (Figure 46). As controls for these experiments, glucose incubated with 
duvelisib for a minimum of 4 hr (by which time, it should block the PI3K/AKT pathway) and 
stimulated with IgM or insulin for 30 minutes before addition of the radioactive compounds. 
However, this did not induce any change in glucose/glutamine uptake. 
 
Effect of duvelisib on Acetyl coA Carboxylase and fatty acid metabolism 
To test if duvelisib affects metabolism of fatty acids, which in turn, may fuel CLL 
OxPhos, Acetyl CoA Carboxylase (ACC1) were probed for phosphorylation. ACC1 is 
enzyme necessary for fatty acid synthesis. However, no significant changes were detected 
(Figure 47A). CLL cells were cultured in glucose and glutamine free media and with L-
carnitine (which helps utilize fatty acids for energy production in the cell) for 24hr ± 
duvelisib to assay for OCR. 
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Figure 46.Effect of duvelisib on glucose (Glu) and glutamine (Gln) uptake in CLL cells.  
Uptake of [
3
H] 2-deoxy-ᴅ-glucose was compared in 7 CLL patient samples, either untreated 
or duvelisib treated. Three technical replicates were performed for control and drug 
treatment. Disintegrations per minute (DPM)/60 min counted using a scintillation counter 
and the values were normalized to 10
6
 cells. Similarly, [
3
H] glutamine uptake was compared 
in 5 CLL patient samples, untreated and duvelisib treated; DPM/40 min were normalized to 
10
6
 cells. The results were analyzed by a paired student’s t –test. 
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Figure 47. Influence of duvelisib on fatty acid oxidation in CLL.  
A. Immunoblot analysis of whole-cell extracts of control (C) and duvelisib treated (I) CLL 
(n= 6). Proteins were extracted and analyzed using antibodies to detect phosphorylation of 
Acetyl COA Carboxylase on Ser79. B. CLL cells analyzed for OCR in control : BSA 
supplemented media (red curve) versus BSA conjugated palmitate supplemented media. 
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CLL cells were assayed for OCR using palmitate conjugated to bovine serum albumin 
(BSA) as the substrate (Figure 47B). CLL cells (n= 4) did not exhibit higher OCR with 
palmitate when compared to BSA only control indicating that CLL cells were not able to 
utilize extrinsic fatty acids as substrate to fuel OxPhos. 
 
Effect of duvelisib on ATP production in CLL 
Since, PI3K δ/ɣ inhibition resulted in decline in OxPhos. I next tested the effect of 
duvelisib on NTP pools. CLL cells from 7 patients were treated with duvelisib for 24hrs and 
later harvested for perchloric acid extraction. These samples were assayed for NTP pools by 
HPLC. A 25% to 50% decrease in intracellular ribonucleotide triphosphate pools was 
observed (Figure 48). Endogenous intracellular concentrations of NTP were normalized as 
100%. Decline in ATP is consistent with mitigation of OxPhos by the drug. Decrease in other 
NTP pools suggest that overall energy metabolism is affected by inhibiting PI3K pathway. 
 
Effect of duvelisib on mitochondrial functionalities and biology of CLL  
As with stroma co-cultures, mitochondrial ROS, membrane potential, mitochondrial 
mass (Figure 49A) and mitochondrial DNA copy number (Figure 49B) were assayed after 
drug treatment. None of these parameters were affected in contrast to decrease in OCR and 
ATP pools. No significant changes were observed in the protein levels or enzyme activity of 
respiratory chain complexes (I-V) after duvelisib treatment (Figure 50A-B).   
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Figure 48. Influence of duvelisib treatment on the intracellular nucleotide pools in CLL 
lymphocytes.  
NTP pools were extracted from CLL cells from blood of patients (n = 7) that were either 
untreated or treated with 1µM duvelisib for 24 hours and analyzed using HPLC.   Each 
symbol represents a patient sample.  The p-value is determined by one way ANOVA and 
dunnett’s multiple comparisons t-test of Ctrl versus each NTP pool. 
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Figure 49. Effect of duvelisib on CLL mitochondrial biology and functionalities.  
A. Geometric means of CLL cells (obtained by Flow Jo software analysis) from 7 patient 
samples were analyzed to compare mitochondrial reactive oxygen species (ROS, left y-axis) 
before and after duvelisib treatment. Similarly, 6 patient samples were analyzed for 
mitochondrial outer membrane potential (MOMP, right y-axis) and mitochondrial mass (right 
y-axis) before and after drug treatment.  B. DNA was extracted from CLL cells obtained 
from 4 patient samples , and were treated with 1 μM duvelisib for 24hr. qPCR analysis for 
CLL mtDNA from suspension culture (black bar), and post duvelisib treatment (red bar) was 
performed in triplicate. The results were analyzed by a paired student’s t –test p=0.98.    
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Figure 50. Effect of duvelisib on CLL mitochondrial electron transport chain protein 
expression and function. 
A. Immunoblot analysis of whole-cell extracts of untreated (U), DMSO (D), and duvelisib–
treated (I) CLL cells from patients (n=4) to detect protein levels of all 5 mitochondrial 
respiratory chain complexes (I, II, III, IV, and V). GAPDH serves as loading control.  B. 
Mitochondrial respiratory complexes activity comparison in suspension (Ctrl) and duvelisib 
(IPI-145) treated samples.  
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Aim 3.3. Determine the impact of genetic ablation of PIK3CD in malignant B cell lines 
Since, pharmacologic inhibition of PI3K signaling lowered OCR, genetic ablation of 
PI3K δ should cause a similar effect on cellular metabolism. Firstly, MCL cell lines, JeKo-1 
and Sp53 were assayed for glycolysis and OxPhos to evaluate if they mimic CLL cells, after 
they are co-cultured with stroma (NK.Tert) and treated with duvelisib (10 µM). Similar to 
CLL, MCL cells also displayed increased OxPhos when co-cultured with stroma and reverse 
impact was observed when treated with duvelisib (Figure 51). 
 
JeKo-1 was employed to obtain a genetic knockout (KO) of PIK3CD (coding for 
catalytic subunit p110δ). To establish a knockout cell line, JeKo-1 cells were co-transfected 
with a plasmid expressing Cas9 and a PIK3CD-targeting guide RNA for KO of PIK3CD, 
along with a plasmid for knock-in of Green Fluorescent Protein (GFP) in its position. GFP-
positive (PIK3CD KO) cells were sorted by FACS after the 3
rd
 day after transfection and 
expanded in cell culture for a week. They were analyzed for OxPhos and glycolysis, along 
with unmodified cells (WT) from a parallel culture. The PIK3CD KO cells displayed reduced 
glycolysis (Figure 52) and respiration levels (basal OCR and spare respiratory capacity) as 
compared to the WT (Figure 53; n=3,p=<0.0001).The PIK3CD KO did not result in decrease 
in cell proliferation rate or size as compared to WT (Figure 54). The PIK3CD KO cell line 
was further validated for KO by RT-PCR.  
 
PI3K signaling is very critical for survival of cells as another cell line Ly19 (diffuse 
large B cell lymphoma employed for PIK3CD KO did not proliferate after FACS and thereby 
the cells did not survive in culture for more than 4 days.  
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Figure 51. Effect of stroma and duvelisib on OxPhos in mantle cell lymphoma cell lines. 
A. JeKo-1 cells which were co-cultured with NK.Tert (N) or treated with duvelisib (I) in 
presence or absence of NK.Tert, were assayed for OxPhos along with untreated controls (C). 
B. Sp53 cells, co-cultured with stroma or treated with duvelisib (I) in presence or absence of 
NK.Tert, were assayed for OxPhos along with untreated controls (C). n=3 biological 
replicates for each treatment with both cell lines. Statistical significance was calculated using 
paired student’s t test between the specified groups. 
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Figure 52.  Impact of PIK3CD knockout on glycolysis in mantle cell lymphoma cell line. 
JeKo-1 wild –type (WT) and PIK3CD KO cells were analyzed for (A) glycolytic flux and 
(B) glycolytic capacity (n=4 technical replicates and biological triplicate). Student’s paired t-
test was used in the statistical analysis. 
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Figure 53.Impact of PIK3CD knockout on mitochondrial OxPhos in mantle cell 
lymphoma. 
JeKo-1 wild –type (WT) and PIK3CD KO cells were analyzed for (A) basal OCR and (B) 
spare respiratory capacity (n=4 technical replicates and biological triplicate. Student’s paired 
t-test was used in the statistical analysis. 
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Figure 54. Comparison of cell proliferation and cell size of JeKo-1 wild type versus 
PIK3CD knock out cells. 
A.WT and PIK3CD KO JeKo-1 clones were plated at a concentration of (2×10
5
)/mL in 
RPMI 1640 media supplemented with 10% FBS and 1% penicillin-streptomycin solution on 
day 1 and the cell numbers were measured on days 2, 3, 4 and 5. B. Under similar conditions 
to A, median cell size was recorded on days 2, 3, 4, 5. 
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To elucidate the impact of B cell receptor signaling in regulating CLL metabolism, 
JeKo-1 cell line was employed to create BCR KO (CH2 region of heavy chain IgM). Three 
clones of BCR KO, MC4, MC5 and MC6 were generated. BCR KO along with WT cells 
were tested for OCR. BCR KO clones similar to PI3KCD KO cells displayed reduced 
OxPhos levels (Figure 55). They did not differ from wild type JeKo-1 cells in proliferation 
rate or cell size (Figure 56).Immunoblotting further confirmed that AKT signaling (p-AKT 
Ser 727) and MAPK signaling (p-MAPK 44/were mitigated upon serum starvation and 
stimulation with IgM (Figure 57). These results substantiate the importance of B cell receptor 
pathway and PI3K signaling in regulating CLL metabolism.  
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Figure 55. Impact of BCR knockout on mitochondrial OxPhos in mantle cell 
lymphoma.  
 JeKo-1wild –type (WT) and BCR KO clones (MC4, MC5, MC6) were analyzed for basal 
OCR (A) and spare respiratory capacity (B) using extracellular flux analyzer (n=6) technical 
replicates and biological triplicate). One-way ANOVA with multiple comparisons was used 
to compare control values with that of KO.  
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Figure 56. Comparison of cell proliferation and cell size of JeKo-1 wild type versus 
BCR knock out clones.  
BCR wild type (WT) and three BCR KO JeKo-1 clones (MC4, MC5, MC6) were plated at a 
concentration of (2×10
5
)/mL in RPMI 1640 media supplemented with 10% FBS on day 1 
and the cell number (A)  and median cell volume (B)  were measured on days 2, 3, 4 and 5. 
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Figure 57. Impact of BCR knockout on BCR signaling in mantle cell lymphoma cell 
line.     
Immunoblot analysis of BCR pathway proteins from whole-cell extracts of JeKo-1 WT and 
three BCR KO clones ± IgM stimulation. WT and BCR clones were serum starved (RPMI 
1640 media supplemented with 0.5% serum) for 2 hr followed by addition of 10 μM IgM for 
20 min.  The p-AKT Thr308 and total AKT were probed using antibodies from two different 
species.  The p-MAPK p(44/42) Thr202/Tyr204 and total MAPK were probed using 
antibodies from two different species followed by GAPDH immunogenicity.    
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CHAPTER 4. DISCUSSION 
Cancer cells have high energy demands owing to their rapid proliferation rates. 
However, in CLL, the malignant B cells are mature and arrested in the G0 stage of the cell 
cycle. In some cases, stimulus from the microenvironment (lymph node) may lead to their 
proliferation, otherwise, they remain quiescent. As a result, CLL is not an attractive model to 
study the rewiring of metabolism in malignant neoplasms. Not many studies have been 
conducted to decipher the bioenergetic profile of CLL B cells. Although, CLL cells may not 
actively proliferate, they need bioenergy for survival and sustenance.  
 
CLL vs normal lymphocytes metabolism 
CLL literature may not be replete with studies on metabolism, however, there were a 
few reports in 60s and 70s that showed glucose uptake is reduced in CLL when compared to 
normal B cells, indicating that glycolysis is not a major pathway in CLL cell metabolism 
(Brody et al. 1969, Brody and Merlie 1970). In contrast to what was reported earlier, recent 
findings demonstrated an increase in glycolytic intermediates, 2-phosphoglycerate and lactic 
acid along with increase in glutamine metabolism and TCA cycle intermediates in indolent 
and aggressive CLL cases in which miR-125b is overexpressed (Tili et al. 2012).  Another 
study characterized the transcriptome of CLL cells and found that genes involved in 
metabolic pathways were upregulated in CLL cells compared with normal lymphocytes in a 
cohort of 98 patients (Ferreira et al. 2014). Ingenuity pathway analysis of this study’s data 
revealed that activity of mTOR and PI3K/AKT signaling pathways are elevated in CLL cells 
compared to normal B cells. Jitschin et al, demonstrated that CLL cells compared to normal 
B cells displayed increase in mitochondrial respiration in 4 samples (Jitschin et al. 2014). The 
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above studies indicate the upregulation of energy generating pathways in malignant B 
lymphocytes compared to normal lymphocytes.  
 
I performed a comprehensive study, encompassing the metabolic phenotype of CLL 
cells, its association with prognostic features, the effect of stroma and role of PI3 kinase.  
The present study evaluates the metabolic characteristic of freshly isolated malignant 
lymphocytes from peripheral blood of 41 CLL patients. Glycolysis and Oxidative 
Phosphorylation, the two major pathways contributing to cellular bioenergy (ATP) have been 
measured. These malignant B lymphocytes are oxidative in their phenotype and overall 
metabolically less active than normal B cells (Figure 1). Metabolic activities reported in CLL 
cells are synchronized as all the cells are arrested in G0 phase of cell cycle.  
 
Mitochondria in CLL 
Mitochondria play a significant role in energy metabolism. Mitochondrial genome in 
CLL is very stable with hardly any mutations detected (Cerezo et al. 2009). Mitochondrial 
DNA (mtDNA) is more vulnerable to DNA damage than nuclear DNA, due to the lack of 
histone proteins (Caron et al. 1979, DeFrancesco and Attardi 1981). In CLL, heteroplasmic 
mutations were detected in mtDNA post chemotherapy, esp. with the use of alkylating 
agents. A study reported that patients who did not respond to chemotherapy had higher 
number of mtDNA mutations (in cytochrome c oxidase) resulting in excess ROS generation, 
than patients that responded to therapy (Carew et al. 2003). ROS is a byproduct of 
mitochondria ETC; therefore it becomes necessary to study changes in ETC in a complex 
disease like cancer.  
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A recent study reported increase in expression of molecules involved in 
mitochondrial biogenesis; e.g., TFAM was upregulated in CLL cells compared to normal B 
cells along with mitochondrial respiration (Jitschin et al. 2014). The same study also reported 
that ROS is overproduced in CLL as result of increased mitochondrial activity, suppressing 
the activity of T cells. Additionally, another group reported that free oxygen radicals in cells 
are heterogeneous among patients with CLL but significantly higher in CLL cells from 
patients with prior chemotherapy (Zhou et al. 2003).  Also, increase in mtDNA copy 
numbers was associated with increased risk of CLL (Hosnijeh et al. 2014).  
However, I did not find significant change in mitochondrial ROS levels post co-
culture with stroma or treatment with PI3K inhibitor, duvelisib (Figure 35, 49). I tested for 
changes in mtDNA copy number and mitochondrial mass; however, no major changes were 
found in either (Figure 35, 49). Also, no changes were found in mitochondrial biogenesis 
markers like NRF1 and DNA pol γ in CLL post co-culture with stroma. 
 
CLL metabolism correlates with prognostic factors of the disease 
According to a recent meta-analysis to come up with suitable prognostic markers for 
CLL globally; in which a comprehensive analysis of 26 prognostic factors in 845 patients 
was evaluated. IgVH mutation status, Rai stage, age and β2M and cytogenetic deletions –
TP53 were considered independent prognostic markers. 
 
ZAP 70 and CLL OCR 
ZAP 70 is present on T cells and is involved in signaling and activation. ZAP 70 has 
two SH2 containing domains and a carboxyl terminal domain. ZAP 70 is recruited by 
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immunoreceptor tyrosine-based activation motif (ITAM) after T cell receptor encounters an 
antigen. Multiple tyrosine residues in ZAP 70 are phosphorylated upon recruitment that acts 
as docking sites for downstream signaling molecules. One among them is PI3K regulatory 
subunit p85 (Moon et al. 2005). However, the mechanism by which ZAP 70 activates B cell 
receptor signaling is still unclear; even when ZAP 70 is insufficiently phosphorylated in CLL 
cells, it still recruits and activates its downstream effectors. CLL cells that express high levels 
of ZAP 70 are reported to have increase in tyrosine phosphorylation in the BCR complex 
after BCR crosslinking (Chen et al. 2002). CLL cells from different patients differ in their 
ability to respond to BCR crosslinking and this is said to be related to ZAP 70 expression 
(Gobessi et al. 2007). However, it is to be noted that ZAP 70 is not present on normal B cells 
and their B cell signaling is intact.  A study reported that ZAP 70’s role in malignant B cell 
signaling is different from T cell signaling, as its activation in CLL cells upon B cell 
stimulation is inefficient. However, it was reported to amplify BCR signaling for a long time 
(Gobessi et al. 2007). It is postulated that it may act as an adaptor protein, recruiting the 
proteins necessary for formation of signalosome. ZAP 70 activates BCR complex even in the 
absence of SYK, which is another tyrosine kinase that serves a similar function. IgM ligation 
of BCR complex in ZAP 70 positive patients’ results increased phosphorylation of in SYK, 
BLNK, and phospholipase-C γ and boost calcium flux (Chen et al. 2005). 
Induction of calcium levels in the mitochondrial matrix is linked to the increase in 
ATP production by OxPhos (Jouaville et al. 1999). In the present study, OxPhos is higher in 
the ZAP 70 positive cohort as compared to the negative cohort. This can be linked to 
amplified BCR signaling leading to increased cell metabolism as the BCR knockout cells 
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displayed lower mitochondrial respiration when compared to wild type cells of mantle cell 
lymphoma cell line.  
Gene expression profiling of CLL identified an upregulation of lipoprotein lipase 
(LPL) levels, an enzyme central to lipid metabolism (Klein et al. 2001). A follow up study 
revealed the correlation between LPL and ZAP 70 expression and IgVH status (Heintel et al. 
2005), proposing it as a diagnostic target in CLL. High levels of LPL correlated with shorter 
progression free survival. 
 
IgVH and CLL OCR 
Among the molecular markers that are employed in risk stratification analysis for 
CLL is the mutational status of immunoglobulin heavy chain (IgVH) (Pflug et al. 2014). 
Earlier studies established that unmutated IgVH was associated with more aggressive disease 
(Hamblin et al. 1999), high CD38 expression (Damle et al. 1999) and correlated with ZAP 70 
expression (Figure 58) (Wiestner et al. 2003, Rassenti et al. 2004). Patients with unmutated 
IgVH genes had far inferior median survival than patients with mutated IgVH genes (Oscier 
et al. 2002). 
The heavy chain of the antibody is encoded by genetic elements that are rearranged 
during B-cell development (Tonegawa 1983, Yancopoulos and Alt 1986). One of several 
diversity (D) segments combines with one of six joining (JH) gene segments to form a novel 
DJH segment. Rearrangement of this DJH segment with one of several immunoglobulin 
heavy chain variable region (VH) genes generates a VHDJH gene complex that encodes the 
variable (V) region of the immunoglobulin (Ig) heavy chain.  
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Figure 58. Signaling in CLL cell based on IgVH mutation status and ZAP 70 
expression. 
CLL cells that do not undergo gene rearrangements leading to IgVH mutations commonly 
express high ZAP 70 levels and therefore are classified as IgVH unmutated and ZAP 70 
positive. They have enhanced BCR signaling compared to their counterpart (depicted on the 
left), along with expression of CD38. 
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The combination of VH, D JH is said to be a non-random process in CLL. It was 
discovered that the VH regions expressed in CLL are attained from a restricted reservoir (of 
VH genes) used during B cell development (Kipps et al. 1989). Along with co-stimulatory 
molecules, IgVH impacts cell survival, proliferation and differentiation through signaling. 
Somatic mutations indicate the antigen exposure of B cells. Mutations occur in the antigen 
binding site of the variable region. High rates of somatic mutations are said to occur in B 
cells in germinal centers as clonal evolution occurs within these centers. Once the cells leave 
the germinal centers the VH expression is reported to be relatively stable. IgVH mutations 
give an insight into the ontology and pathogenesis of the malignant B cells and therefore, the 
study of IgVH is of importance (Schroder et al. 1996). Gene expression profiling in IgVH 
unmutated versus mutated patients, identified many genes that differentially expressed in 
these 2 subsets of CLL. The expression of genes involved in metabolism like glutathione 
synthase, HPRT, and nucleotide phosphorylases and translocators was markedly upregulated 
in Ig unmutated cases (Rosenwald et al. 2001). Additionally, PI3K and CCND2 (cyclin D2) 
genes were overexpressed in the unmutated cohort (Kienle et al. 2006). 
 
In the current study, cells from IgVH unmutated CLL cases displayed higher OCR 
than unmutated cases (Figure 13C). Unmutated IgVH usually co-occurs with high expression 
of ZAP 70 and CD38 markers (Wiestner et al. 2003, Rassenti et al. 2004). Patients with these 
markers have markedly decreased progression free survival. IgVH unmutated samples 
displaying significantly higher OCR, which may reflect on its association with ZAP 70 
expression as ZAP 70 positive CLL cases also displayed high OCR aggressiveness of this 
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subtype of CLL.  This observation is also in concert with increased expression of enzymes 
involved in metabolic activity in IgVH unmutated CLL. 
 
Rai stage and CLL OCR 
Rai is the most commonly used grading system for CLL progression. This system 
considers lymphadenopathy, organomegaly, anemia, and thrombocytopenia to classify 
patients into one of five stages, stage 0, I, II, III and IV.  Median survival for stage 0 is 
around 12 years and for advanced stages III-IV is 19 months. Treatment plan for patients are 
decided based on staging.  
CLL patients were classified as stage 0 if they harbored high lymphocyte counts, 
stage I- lymphomegaly, stage II enlargement of spleen or liver, stage III – anemia and stage 
IV thrombocytopenia. Advanced disease also has neovasculature in bone marrow and lymph 
nodes along with increased secretion of VEGF and bFGF (Menzel et al. 1996, Kini et al. 
2000).  A previous study reported that metabolic responses of CLL to hypoxia and glucose 
consumption correlated with the stage of disease (Koczula et al. 2015). This group also found 
that CLL cells from patients’ samples (n=6) that were in early stage of the disease (Binet A0) 
were marked by low glucose and glutamine consumption and similarly, low lactate 
production. 
In the present study, increased mitochondrial respiration (OCR) was observed at 
higher Rai stage in a pool of 51 patients (Figure 14A). Since, higher OCR was corresponding 
with markers of aggressive disease; therefore, increased oxygen consumption rates can act as 
a surrogate for aggressive disease. 
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A caveat of working with primary CLL cells is that, in suspension cultures, these cells 
are not supported by the microenvironment, as in the human body; therefore, the extent to 
which the their cell metabolism would represent that of the cells in the original state (human 
body) is in question. Although cell death was measured and only samples with highest 
percentage of live cells were incorporated in the study, the fact that these cells are on the path 
to apoptosis cannot be discounted.  The time transpired between collection of blood from the 
patients and isolation of the CLL lymphocytes would also likely affect the cell survival and 
behavior. 
Correlation between CLL patients’ age and glycolysis 
According to the study by Rai et al, age differences among patients with different 
stages of disease was statistically significant with stage 0-II patients younger than stage III 
patients. This is relatable as CLL progresses with time. Also, chances of survival post 
therapy declined with age. Therefore, when CLL glycolysis and OxPhos were analyzed for 
correlation with age, glycolysis (ECAR) displayed a significant increase in patients of older 
age (Figure 16B). This observation could be further elaborated by selecting patients from 
different age groups (early stage and comparatively young patient and advanced stage and 
older patients) and test how they would respond to insulin stimulation and glycolysis 
inhibition. 
Lactate dehydrogenase (LDH) is a glycolytic enzyme that converts lactate to 
pyruvate. High levels of LDH in serum are an indicator of tissue damage. Studies 
demonstrated that high LDH levels correlated with CLL patients with shorter median 
survival (Itoyama et al. 2001). Tumor aggressiveness is directly proportional to serum LDH 
levels (Dumontet et al. 1999). LDH levels greater than 500 µg/mL correspond with poor 
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prognosis in CLL. However, a recent study reported that LDH levels may not be reliable 
surrogate marker for disease prediction (Bergmann et al. 2007). In the present study, CLL 
oxygen consumption rates did not vary significantly between patients in with normal and 
high LDH groups. 
 
Beta-2-microglobulin (β2M) is a membrane protein (12 kDa) associated with the 
heavy chains of class I major histocompatibility complex proteins. It belongs to 
immunoglobulin superfamily. β2M is implicated in chemotaxis and suppresses immune 
response from T cells (Bernier 1980). However not much is known in term of its signaling 
and function. The presence of high levels of β2M, another poor prognostic feature (Hallek et 
al. 1996, Pflug et al. 2014), also showed a trend for increased OCR (Figure 15A).  
 
  Gender is also considered for prognosis in CLL. Previous studies showed that 
females fared better in response to therapy than male counterparts (Berger et al. 1978, Kelly 
et al. 2011, Robitaille et al. 2013). However, the reason behind the better prognosis of 
females remains unclear. CLL is also more common in men than women. In fact, a gender 
based score system was developed by GIMEMA, since, changes in progression free survival 
for CLL patients correlated only with gender (Kienle et al. 2006). This group also reported 
that females had an indolent disease course as IgVH mutations were frequent in this cohort 
and 17p and 11q deletions was less frequent this subgroup. CLL OxPhos did not vary in both 
male and female subsets of CLL. 
CD38 is an ectoenzyme, present on the cell surface. It is also known as cyclic ADP 
ribose hydrolase that hydrolysis of cyclic ADP-ribose from NAD+ to ADP-ribose. It 
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regulates cell adhesion, signal transduction, and calcium regulation (Malavasi et al. 1994). 
CD38 is able to metabolize extracellular nucleotides, e.g., ATP and NAD, into nucleosides 
that can be taken up by cells (Aarhus et al. 1995). Increased CD38 expression, along with 
increased vascular density in lymph nodes, correlates with increased lymphocyte 
proliferation and disease progression. CD38 is used to distinguish B cells at various stages of 
differentiation (Shaik et al. 2008). As a result, CD38 expression inversely correlates with 
mutational status of IgVH, i.e., CLL B cells with elevated expression of CD38 (>20%) have 
unmutated IgVH. CD38 data was not available for most of the patients used in the present 
study. Out of the available patients’ samples, 13 had low levels of CD38 (negative) and 8 had 
high levels (positive). Due to the limited sample size, not much variation in OCR was seen 
between the two groups (Figure 17A). 
 
CLL cytogenetics and metabolism 
Genetic mutations, indels and rearrangements also dictate the course of treatment. 
Deletion of TP53 (tumor suppressor 53) located on chromosome 17q and ATM (Ataxia –
telangiectasia mutated) are related with poor clinical response of the disease. While, TP53 is 
the master tumor suppressor which regulates cell cycle progression and apoptosis, ATM 
functions primarily in DNA repair (Banin et al. 1998, Canman and Lim 1998). Trisomy 12 is 
another common genomic aberration in CLL. These deletions are not common in untreated 
CLL, but arise as a result of chemotherapy. Therefore, treatment for CLL after its first onset 
and reoccurrence would be based on the percent lymphocytosis and genetic aberrations. 
Clonal evolution does take place in CLL, to sustain activated signaling and become 
refractory to therapy. Mutations in SF3B1 (splicing factor 3B subunit 1) and XPO1 (exportin 
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1) are other new markers identified by exome sequencing that result in diminished response 
to therapy (Dohner et al. 2000, Landau et al. 2013, Ferreira et al. 2014). 
 
TP53 negatively regulates cancer cell metabolism, therefore deletion of this gene, 
should alleviate the negative regulation on metabolic targets. However, the deletion of this 
genetic locus occurs least frequently (Dohner et al. 2000). Genetic deletion on chromosome 
13q harboring retinoblastoma (RB) gene has very good clinical outcome, although patients 
with a higher percentage of nuclei exhibiting a 13q deletion had short survival (Cerezo et al. 
2009). It is also the most common cytogenetic anomaly in CLL. Not many patient samples 
were available for the present study to evaluate the effect of a single genomic aberration on 
CLL OxPhos. Four patients harboring one or more of these cytogenetic abnormalities have 
relatively high OCR, but it is difficult to arrive at a conclusion in cases, as in most other 
patients the mutations are relatively insignificant or unknown (Figure 17B). 
 
Microenvironment and CLL metabolism 
Relapse rates for CLL are high in spite of promising targeted therapies (Ding et al. 
2014). The primary reason for relapse is due to the residual disease in the bone marrow and 
lymph node compartments. Microenvironment confers protection to CLL by activating the 
signaling pathways in CLL and helps in survival, proliferation, chemotaxis, metabolism and 
angiogenesis. Microenvironment in CLL is diverse and contextual in different compartments, 
mainly, bone marrow (BM), lymph node (LN) and peripheral blood (PB). As discussed in the 
introduction, several cell types offer protection to CLL cells namely, bone marrow stroma 
cells, nurse-like cells, macrophages and T cells. Crosstalk between CLL cells and adjacent 
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cells take place by direct contact (adhesion molecules) or by secretion of cytokines into the 
extracellular matrix (ECM). Studies reported that CLL gene expression varies in depending 
on their location. CLL cells also proliferate in the germinal centers of BM and LN not in PB. 
CCL3 and CCL4 are secreted by CLL upon activation of BCR pathway which homes 
monocytes and T lymphocytes. High levels of CCL3 correlate with prognostic markers of the 
disease. Activation of BCR pathway leads to raised CCL3 and CCL4 levels (Burger et al. 
2009, Herishanu et al. 2011). 
 
A number of cell lines derived from human bone marrow as well as mouse bone 
marrow are employed for studying CLL- stroma interactions in vitro. These are NK.Tert, HS-
5 (human), M2-10B4, KUSA-H1, KUSA (mouse). These cells mimic the stroma cells in vivo 
and provide survival advantage to CLL cells. Integrins α, β are adhesion molecules that 
mediate cell to cell interactions. Intergrin CD49d is a receptor for fibronectin and vascular 
cell adhesion molecule 1 (VCAM1). These integrins are expressed on most lymphocytes and 
mediate lymphocyte trafficking and immune surveillance (Butcher and Picker 1996). CLL B 
cells also adhere to bone marrow or lymph nodes via these integrins.  
 
There is minimal understanding of interactions between CLL and its 
microenvironment in terms of metabolism. Therefore, studying the metabolic characteristics 
of CLL cells in context of microenvironment is critical. With exception of studies conducted 
by Huang’s group (Zhang et al. 2012) and Mougiakakos’s group (Jitschin et al. 2015), not 
many studies have been conducted to elucidate the metabolic responses and rewiring in CLL 
cells with context with microenvironment. Jitschin et al. reported that stroma cells modulate 
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CLL metabolism by upregulating glycolysis and genes involved in glycolytic pathway in a 
NOTCH- MYC dependent manner (Jitschin et al. 2015). They found overexpression of 
GLUT3 transporters on CLL cell surface, followed by increased ECAR post 6 day co-culture 
of 4 CLL samples with HS-5 (bone marrow derived stroma cells).However, ECAR levels 
observed in the CLL cells co-cultured with stromal cell lines and mesenchymal stroma cells 
obtained from patient biospies varied significantly. Although, glycolysis in the CLL cells  
increased with stroma in both the cases, the ECAR levels of CLL cells co-cultured with 
patient stromal cells was 10 fold lower as compared with cell lines. Furthermore, prolonged 
co-culture with stroma cells will generate nurse like cells and therefore changes the dynamics 
of CLL-stroma interaction (Burger et al. 2000). And with such few patients’ samples, that 
were used in the Jitschin et al. study, it is hard to discern if glycolysis is upregulated in CLL 
cells upon stromal co-culture. 
Zhang et al. demonstrated that CLL cells were dependent on stromal cells to import 
cysteine and synthesize glutathione, an antioxidant to relieve endogenous oxidative stress. 
The CLL cells have limited ability to take up cystine. After stroma cells take up cystine and 
convert to cysteine, CLL cell utilize the cysteine and synthesize glutathione (Zhang et al. 
2012). These studies demonstrate the dependence of CLL cells on stroma for survival. 
 
Several approaches used in the current study demonstrate that stroma interaction 
elevates mitochondrial respiration in CLL cells. Almost all samples displayed an increase in 
the OCR after 24-hour co-culture with NK.Tert cells. However, changes in glycolytic flux 
were variable when CLL were co-cultured with stroma and overall not significantly induced. 
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Co-culture with two other stromal cell lines recapitulated the effect on CLL the OCR and 
ECAR.  
I also tested the impact of prognostic factors on stroma induced OCR.  Owing to the 
overall increase in OCR across the patient samples tested, no differential impact on OCR was 
observed based on the expression levels of prognostic factors (Figures 25-28). Nonetheless, 
patients with low and high LDH levels did not display a significant increase in OCR upon 
stroma co-culture, in contrast to patients with medium LDH levels (Figures 26C). Similarly, 
patients of ages 60 to 69 did not exhibit significant increase in oxygen consumption (Figures 
27B). 
One of the main axes that is studied in bone marrow-CLL interactions is of CXCR4-
CXCL12. Stroma derived factor 1(SDF-1/CXCL 12) is secreted by stromal cells and 
interacts with the CXCR4 receptor overexpressed on the CLL cell surface. ZAP 70 positive 
cells respond better to SDF-1 signaling which mediates chemotaxis towards BM/LN. This 
also results in migration of CLL cells beneath the stromal cell known as 
‘pseudoemperipolesis’ (Burger et al. 1999). Additionally, SDF-1 protects CLL cells from 
undergoing spontaneous apoptosis. SDF-1 activates AKT and MAPK signaling pathways in 
CLL. Since, contact with bone marrow stroma cells upregulated OCR; I also tested if 
incubation with SDF-1 will recapitulate the response. Nevertheless, SDF-1 treatment did not 
augment CLL metabolism. 
 
Similarly, the effect of B cell activating factor (BAFF) was also tested in inducing 
CLL OxPhos. BAFF is secreted by nurse like cells and promote CLL survival via paracrine 
signaling. BAFF-R, BCMA and TACI are the receptors for BAFF expressed on CLL. BAFF 
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belongs to the tumor necrosis family (TNF). It activates NF-κB and increases the expression 
of anti-apoptotic protein MCL-1 and promotes CLL cell survival. Incubation with BAFF for 
24 hrs had a negative impact on oxygen consumption, contrary to what was expected. BAFF 
decreased CLL OCR, even in combination with SDF-1. The reason behind the decrease is 
unknown. These experiments further indicate the necessity of cell to cell contact for 
augmentation of OxPhos. This phenomenon of stroma induced CLL OCR is relatively quick, 
happens within 2 hrs of co-culture with stroma (Figure 32B). Nevertheless, CLL cells from 
two patient samples tested displayed higher levels of spare respiratory capacity after 24hr co-
culture with stroma as compared to 2hr co-culture. And this may mean longer exposure to 
stromal cells may be necessary for CLL for mitochondrial respiration to be further elevated. 
 
PI3K/AKT pathway regulates CLL metabolism 
In concert with many previous studies, co-culture with stroma activated PI3K/AKT 
pathway, identified by phosphorylation of AKT (Figure 39A). Similarly, mTOR signaling 
pathway was also active determined by the phosphorylation of ribosomal S6 protein (Figure 
38). PI3K is a lipid kinase that is most commonly activated in CLL. Mutations in the genes 
coding for PI3K isoforms are rare in CLL. Although infrequent, PIK3CA mutations (gene 
amplifications) are identified in 3.5% CLL cases (Brown et al. 2012). However, PI3K α is 
not the major player, when it comes to hematological malignancies; the delta isoform is the 
predominant active signaling molecule of this family.  
PI3K/AKT/mTOR is a crucial regulatory pathways of cellular metabolism. In 
addition, PI3K can regulate metabolism in an AKT independent manner by activating MAPK 
(Mitogen activated protein kinase). MAPK is activated in CLL cells upon stromal interaction 
 
 
143 
 
by phosphorylation at Thr 44/42 residue (Balakrishnan et al. 2014). MAPK further activates 
p90RSK which in turn phosphorylates ribosomal S6 protein which regulates translation. 
MAPK can activate early response genes like c-MYC and c-FOS and thereby regulates 
transcription as well. c-MYC regulates glutamine uptake and genes involved in pyrimidine 
de novo synthesis (Huang and Graves 2003), cell cycle transition, e.g., E2F1. To be 
completely activated, AKT needs to be phosphorylated on Ser 473 by mTOR after initial 
activation by PDK1 on Thr 308. After both these sites are phosphorylated, AKT affects its 
downstream molecules.  
The most well studied mode of PI3K signaling is through its ability to activate AKT. 
To be completely activated, AKT needs to be phosphorylated on Ser 273 473 by mTOR after 
initial activation by PDK1 on Thr 308. After both these sites are phosphorylated, AKT 
affects its downstream molecules. AKT plays an important role in cell proliferation by 
modulating numerous factors affecting cell growth. First, it regulates glycogen synthase 
kinase β (GSK3β) and cyclin dependent kinase (CDK) inhibitors. AKT can also directly 
boost ribosome biogenesis independent of TOR, thus promoting growth and proliferation 
(Chan et al. 2011). As mentioned in the introduction, AKT regulates insulin mediated 
glucose uptake and metabolism by trafficking glucose transporters to the cell membrane 
(GLUT1, GLUT4) and influencing the activity of the key enzymes of the glycolytic pathway  
including hexokinase and phosphofructokinase. 
In the present study, neither glucose uptake nor the expression levels of the 
transporter, GLUT4 were augmented in CLL cells after stromal interactions. In fact, glucose 
uptake was markedly reduced in all samples, implying decreased dependence on glucose in 
CLL in context of microenvironment. However, additional studies need to be performed to 
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verify the reason behind decreased metabolic flux. Likewise, glutamine uptake was not 
particularly elevated in CLL cells post co-culture, although there was heterogeneity. 
AKT was also shown to regulate the activity of mitochondrial electron chain 
complexes via 4E-BP-1. Downregulation of 4E-BP-1 activity by AKT increased the activity 
of all the respiratory complexes (Goo et al. 2012). Increase in the expression or activity was 
not found in CLL cells post co-culture, indicating that increased respiration is not due to 
amplification of ETC expression and activity (Figure 36). 
 
AKT and nucleotide biosynthesis 
AKT also regulates purine nucleotide biosynthesis. There are very few studies that 
evaluated nucleotide metabolism in CLL cells in comparison with normal cells (Henderson et 
al. 1974, Carlucci et al. 1997). Nucleotide metabolism provides precursors for both RNA and 
DNA synthesis. Therefore, it important to determine how the pathways of their synthesis are 
regulated. In case of CLL, the nucleotide pools are not directed towards DNA synthesis, as 
the latter does not take place as the cells are in a resting phase (Berger et al. 1978). In 
contrast, precursors for RNA synthesis are expected to increase, as RNA synthesis increases 
in CLL upon co-culture with stroma. AKT regulates phosphoribosylpyrophosphate (PRPP) 
production by the non-oxidative pentose phosphate pathway and also modulates the activity 
of aminoimidazole-carboxamide ribonucleotide transformylase (AICAR Transformylase), 
and inositide mono phosphate cyclohydrase (IMP cyclohydrase). IMP is center point of the 
de novo and salvage pathway of purine synthesis. Metabolite analysis has revealed that 
inosine levels increased in CLL cells after CLL co-culture with stromal cells, implying a 
increase in the metabolic flux of purine synthesis. In concordance, the rise in adenosine 
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monophosphate (AMP) and guandine monophosphate levels (GMP) signifies that purine 
synthesis is augmented in presence of stroma. IMP directly feeds into AMP synthesis and 
IMP is converted to xanthosine monophosphate before conversion to GMP (Henderson and 
Paterson 1973).  
On the basis of the augmentation of the OCR after co-culturing with stroma, the 
cellular ATP pool in CLL lymphocytes might increase. As expected, in concert with 
increased OxPhos, ATP pools increased as well. Increase in the other nucleotide pools (CTP, 
GTP and UTP can be explained by altered enzymatic activity of purine and pyrimidine 
biosynthesis pathways.  
Pyrimidine synthesis on the other hand is linked to mitochondrial ETC, by the 
enzyme dihydro orotate dehydrogenase (DHODH) that resides in the inner mitochondrial 
membrane, the only enzyme in that pathway that is located in the mitochondria (Figure 59). 
It reduces ubiquinone to ubiquitol and converts dihydroorotate to orotate (Jones 1980). 
Marginal increase in cellular orotate levels indicates the induction of DHODH activity along  
with OxPhos. Furthermore, UTP is converted to CTP directly by CTP synthase (Evans and 
Guy 2004). Additionally, mTOR signaling has recently been implicated in pyrimidine 
synthesis by phosphorylating carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
dihydroorotase (CAD) (Ben-Sahra et al. 2013, Robitaille et al. 2013). However, this has not 
been tested in present study. CAD phosphorylation can be tested in CLL cells co-cultured 
with stroma by immunoblotting. 
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Figure 59. De novo pyrimidine synthesis pathway in the cell. 
Cytidine triphosphate and Uridine triphosphate are the end products of the de novo 
pyrimidine synthesis pathway. One of critical steps in the pathway is catalyzed by the 
enzyme dihydroorotate dehydrogenase (DHODH) that resides in the inner mitochondrial 
membrane. It converts dihydroorotate to orotate. Broken red arrows depict the flow of 
electrons. 
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PI3K inhibitors in CLL 
CLL bioenergetic rewiring is also associated with kinase sensitivity; for example, 
CLL was classified into subsets based on the dasatinib-induced differential dependency on 
mitochondrial respiration to cope with cellular stress and meet the ATP demands (Martinez 
Marignac et al. 2013).  Although genetic lesions are absent in PI3K/AKT pathway in CLL, it 
is hyper activated by the microenvironment and therefore is a hot target for therapy. It is a 
key component of both chronic and tonic B-cell receptor-signaling pathways. Over the years, 
many PI3K inhibitors have been developed to treat lymphoid malignancies, starting with 
pan-PI3K inhibitors and gradually moved to isoform specific inhibitors. Some of the pan- 
PI3K inhibitors include copanlisib, buparlisib and GDC0941. PI3K δ responds to activation 
of many cell receptors like BCR, CD40, IL6, CXCR4 and 5 among others and therefore 
contributes to majority of the cancer hallmarks. Amongst the array of PI3K, AKT and mTOR 
inhibitors, it was the isoform specific PI3K inhibitors that were well tolerated as the others 
failed in clinical trials to high cytotoxity (Kelly et al. 2011). 
Duvelisib is a small molecule inhibitor that binds to the ATP-binding site of the 
kinases, thereby preventing activation of the PI3Kδ/γ isoforms (Figure 60) (Winkler et al. 
2013). It is currently in clinical trials as monotherapy # NCT02004522.  It has shown better 
efficiency than idelalisib in inactivating AKT and reduced CLL cell survival in presence of 
stroma.  
Duvelisib mitigates AKT and mTOR activity (Balakrishnan et al. 2015). In concert 
with these effects AKT on metabolic pathways, duvelisib treatment reduced glycolysis and  
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Figure 60. Targeting PI3K pathway inhibits cellular biosynthesis.  
Contact with stroma enhances CLL survival and metabolism. Pharmacological inhibition 
using PI3K δ/γ inhibitor targets AKT pathway and impacts CLL cell metabolism and 
nucleotide biosynthesis. S6K1 ribosomal protein is activated by AKT and/or MAPK 
pathway, which in turn stimulates purine and pyrimidine synthesis, leading to an increase in 
the nucleotide pools. 
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mitochondrial respiration in CLL (Figure 41-42). Glycolysis was an anticipated target as it 
directly regulates glycolysis. Glucose uptake, nonetheless, was not affected (Figure 46). 
It is speculated that glucose utilization by CLL cells is being affected because uptake 
of glucose did not decrease, and yet glycolysis and OxPhos were significantly down-
regulated. Mitochondrial OCR may have decreased as AKT was postulated to regulate the 
function of mitochondrial ETC (Shaik et al. 2008) in addition to what was reported by Goo et 
al, i.e., AKT acting via 4E-BP-1 to control OxPhos. In context of CLL, there is no direct 
evidence of AKT affecting the mitochondrial complexes activity. Duvelisib did not impact 
mitochondrial biology or other functionalities tested in spite of mitigating the ATP levels in 
CLL cells (Figure 49). Moreover, the decline in CLL OxPhos and glycolysis with MK2206 
demonstrated that the mitigation was AKT-dependent (Figure 44-45).  
To evaluate if PI3K γ signaling is necessary for glycolysis and OxPhos, PI3K δ only 
inhibitor, idelalisib was used. Idelalisib also mitigated both the energy generating pathways, 
implying PI3K δ signaling alone is sufficient to curtail metabolism (Figure 44-45). Genetic 
ablation of PIK3CD, the gene coding for PI3K δ significantly lowered OCR and ECAR in 
mantle cell lymphoma cell line. This further demonstrates the importance of PI3K δ in 
regulating metabolism. This is the first study to highlight the significance of PI3K δ signaling 
in regulating CLL metabolism. Cell lines employed to create the knockout were those of 
mantle cell lymphoma, JeKo-1 and diffuse large B-cell lymphoma (DLBCL), Ly19. Ly19 
cells failed to proliferate after separation from a mixed population of WT and KO cells. 
PI3K δ knockout was also very toxic to cells, underlining its importance in 
proliferation and survival. These data explain why PI3K δ knockout is not tolerated in some 
cell lines. A recent study demonstrated the importance of PI3K pathway in survival of mature 
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B cells lacking B cell receptor (Srinivasan et al. 2009). In the same study, the significance of 
AKT signaling is highlighted when PTEN deletion rescued the cells.  
BCR pathway is largely the central pathway in CLL. Since, PI3K and AKT fall under 
the umbrella of BCR signaling, I tested the significance and role of B cell receptor in CLL 
metabolism. PI3K/AKT act as second messengers for signals from a variety of receptors, 
therefore, the importance of BCR in context of metabolism is still under question. 
BCR knockout cells from JeKo-1 cell line dramatically decreased OxPhos similar to PI3K 
knockout. BCR KO cells retained basal levels of p-AKT ser473 and p-MAPK thr44/42, 
similar to WT cells; however, they were unresponsive to IgM stimulation. Addition of IgM, 
abrogated their ability to further activate AKT and MAPK signaling. BCR signaling is of 
paramount important regarding every aspect of CLL survival and sustenance. 
Future directions 
 
‘Firstly, amongst the prognostic factors considered for this study that correlated with 
glycolysis and OxPhos rates of CLL cells, ZAP 70 and IgVH status impacts the signaling of 
these cells; therefore, it would be necessary to test if patients’ samples from ZAP 70 positive 
and IgVH unmutated CLL cohort respond better (cell death) to inhibition of OxPhos by PI3K 
inhibitors’ 
 The exact mechanism underlying the augmentation of OxPhos in CLL cells, when it 
comes in contact with stroma in yet to be unfurled. The overall bioenergy (ATP) and 
biosynthesis (nucleotide pools) increased due to bone marrow stromal co-culture in CLL in a 
span of 24hrs. Tricarboxylic acid cycle (TCA) intermediates as well as OxPhos augmented, 
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suggesting energy in CLL cells is predominantly generated by oxidative metabolism in 
presence of microenvironment. 
The pathways governing the metabolic activities are upregulated (PI3K/AKT/mTOR) 
in CLL. However, the downstream effectors of these pathways impacting mitochondrial 
metabolism are elusive. 
Mitochondrial biogenesis may not the reason behind increase in OxPhos. Similarly, 
the activity of the electron transport chain does not particularly change upon stromal 
interaction with CLL. It maybe speculated that the increase of substrate availability to the 
ETC complexes could be a possibility as to why OxPhos was amplified. Carbon tracing 
experiments will give a better idea for delineating the substrate flow in the metabolic 
pathways.   
STAT3 has been implicated in mitochondrial biogenesis. STAT3 could be impacting 
mitochondrial activity by localizing and thereby, interacting with complex I proteins. So far, 
only one study so far has been able to conclusively prove the relocation of STAT3 to 
mitochondria (Wegrzyn et al. 2009). Estov’s group demonstrated that STAT3 is responsible 
for the dependence of CLL on fatty acid utilization. In the present study, phosphorylated 
STAT3 was one of the proteins whose levels were elevated upon stroma co-culture, upon 
RPPA analysis. Nonetheless, CLL cells were unable to fuel OxPhos upon providing fatty 
acid as a substrate, when tested using the extracellular flux analyzer. The utilization of 
intrinsic fatty acid to fuel OxPhos can be tested, by inhibiting fatty acid synthesis using a 
drug, etoximir that blocks the activity of fatty acid synthase. Carbon tracing as mentioned 
previously along with this experiment should identify the fuel source for OxPhos in CLL. 
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Cellular NADH/ NAD
+   
ratio determines the redox state of a cell. This ratio in CLL needs to 
be measured after stroma co-culture to check for elevated substrate levels for complex I of 
mitochondria. Additionally, STAT3 inhibitors could be tested to check if OxPhos or 
glycolysis is affected. 
Preliminary data from the metabolite analysis of CLL post stromal co-culture, 
indicated elevated DHODH enzyme activity, as orotate levels increased. This observation 
can be further extended using 10 patient samples for stroma co-cultures and for longer time 
points (48hrs), then assay OxPhos, DHODH activity (by spectrophotometry) and pyrimidine 
pools (by mass spectroscopy). This would give us an insight, if OxPhos induction and 
DHODH activity are correlated and increased DHODH activity corresponds to pyrimidine 
synthesis.    
The major pathway in CLL resulting in increased purine and pyrimidine synthesis, 
upon stroma co-culture still remains elusive. While ribosomal protein S6 is phosphorylated 
upon co-culture in CLL, it could be activated via mTOR signaling or MAPK signaling.  BCR 
KO in JeKo-1 cell lines abrogated MAPK signaling, whereas, AKT phosphorylation at 
Ser473 remained intact (not shown), indicating mTOR activity maybe unperturbed. If NTP 
pools in BCR KO JeKo-1 cells show a drop in purine and pyrimidine levels when compared 
to wild-type cells when measured, it is implied that MAPK pathway mainly regulates 
nucleotide synthesis in malignant B cells. To further ensure that increase in activity of S6 
protein leads to augmentation of purine and pyrimidine synthesis, microRNA targeting S6 
can be employed. If suppression of S6 protein leads to decrease in NTP pools, then S6 is 
upstream of nucleotide synthesis as postulated. If the nucleotide levels do not decrease, upon 
loss of S6 activity, then an alternative pathway for nucleotide metabolism like c-MYC needs 
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to be tested (Liu et al. 2008). Additional BCR KO cell lines should be used to test this 
hypothesis. 
RNA sequencing may help identify non coding RNAs, that regulate metabolism 
(Tomasetti et al. 2014) in CLL and whose expression is altered upon co-culture. MicroRNAs 
(miRs) are reported to localize to mitochondria and influence ATP synthesis (Das et al. 
2012). These miRs are also implicated in mediating tumor-stroma interactions (Bronisz et al. 
2012, Ell and Kang 2013). It would be interesting to check if any of the miRs whose 
expression is affected, control mitochondrial metabolism in CLL. 
This study underpins the necessity for using drugs that target cancer cell metabolism. 
CLL relapse rates can be decreased and disease free survival can be prolonged, if metabolic 
pathways are targeted. Existing drugs like the kinase and AKT inhibitors have a dual role, 
they repress the activity of the target pathway as well as affect metabolism. Meanwhile, 
drugs that specifically inhibit mitochondrial respiration and glycolysis are being tested 
(Toogood 2008, Mathupala et al. 2009, Liu et al. 2012). Drugs should be tailored to target 
oncogenes or pathways that are hyper activated in CLL along with cell metabolism, as solely 
targeting metabolism may not be beneficial to CLL as the disease is compartmentalized and 
as cells in circulation do not proliferate. The anti-metabolic drugs can be used against 
residual disease after traditional chemotherapy.  
Using anti-metabolites for therapy is not a new concept. First antimetabolites that 
were used in cancer therapy were purine and pyrimidine analogous. 5-flurouracil was one of 
them. Gemcitabine is another popular drug that inhibits DNA and RNA synthesis, therefore it 
is used a frontline treatment for pancreatic and metastatic breast cancers (www.cancer.org). 
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Fludarabine, which is highly effective for treatment of CLL, is purine analogue that targets 
DNA synthesis. And clearly, interaction with stroma is providing a survival advantage for 
CLL cells not just by activating the pathways for cell survival and anti-apoptotic protein, but 
also by increasing the RNA synthesis as well as protein translation. 
  
 
 
155 
 
References 
 
Aarhus, R., R. M. Graeff, D. M. Dickey, T. F. Walseth and H. C. Lee (1995). "ADP-ribosyl 
cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from 
NADP." J Biol Chem 270(51): 30327-30333. 
Alcazar, I., M. Marques, A. Kumar, E. Hirsch, M. Wymann, A. C. Carrera and D. F. Barber 
(2007). "Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T 
cell activation." J Exp Med 204(12): 2977-2987. 
Andrews, Z. B., S. Diano and T. L. Horvath (2005). "Mitochondrial uncoupling proteins in 
the CNS: in support of function and survival." Nat Rev Neurosci 6(11): 829-840. 
Arvisais, E. W., A. Romanelli, X. Hou and J. S. Davis (2006). "AKT-independent 
phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase 
signaling by prostaglandin F2alpha." J Biol Chem 281(37): 26904-26913. 
Balakrishnan, K., J. A. Burger, M. Fu, T. Doifode, W. G. Wierda and V. Gandhi (2014). 
"Regulation of Mcl-1 expression in context to bone marrow stromal 
microenvironment in chronic lymphocytic leukemia." Neoplasia 16(12): 1036-1046. 
Balakrishnan, K., M. Peluso, M. Fu, N. Y. Rosin, J. A. Burger, W. G. Wierda, M. J. Keating, 
K. Faia, S. O'Brien, J. L. Kutok and V. Gandhi (2015). "The phosphoinositide-3-
kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals 
from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL." Leukemia 29(9): 
1811-1822. 
Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. 
Prives, Y. Reiss, Y. Shiloh and Y. Ziv (1998). "Enhanced phosphorylation of p53 by 
ATM in response to DNA damage." Science 281(5383): 1674-1677. 
Barretina, J., J. Junca, A. Llano, A. Gutierrez, A. Flores, J. Blanco, B. Clotet and J. A. Este 
(2003). "CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and 
stage of the disease." Ann Hematol 82(8): 500-505. 
Ben-Sahra, I., J. J. Howell, J. M. Asara and B. D. Manning (2013). "Stimulation of de novo 
pyrimidine synthesis by growth signaling through mTOR and S6K1." Science 
339(6125): 1323-1328. 
 
 
156 
 
Benistant, C., H. Chapuis and S. Roche (2000). "A specific function for phosphatidylinositol 
3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-
kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon 
carcinoma cells." Oncogene 19(44): 5083-5090. 
Berger, N. A., J. W. Adams, G. W. Sikorski, S. J. Petzold and W. T. Shearer (1978). 
"Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic 
lymphocytic leukemia lymphocytes." J Clin Invest 62(1): 111-118. 
Bergmann, M. A., B. F. Eichhorst, R. Busch, D. Adorf, S. Stilgenbauer, M. J. Eckart, C. M. 
Wendtner, M. Hallek and Gcllsg (2007). "Prospective evaluation of prognostic 
parameters in early stage chronic lymphocytic leukemia (CLL): Results of the CLL1-
protocol of the German CLL study group (GCLLSG)." Blood 110(11): 193a-193a. 
Bernier, G. M. (1980). "beta 2-Microglobulin: structure, function and significance." Vox 
Sang 38(6): 323-327. 
Bi, L., I. Okabe, D. J. Bernard and R. L. Nussbaum (2002). "Early embryonic lethality in 
mice deficient in the p110beta catalytic subunit of PI 3-kinase." Mamm Genome 
13(3): 169-172. 
Bi, L., I. Okabe, D. J. Bernard, A. Wynshaw-Boris and R. L. Nussbaum (1999). 
"Proliferative defect and embryonic lethality in mice homozygous for a deletion in 
the p110alpha subunit of phosphoinositide 3-kinase." J Biol Chem 274(16): 10963-
10968. 
Brody, J. I. and K. Merlie (1970). "Metabolic and biosynthetic features of lymphocytes from 
patients with diabetes mellitus: similarities to lymphocytes in chronic lymphocytic 
leukaemia." Br J Haematol 19(2): 193-201. 
Brody, J. I., F. A. Oski and D. E. Singer (1969). "Impaired pentose phosphate shunt and 
decreased glycolytic activity in lymphocytes of chronic lymphocytic leukemia. 
Metabolic pathway." Blood 34(4): 421-429. 
Bronisz, A., J. Godlewski, J. A. Wallace, A. S. Merchant, M. O. Nowicki, H. Mathsyaraja, R. 
Srinivasan, A. J. Trimboli, C. K. Martin, F. Li, L. Yu, S. A. Fernandez, T. Pecot, T. J. 
Rosol, S. Cory, M. Hallett, M. Park, M. G. Piper, C. B. Marsh, L. D. Yee, R. E. 
Jimenez, G. Nuovo, S. E. Lawler, E. A. Chiocca, G. Leone and M. C. Ostrowski 
 
 
157 
 
(2012). "Reprogramming of the tumour microenvironment by stromal PTEN-
regulated miR-320." Nat Cell Biol 14(2): 159-167. 
Brown, J. R. (2011). "The treatment of relapsed refractory chronic lymphocytic leukemia." 
Hematology Am Soc Hematol Educ Program 2011: 110-118. 
Brown, J. R., M. Hanna, B. Tesar, L. Werner, N. Pochet, J. M. Asara, Y. E. Wang, P. Dal 
Cin, S. M. Fernandes, C. Thompson, L. Macconaill, C. J. Wu, Y. Van de Peer, M. 
Correll, A. Regev, D. Neuberg and A. S. Freedman (2012). "Integrative genomic 
analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic 
lymphocytic leukemia." Clin Cancer Res 18(14): 3791-3802. 
Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. 
Arden, J. Blenis and M. E. Greenberg (1999). "Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor." Cell 96(6): 857-868. 
Burger, J. A., M. Burger and T. J. Kipps (1999). "Chronic lymphocytic leukemia B cells 
express functional CXCR4 chemokine receptors that mediate spontaneous migration 
beneath bone marrow stromal cells." Blood 94(11): 3658-3667. 
Burger, J. A. and N. Chiorazzi (2013). "B cell receptor signaling in chronic lymphocytic 
leukemia." Trends Immunol 34(12): 592-601. 
Burger, J. A., M. P. Quiroga, E. Hartmann, A. Burkle, W. G. Wierda, M. J. Keating and A. 
Rosenwald (2009). "High-level expression of the T-cell chemokines CCL3 and CCL4 
by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR 
stimulation." Blood 113(13): 3050-3058. 
Burger, J. A., N. Tsukada, M. Burger, N. J. Zvaifler, M. Dell'Aquila and T. J. Kipps (2000). 
"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from 
spontaneous apoptosis through stromal cell-derived factor-1." Blood 96(8): 2655-
2663. 
Butcher, E. C. and L. J. Picker (1996). "Lymphocyte homing and homeostasis." Science 
272(5258): 60-66. 
Caligaris-Cappio, F. and T. J. Hamblin (1999). "B-cell chronic lymphocytic leukemia: a bird 
of a different feather." J Clin Oncol 17(1): 399-408. 
Canman, C. E. and D. S. Lim (1998). "The role of ATM in DNA damage responses and 
cancer." Oncogene 17(25): 3301-3308. 
 
 
158 
 
Cantley, L. C. (2002). "The phosphoinositide 3-kinase pathway." Science 296(5573): 1655-
1657. 
Carew, J. S., Y. Zhou, M. Albitar, J. D. Carew, M. J. Keating and P. Huang (2003). 
"Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: 
clinical significance and therapeutic implications." Leukemia 17(8): 1437-1447. 
Carlucci, F., F. Rosi, C. Di Pietro, E. Marinello, M. Pizzichini and A. Tabucchi (1997). 
"Purine nucleotide metabolism: specific aspects in chronic lymphocytic leukemia 
lymphocytes." Biochim Biophys Acta 1360(3): 203-210. 
Caron, F., C. Jacq and J. Rouviere-Yaniv (1979). "Characterization of a histone-like protein 
extracted from yeast mitochondria." Proc Natl Acad Sci U S A 76(9): 4265-4269. 
Cerezo, M., H. J. Bandelt, I. Martin-Guerrero, M. Ardanaz, A. Vega, A. Carracedo, A. 
Garcia-Orad and A. Salas (2009). "High mitochondrial DNA stability in B-cell 
chronic lymphocytic leukemia." PLoS One 4(11): e7902. 
Cerniglia, G. J., S. Dey, S. M. Gallagher-Colombo, N. A. Daurio, S. Tuttle, T. M. Busch, A. 
Lin, R. Sun, T. V. Esipova, S. A. Vinogradov, N. Denko, C. Koumenis and A. Maity 
(2015). "The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate 
Dehydrogenase (PDH)-E1alpha Phosphorylation." Mol Cancer Ther 14(8): 1928-
1938. 
Chan, J. C., K. M. Hannan, K. Riddell, P. Y. Ng, A. Peck, R. S. Lee, S. Hung, M. V. Astle, 
M. Bywater, M. Wall, G. Poortinga, K. Jastrzebski, K. E. Sheppard, B. A. Hemmings, 
M. N. Hall, R. W. Johnstone, G. A. McArthur, R. D. Hannan and R. B. Pearson 
(2011). "AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate 
ribosome biogenesis in cancer." Sci Signal 4(188): ra56. 
Chen, L., J. Apgar, L. Huynh, F. Dicker, T. Giago-McGahan, L. Rassenti, A. Weiss and T. J. 
Kipps (2005). "ZAP-70 directly enhances IgM signaling in chronic lymphocytic 
leukemia." Blood 105(5): 2036-2041. 
Chen, L., G. Widhopf, L. Huynh, L. Rassenti, K. R. Rai, A. Weiss and T. J. Kipps (2002). 
"Expression of ZAP-70 is associated with increased B-cell receptor signaling in 
chronic lymphocytic leukemia." Blood 100(13): 4609-4614. 
Chiorazzi, N., K. R. Rai and M. Ferrarini (2005). "Chronic lymphocytic leukemia." N Engl J 
Med 352(8): 804-815. 
 
 
159 
 
Clayton, E., G. Bardi, S. E. Bell, D. Chantry, C. P. Downes, A. Gray, L. A. Humphries, D. 
Rawlings, H. Reynolds, E. Vigorito and M. Turner (2002). "A crucial role for the 
p110delta subunit of phosphatidylinositol 3-kinase in B cell development and 
activation." J Exp Med 196(6): 753-763. 
Crespo, M., F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marce, A. 
Lopez-Guillermo, E. Campo and E. Montserrat (2003). "ZAP-70 expression as a 
surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic 
leukemia." N Engl J Med 348(18): 1764-1775. 
Cui, B., L. Chen, S. Zhang, M. Mraz, J. F. Fecteau, J. Yu, E. M. Ghia, L. Zhang, L. Bao, L. 
Z. Rassenti, K. Messer, G. A. Calin, C. M. Croce and T. J. Kipps (2014). 
"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive 
disease in chronic lymphocytic leukemia." Blood 124(4): 546-554. 
Cuni, S., P. Perez-Aciego, G. Perez-Chacon, J. A. Vargas, A. Sanchez, F. M. Martin-
Saavedra, S. Ballester, J. Garcia-Marco, J. Jorda and A. Durantez (2004). "A 
sustained activation of PI3K/NF-kappaB pathway is critical for the survival of 
chronic lymphocytic leukemia B cells." Leukemia 18(8): 1391-1400. 
Cuttner, J. (1992). "Increased incidence of hematologic malignancies in first-degree relatives 
of patients with chronic lymphocytic leukemia." Cancer Invest 10(2): 103-109. 
Damle, R. N., F. M. Batliwalla, F. Ghiotto, A. Valetto, E. Albesiano, C. Sison, S. L. Allen, J. 
Kolitz, V. P. Vinciguerra, P. Kudalkar, T. Wasil, K. R. Rai, M. Ferrarini, P. K. 
Gregersen and N. Chiorazzi (2004). "Telomere length and telomerase activity 
delineate distinctive replicative features of the B-CLL subgroups defined by 
immunoglobulin V gene mutations." Blood 103(2): 375-382. 
Damle, R. N., S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. 
Allen, K. R. Rai and N. Chiorazzi (2007). "CD38 expression labels an activated 
subset within chronic lymphocytic leukemia clones enriched in proliferating B cells." 
Blood 110(9): 3352-3359. 
Damle, R. N., T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. 
Budman, K. Dittmar, J. Kolitz, S. M. Lichtman, P. Schulman, V. P. Vinciguerra, K. 
R. Rai, M. Ferrarini and N. Chiorazzi (1999). "Ig V gene mutation status and CD38 
 
 
160 
 
expression as novel prognostic indicators in chronic lymphocytic leukemia." Blood 
94(6): 1840-1847. 
Das, S., M. Ferlito, O. A. Kent, K. Fox-Talbot, R. Wang, D. Liu, N. Raghavachari, Y. Yang, 
S. J. Wheelan, E. Murphy and C. Steenbergen (2012). "Nuclear miRNA regulates the 
mitochondrial genome in the heart." Circ Res 110(12): 1596-1603. 
Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh and M. E. Greenberg (1997). 
"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death 
machinery." Cell 91(2): 231-241. 
Deaglio, S., T. Vaisitti, S. Serra, V. Audrito, C. Bologna, G. D'Arena, L. Laurenti, D. 
Gottardi and F. Malavasi (2011). "CD38 in chronic lymphocytic leukemia: from 
bench to bedside?" Mini Rev Med Chem 11(6): 503-507. 
DeBerardinis, R. J., J. J. Lum, G. Hatzivassiliou and C. B. Thompson (2008). "The biology 
of cancer: metabolic reprogramming fuels cell growth and proliferation." Cell Metab 
7(1): 11-20. 
DeFrancesco, L. and G. Attardi (1981). "In situ photochemical crosslinking of HeLa cell 
mitochondrial DNA by a psoralen derivative reveals a protected region near the origin 
of replication." Nucleic Acids Res 9(22): 6017-6030. 
Demaria, M., C. Giorgi, M. Lebiedzinska, G. Esposito, L. D'Angeli, A. Bartoli, D. J. Gough, 
J. Turkson, D. E. Levy, C. J. Watson, M. R. Wieckowski, P. Provero, P. Pinton and 
V. Poli (2010). "A STAT3-mediated metabolic switch is involved in tumour 
transformation and STAT3 addiction." Aging (Albany NY) 2(11): 823-842. 
Deprez, J., D. Vertommen, D. R. Alessi, L. Hue and M. H. Rider (1997). "Phosphorylation 
and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other 
protein kinases of the insulin signaling cascades." J Biol Chem 272(28): 17269-
17275. 
Diehl, J. A., M. Cheng, M. F. Roussel and C. J. Sherr (1998). "Glycogen synthase kinase-
3beta regulates cyclin D1 proteolysis and subcellular localization." Genes Dev 
12(22): 3499-3511. 
Ding, W., T. D. Shanafelt, C. E. Lesnick, C. Erlichman, J. F. Leis, C. Secreto, T. R. Sassoon, 
T. G. Call, D. A. Bowen, M. Conte, S. Kumar and N. E. Kay (2014). "Akt inhibitor 
MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes 
 
 
161 
 
lymphocytes and synergizes with bendamustine to induce CLL apoptosis." Br J 
Haematol 164(1): 146-150. 
Dohner, H., S. Stilgenbauer, A. Benner, E. Leupolt, A. Krober, L. Bullinger, K. Dohner, M. 
Bentz and P. Lichter (2000). "Genomic aberrations and survival in chronic 
lymphocytic leukemia." N Engl J Med 343(26): 1910-1916. 
Dong, S., D. Guinn, J. A. Dubovsky, Y. Zhong, A. Lehman, J. Kutok, J. A. Woyach, J. C. 
Byrd and A. J. Johnson (2014). "IPI-145 antagonizes intrinsic and extrinsic survival 
signals in chronic lymphocytic leukemia cells." Blood 124(24): 3583-3586. 
Dreger, P., J. Schetelig, N. Andersen, P. Corradini, M. van Gelder, J. Gribben, E. Kimby, M. 
Michallet, C. Moreno, S. Stilgenbauer, E. Montserrat, C. L. L. European Research 
Initiative on, B. the European Society for and T. Marrow (2014). "Managing high-
risk CLL during transition to a new treatment era: stem cell transplantation or novel 
agents?" Blood 124(26): 3841-3849. 
Dumontet, C., J. Drai, J. Bienvenu, E. N. Berard, C. Thieblemont, F. Bouafia, F. Bayle, I. 
Moullet, G. Salles and B. Coiffier (1999). "Profiles and prognostic values of LDH 
isoenzymes in patients with non-Hodgkin's lymphoma." Leukemia 13(5): 811-817. 
Durig, J., M. Naschar, U. Schmucker, K. Renzing-Kohler, T. Holter, A. Huttmann and U. 
Duhrsen (2002). "CD38 expression is an important prognostic marker in chronic 
lymphocytic leukaemia." Leukemia 16(1): 30-35. 
Eagle, H. (1955). "Nutrition needs of mammalian cells in tissue culture." Science 122(3168): 
501-514. 
Ell, B. and Y. Kang (2013). "MicroRNAs as regulators of tumor-associated stromal cells." 
Oncotarget 4(12): 2166-2167. 
Engelman, J. A., J. Luo and L. C. Cantley (2006). "The evolution of phosphatidylinositol 3-
kinases as regulators of growth and metabolism." Nat Rev Genet 7(8): 606-619. 
Enns, G. M., C. L. Hoppel, S. J. DeArmond, S. Schelley, N. Bass, K. Weisiger, D. Horoupian 
and S. Packman (2005). "Relationship of primary mitochondrial respiratory chain 
dysfunction to fiber type abnormalities in skeletal muscle." Clin Genet 68(4): 337-
348. 
Evans, D. R. and H. I. Guy (2004). "Mammalian pyrimidine biosynthesis: fresh insights into 
an ancient pathway." J Biol Chem 279(32): 33035-33038. 
 
 
162 
 
Ferreira, P. G., P. Jares, D. Rico, G. Gomez-Lopez, A. Martinez-Trillos, N. Villamor, S. 
Ecker, A. Gonzalez-Perez, D. G. Knowles, J. Monlong, R. Johnson, V. Quesada, S. 
Djebali, P. Papasaikas, M. Lopez-Guerra, D. Colomer, C. Royo, M. Cazorla, M. 
Pinyol, G. Clot, M. Aymerich, M. Rozman, M. Kulis, D. Tamborero, A. Gouin, J. 
Blanc, M. Gut, I. Gut, X. S. Puente, D. G. Pisano, J. I. Martin-Subero, N. Lopez-
Bigas, A. Lopez-Guillermo, A. Valencia, C. Lopez-Otin, E. Campo and R. Guigo 
(2014). "Transcriptome characterization by RNA sequencing identifies a major 
molecular and clinical subdivision in chronic lymphocytic leukemia." Genome Res 
24(2): 212-226. 
Fink, S. R., S. A. Smoley, K. J. Stockero, S. F. Paternoster, E. C. Thorland, D. L. Van Dyke, 
T. D. Shanafelt, C. S. Zent, T. G. Call, N. E. Kay and G. W. Dewald (2006). "Loss of 
TP53 is due to rearrangements involving chromosome region 17p10 approximately 
p12 in chronic lymphocytic leukemia." Cancer Genet Cytogenet 167(2): 177-181. 
Foster, F. M., C. J. Traer, S. M. Abraham and M. J. Fry (2003). "The phosphoinositide (PI) 
3-kinase family." J Cell Sci 116(Pt 15): 3037-3040. 
Fruman, D. A. and L. C. Cantley (2014). "Idelalisib--a PI3Kdelta inhibitor for B-cell 
cancers." N Engl J Med 370(11): 1061-1062. 
Ghia, P., N. Chiorazzi and K. Stamatopoulos (2008). "Microenvironmental influences in 
chronic lymphocytic leukaemia: the role of antigen stimulation." J Intern Med 264(6): 
549-562. 
Gobessi, S., L. Laurenti, P. G. Longo, S. Sica, G. Leone and D. G. Efremov (2007). "ZAP-70 
enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase 
activation in chronic lymphocytic leukemia and lymphoma B cells." Blood 109(5): 
2032-2039. 
Goo, C. K., H. Y. Lim, Q. S. Ho, H. P. Too, M. V. Clement and K. P. Wong (2012). 
"PTEN/Akt signaling controls mitochondrial respiratory capacity through 4E-BP1." 
PLoS One 7(9): e45806. 
Gopal, A. K., B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jurczak, I. 
W. Flinn, C. R. Flowers, P. Martin, A. Viardot, K. A. Blum, A. H. Goy, A. J. Davies, 
P. L. Zinzani, M. Dreyling, D. Johnson, L. L. Miller, L. Holes, D. Li, R. D. Dansey, 
 
 
163 
 
W. R. Godfrey and G. A. Salles (2014). "PI3Kdelta inhibition by idelalisib in patients 
with relapsed indolent lymphoma." N Engl J Med 370(11): 1008-1018. 
Gottlob, K., N. Majewski, S. Kennedy, E. Kandel, R. B. Robey and N. Hay (2001). 
"Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed 
step of glycolysis and mitochondrial hexokinase." Genes Dev 15(11): 1406-1418. 
Gough, D. J., A. Corlett, K. Schlessinger, J. Wegrzyn, A. C. Larner and D. E. Levy (2009). 
"Mitochondrial STAT3 supports Ras-dependent oncogenic transformation." Science 
324(5935): 1713-1716. 
Hahn-Windgassen, A., V. Nogueira, C. C. Chen, J. E. Skeen, N. Sonenberg and N. Hay 
(2005). "Akt activates the mammalian target of rapamycin by regulating cellular ATP 
level and AMPK activity." J Biol Chem 280(37): 32081-32089. 
Hallek, M., L. Wanders, M. Ostwald, R. Busch, R. Senekowitsch, S. Stern, H. D. Schick, I. 
Kuhn-Hallek and B. Emmerich (1996). "Serum beta(2)-microglobulin and serum 
thymidine kinase are independent predictors of progression-free survival in chronic 
lymphocytic leukemia and immunocytoma." Leuk Lymphoma 22(5-6): 439-447. 
Hamada, K., T. Sasaki, P. A. Koni, M. Natsui, H. Kishimoto, J. Sasaki, N. Yajima, Y. Horie, 
G. Hasegawa, M. Naito, J. Miyazaki, T. Suda, H. Itoh, K. Nakao, T. W. Mak, T. 
Nakano and A. Suzuki (2005). "The PTEN/PI3K pathway governs normal vascular 
development and tumor angiogenesis." Genes Dev 19(17): 2054-2065. 
Hamblin, T. J., Z. Davis, A. Gardiner, D. G. Oscier and F. K. Stevenson (1999). "Unmutated 
Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic 
leukemia." Blood 94(6): 1848-1854. 
Heintel, D., D. Kienle, M. Shehata, A. Krober, E. Kroemer, I. Schwarzinger, D. Mitteregger, 
T. Le, A. Gleiss, C. Mannhalter, A. Chott, J. Schwarzmeier, C. Fonatsch, A. Gaiger, 
H. Dohner, S. Stilgenbauer, U. Jager and C. L. L. S. Group (2005). "High expression 
of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia." Leukemia 
19(7): 1216-1223. 
Henderson, J. F., J. H. Fraser and E. E. McCoy (1974). "Methods for the study of purine 
metabolism in human cells in vitro." Clin Biochem 7(4): 339-358. 
Henderson, J. F. and A. R. P. Paterson (1973). Nucleotide metabolism; an introduction. New 
York,, Academic Press. 
 
 
164 
 
Herishanu, Y., P. Perez-Galan, D. Liu, A. Biancotto, S. Pittaluga, B. Vire, F. Gibellini, N. 
Njuguna, E. Lee, L. Stennett, N. Raghavachari, P. Liu, J. P. McCoy, M. Raffeld, M. 
Stetler-Stevenson, C. Yuan, R. Sherry, D. C. Arthur, I. Maric, T. White, G. E. Marti, 
P. Munson, W. H. Wilson and A. Wiestner (2011). "The lymph node 
microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and 
tumor proliferation in chronic lymphocytic leukemia." Blood 117(2): 563-574. 
Herman, S. E., A. L. Gordon, E. Hertlein, A. Ramanunni, X. Zhang, S. Jaglowski, J. Flynn, J. 
Jones, K. A. Blum, J. J. Buggy, A. Hamdy, A. J. Johnson and J. C. Byrd (2011). 
"Bruton tyrosine kinase represents a promising therapeutic target for treatment of 
chronic lymphocytic leukemia and is effectively targeted by PCI-32765." Blood 
117(23): 6287-6296. 
Herman, S. E., A. L. Gordon, A. J. Wagner, N. A. Heerema, W. Zhao, J. M. Flynn, J. Jones, 
L. Andritsos, K. D. Puri, B. J. Lannutti, N. A. Giese, X. Zhang, L. Wei, J. C. Byrd 
and A. J. Johnson (2010). "Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 
shows promising preclinical activity in chronic lymphocytic leukemia by 
antagonizing intrinsic and extrinsic cellular survival signals." Blood 116(12): 2078-
2088. 
Hickey, F. B. and T. G. Cotter (2006). "BCR-ABL regulates phosphatidylinositol 3-kinase-
p110gamma transcription and activation and is required for proliferation and drug 
resistance." J Biol Chem 281(5): 2441-2450. 
Hirai, H., H. Sootome, Y. Nakatsuru, K. Miyama, S. Taguchi, K. Tsujioka, Y. Ueno, H. 
Hatch, P. K. Majumder, B. S. Pan and H. Kotani (2010). "MK-2206, an allosteric Akt 
inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or 
molecular targeted drugs in vitro and in vivo." Mol Cancer Ther 9(7): 1956-1967. 
Hirsch, E., V. L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, L. Silengo, S. Sozzani, A. 
Mantovani, F. Altruda and M. P. Wymann (2000). "Central role for G protein-
coupled phosphoinositide 3-kinase gamma in inflammation." Science 287(5455): 
1049-1053. 
Hofbauer, S. W., P. W. Krenn, J. Pinomicronn Hofbauer, S. Pucher, D. Asslaber, A. Egle, T. 
N. Hartmann and R. Greil (2015). "The AKT1 isoform plays a dominant role in the 
 
 
165 
 
survival and chemoresistance of chronic lymphocytic leukaemia cells." Br J 
Haematol. 
Hosnijeh, F. S., Q. Lan, N. Rothman, C. San Liu, W. L. Cheng, A. Nieters, P. Guldberg, A. 
Tjonneland, D. Campa, A. Martino, H. Boeing, A. Trichopoulou, P. Lagiou, D. 
Trichopoulos, V. Krogh, R. Tumino, S. Panico, G. Masala, E. Weiderpass, J. M. 
Huerta Castano, E. Ardanaz, N. Sala, M. Dorronsoro, J. R. Quiros, M. J. Sanchez, B. 
Melin, A. S. Johansson, J. Malm, S. Borgquist, P. H. Peeters, H. B. Bueno-de-
Mesquita, N. Wareham, K. T. Khaw, R. C. Travis, P. Brennan, A. Siddiq, E. Riboli, 
P. Vineis and R. Vermeulen (2014). "Mitochondrial DNA copy number and future 
risk of B-cell lymphoma in a nested case-control study in the prospective EPIC 
cohort." Blood 124(4): 530-535. 
Hsu, P. P. and D. M. Sabatini (2008). "Cancer cell metabolism: Warburg and beyond." Cell 
134(5): 703-707. 
Hu, H., A. Juvekar, C. A. Lyssiotis, E. C. Lien, J. G. Albeck, D. Oh, G. Varma, Y. P. Hung, 
S. Ullas, J. Lauring, P. Seth, M. R. Lundquist, D. R. Tolan, A. K. Grant, D. J. 
Needleman, J. M. Asara, L. C. Cantley and G. M. Wulf (2016). "Phosphoinositide 3-
Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin 
Cytoskeleton." Cell 164(3): 433-446. 
Huang, M. and L. M. Graves (2003). "De novo synthesis of pyrimidine nucleotides; 
emerging interfaces with signal transduction pathways." Cell Mol Life Sci 60(2): 
321-336. 
Itoyama, T., R. S. Chaganti, Y. Yamada, K. Tsukasaki, S. Atogami, H. Nakamura, M. 
Tomonaga, K. Ohshima, M. Kikuchi and N. Sadamori (2001). "Cytogenetic analysis 
and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from 
the human T-cell leukemia virus type-1 endemic area, Nagasaki." Blood 97(11): 
3612-3620. 
Jiang, Z. Y., Q. L. Zhou, K. A. Coleman, M. Chouinard, Q. Boese and M. P. Czech (2003). 
"Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-
mediated gene silencing." Proc Natl Acad Sci U S A 100(13): 7569-7574. 
 
 
166 
 
Jitschin, R., M. Braun, M. Qorraj, D. Saul, K. Le Blanc, T. Zenz and D. Mougiakakos 
(2015). "Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc 
signaling." Blood 125(22): 3432-3436. 
Jitschin, R., A. D. Hofmann, H. Bruns, A. Giessl, J. Bricks, J. Berger, D. Saul, M. J. Eckart, 
A. Mackensen and D. Mougiakakos (2014). "Mitochondrial metabolism contributes 
to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia." 
Blood 123(17): 2663-2672. 
Jones, M. E. (1980). "Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and 
regulation of UMP biosynthesis." Annu Rev Biochem 49: 253-279. 
Jouaville, L. S., P. Pinton, C. Bastianutto, G. A. Rutter and R. Rizzuto (1999). "Regulation of 
mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic 
priming." Proc Natl Acad Sci U S A 96(24): 13807-13812. 
Kelly, C. J., K. Hussien, E. Fokas, P. Kannan, R. J. Shipley, T. M. Ashton, M. Stratford, N. 
Pearson and R. J. Muschel (2014). "Regulation of O2 consumption by the PI3K and 
mTOR pathways contributes to tumor hypoxia." Radiother Oncol 111(1): 72-80. 
Kelly, K. R., J. H. Rowe, S. Padmanabhan, S. T. Nawrocki and J. S. Carew (2011). 
"Mammalian target of rapamycin as a target in hematological malignancies." Target 
Oncol 6(1): 53-61. 
Kienle, D., A. Benner, A. Krober, D. Winkler, D. Mertens, A. Buhler, T. Seiler, U. Jager, P. 
Lichter, H. Dohner and S. Stilgenbauer (2006). "Distinct gene expression patterns in 
chronic lymphocytic leukemia defined by usage of specific VH genes." Blood 107(5): 
2090-2093. 
Kim, S., P. Mangin, C. Dangelmaier, R. Lillian, S. P. Jackson, J. L. Daniel and S. P. 
Kunapuli (2009). "Role of phosphoinositide 3-kinase beta in glycoprotein VI-
mediated Akt activation in platelets." J Biol Chem 284(49): 33763-33772. 
Kini, A. R., N. E. Kay and L. C. Peterson (2000). "Increased bone marrow angiogenesis in B 
cell chronic lymphocytic leukemia." Leukemia 14(8): 1414-1418. 
Kipps, T. J., E. Tomhave, L. F. Pratt, S. Duffy, P. P. Chen and D. A. Carson (1989). 
"Developmentally restricted immunoglobulin heavy chain variable region gene 
expressed at high frequency in chronic lymphocytic leukemia." Proc Natl Acad Sci U 
S A 86(15): 5913-5917. 
 
 
167 
 
Kitada, S., J. Andersen, S. Akar, J. M. Zapata, S. Takayama, S. Krajewski, H. G. Wang, X. 
Zhang, F. Bullrich, C. M. Croce, K. Rai, J. Hines and J. C. Reed (1998). "Expression 
of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with 
In vitro and In vivo chemoresponses." Blood 91(9): 3379-3389. 
Klein, U., Y. Tu, G. A. Stolovitzky, M. Mattioli, G. Cattoretti, H. Husson, A. Freedman, G. 
Inghirami, L. Cro, L. Baldini, A. Neri, A. Califano and R. Dalla-Favera (2001). 
"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a 
homogeneous phenotype related to memory B cells." J Exp Med 194(11): 1625-1638. 
Koczula, K. M., C. Ludwig, R. Hayden, L. Cronin, G. Pratt, H. Parry, D. Tennant, M. 
Drayson, C. M. Bunce, F. L. Khanim and U. L. Gunther (2015). "Metabolic plasticity 
in CLL: adaptation to the hypoxic niche." Leukemia: 1-9. 
Kohn, A. D., S. A. Summers, M. J. Birnbaum and R. A. Roth (1996). "Expression of a 
constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose 
uptake and glucose transporter 4 translocation." J Biol Chem 271(49): 31372-31378. 
Koppenol, W. H., P. L. Bounds and C. V. Dang (2011). "Otto Warburg's contributions to 
current concepts of cancer metabolism." Nat Rev Cancer 11(5): 325-337. 
Krober, A., T. Seiler, A. Benner, L. Bullinger, E. Bruckle, P. Lichter, H. Dohner and S. 
Stilgenbauer (2002). "V(H) mutation status, CD38 expression level, genomic 
aberrations, and survival in chronic lymphocytic leukemia." Blood 100(4): 1410-
1416. 
Kurtova, A. V., K. Balakrishnan, R. Chen, W. Ding, S. Schnabl, M. P. Quiroga, M. Sivina, 
W. G. Wierda, Z. Estrov, M. J. Keating, M. Shehata, U. Jager, V. Gandhi, N. E. Kay, 
W. Plunkett and J. A. Burger (2009). "Diverse marrow stromal cells protect CLL cells 
from spontaneous and drug-induced apoptosis: development of a reliable and 
reproducible system to assess stromal cell adhesion-mediated drug resistance." Blood 
114(20): 4441-4450. 
Lafarge, S. T., J. B. Johnston, S. B. Gibson and A. J. Marshall (2014). "Adhesion of ZAP-
70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and 
blocked by inhibitors of the PI3-kinase pathway." Leuk Res 38(1): 109-115. 
 
 
168 
 
Lafarge, S. T., H. Li, S. D. Pauls, S. Hou, J. B. Johnston, S. B. Gibson and A. J. Marshall 
(2015). "ZAP70 expression directly promotes chronic lymphocytic leukaemia cell 
adhesion to bone marrow stromal cells." Br J Haematol 168(1): 139-142. 
Landau, D. A., S. L. Carter, P. Stojanov, A. McKenna, K. Stevenson, M. S. Lawrence, C. 
Sougnez, C. Stewart, A. Sivachenko, L. Wang, Y. Wan, W. Zhang, S. A. Shukla, A. 
Vartanov, S. M. Fernandes, G. Saksena, K. Cibulskis, B. Tesar, S. Gabriel, N. 
Hacohen, M. Meyerson, E. S. Lander, D. Neuberg, J. R. Brown, G. Getz and C. J. Wu 
(2013). "Evolution and impact of subclonal mutations in chronic lymphocytic 
leukemia." Cell 152(4): 714-726. 
Lanham, S., T. Hamblin, D. Oscier, R. Ibbotson, F. Stevenson and G. Packham (2003). 
"Differential signaling via surface IgM is associated with VH gene mutational status 
and CD38 expression in chronic lymphocytic leukemia." Blood 101(3): 1087-1093. 
Laplante, M. and D. M. Sabatini (2012). "mTOR signaling in growth control and disease." 
Cell 149(2): 274-293. 
Li, C., Y. Li, L. He, A. R. Agarwal, N. Zeng, E. Cadenas and B. L. Stiles (2013). 
"PI3K/AKT signaling regulates bioenergetics in immortalized hepatocytes." Free 
Radic Biol Med 60: 29-40. 
Li, Z., H. Jiang, W. Xie, Z. Zhang, A. V. Smrcka and D. Wu (2000). "Roles of PLC-beta2 
and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction." 
Science 287(5455): 1046-1049. 
Lim, H. Y., Q. S. Ho, J. Low, M. Choolani and K. P. Wong (2011). "Respiratory competent 
mitochondria in human ovarian and peritoneal cancer." Mitochondrion 11(3): 437-
443. 
Liu, Y., Y. Cao, W. Zhang, S. Bergmeier, Y. Qian, H. Akbar, R. Colvin, J. Ding, L. Tong, S. 
Wu, J. Hines and X. Chen (2012). "A small-molecule inhibitor of glucose transporter 
1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth 
in vitro and in vivo." Mol Cancer Ther 11(8): 1672-1682. 
Liu, Y. C., F. Li, J. Handler, C. R. Huang, Y. Xiang, N. Neretti, J. M. Sedivy, K. I. Zeller and 
C. V. Dang (2008). "Global regulation of nucleotide biosynthetic genes by c-Myc." 
PLoS One 3(7): e2722. 
 
 
169 
 
Lu, C. L., L. Qin, H. C. Liu, D. Candas, M. Fan and J. J. Li (2015). "Tumor cells switch to 
mitochondrial oxidative phosphorylation under radiation via mTOR-mediated 
hexokinase II inhibition--a Warburg-reversing effect." PLoS One 10(3): e0121046. 
Malavasi, F., A. Funaro, S. Roggero, A. Horenstein, L. Calosso and K. Mehta (1994). 
"Human CD38: a glycoprotein in search of a function." Immunol Today 15(3): 95-97. 
Manshouri, T., Z. Estrov, A. Quintas-Cardama, J. Burger, Y. Zhang, A. Livun, L. Knez, D. 
Harris, C. J. Creighton, H. M. Kantarjian and S. Verstovsek (2011). "Bone marrow 
stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a 
JAK2 inhibitor." Cancer Res 71(11): 3831-3840. 
Marti, G. E., V. Zenger, N. E. Caproaso, M. Brown, G. C. Washington, P. Carter, G. 
Schechter and P. Noguchi (1989). "Antigenic expression of B-cell chronic 
lymphocytic leukemic lymphocytes." Anal Quant Cytol Histol 11(5): 315-323. 
Martinez Marignac, V. L., S. Smith, N. Toban, M. Bazile and R. Aloyz (2013). "Resistance 
to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-
mediated energetic re-programming." Oncotarget 4(12): 2550-2566. 
Mathupala, S. P., Y. H. Ko and P. L. Pedersen (2009). "Hexokinase-2 bound to 
mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for 
effective therapy." Semin Cancer Biol 19(1): 17-24. 
Matutes, E., K. Owusu-Ankomah, R. Morilla, J. Garcia Marco, A. Houlihan, T. H. Que and 
D. Catovsky (1994). "The immunological profile of B-cell disorders and proposal of a 
scoring system for the diagnosis of CLL." Leukemia 8(10): 1640-1645. 
Menzel, T., Z. Rahman, E. Calleja, K. White, E. L. Wilson, R. Wieder and J. Gabrilove 
(1996). "Elevated intracellular level of basic fibroblast growth factor correlates with 
stage of chronic lymphocytic leukemia and is associated with resistance to 
fludarabine." Blood 87(3): 1056-1063. 
Mitchell, P. (1961). "Coupling of phosphorylation to electron and hydrogen transfer by a 
chemi-osmotic type of mechanism." Nature 191: 144-148. 
Mizoguchi, M., C. L. Nutt, G. Mohapatra and D. N. Louis (2004). "Genetic alterations of 
phosphoinositide 3-kinase subunit genes in human glioblastomas." Brain Pathol 
14(4): 372-377. 
 
 
170 
 
Moon, K. D., C. B. Post, D. L. Durden, Q. Zhou, P. De, M. L. Harrison and R. L. Geahlen 
(2005). "Molecular basis for a direct interaction between the Syk protein-tyrosine 
kinase and phosphoinositide 3-kinase." J Biol Chem 280(2): 1543-1551. 
Mustelin, T. and K. Tasken (2003). "Positive and negative regulation of T-cell activation 
through kinases and phosphatases." Biochem J 371(Pt 1): 15-27. 
Nishio, M., T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. C. Reed, N. J. Zvaifler and T. J. 
Kipps (2005). "Nurselike cells express BAFF and APRIL, which can promote 
survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from 
that of SDF-1alpha." Blood 106(3): 1012-1020. 
Ono, M., S. Bolland, P. Tempst and J. V. Ravetch (1996). "Role of the inositol phosphatase 
SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB." 
Nature 383(6597): 263-266. 
Orchard, J. A., R. E. Ibbotson, Z. Davis, A. Wiestner, A. Rosenwald, P. W. Thomas, T. J. 
Hamblin, L. M. Staudt and D. G. Oscier (2004). "ZAP-70 expression and prognosis in 
chronic lymphocytic leukaemia." Lancet 363(9403): 105-111. 
Oscier, D. G., A. C. Gardiner, S. J. Mould, S. Glide, Z. A. Davis, R. E. Ibbotson, M. M. 
Corcoran, R. M. Chapman, P. W. Thomas, J. A. Copplestone, J. A. Orchard and T. J. 
Hamblin (2002). "Multivariate analysis of prognostic factors in CLL: clinical stage, 
IGVH gene mutational status, and loss or mutation of the p53 gene are independent 
prognostic factors." Blood 100(4): 1177-1184. 
Pankov, R. and K. M. Yamada (2002). "Fibronectin at a glance." J Cell Sci 115(Pt 20): 3861-
3863. 
Patel, V., L. S. Chen, W. G. Wierda, K. Balakrishnan and V. Gandhi (2014). "Impact of bone 
marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia." 
Leuk Lymphoma 55(4): 899-910. 
Pflug, N., J. Bahlo, T. D. Shanafelt, B. F. Eichhorst, M. A. Bergmann, T. Elter, K. Bauer, G. 
Malchau, K. G. Rabe, S. Stilgenbauer, H. Dohner, U. Jager, M. J. Eckart, G. 
Hopfinger, R. Busch, A. M. Fink, C. M. Wendtner, K. Fischer, N. E. Kay and M. 
Hallek (2014). "Development of a comprehensive prognostic index for patients with 
chronic lymphocytic leukemia." Blood 124(1): 49-62. 
 
 
171 
 
Rai, K. R., A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy and B. S. Pasternack 
(1975). "Clinical staging of chronic lymphocytic leukemia." Blood 46(2): 219-234. 
Rassenti, L. Z., L. Huynh, T. L. Toy, L. Chen, M. J. Keating, J. G. Gribben, D. S. Neuberg, I. 
W. Flinn, K. R. Rai, J. C. Byrd, N. E. Kay, A. Greaves, A. Weiss and T. J. Kipps 
(2004). "ZAP-70 compared with immunoglobulin heavy-chain gene mutation status 
as a predictor of disease progression in chronic lymphocytic leukemia." N Engl J Med 
351(9): 893-901. 
Rathmell, J. C., C. J. Fox, D. R. Plas, P. S. Hammerman, R. M. Cinalli and C. B. Thompson 
(2003). "Akt-directed glucose metabolism can prevent Bax conformation change and 
promote growth factor-independent survival." Mol Cell Biol 23(20): 7315-7328. 
Ries L.A.G., E. M. P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., Mariotto A., Fay 
M.P., Feuer E.J. & Edwards B.K. 9 (eds) (2003) "SEER Cancer Statistics Review, 
1975–2000." 
Robitaille, A. M., S. Christen, M. Shimobayashi, M. Cornu, L. L. Fava, S. Moes, C. 
Prescianotto-Baschong, U. Sauer, P. Jenoe and M. N. Hall (2013). "Quantitative 
phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis." Science 
339(6125): 1320-1323. 
Rosenwald, A., A. A. Alizadeh, G. Widhopf, R. Simon, R. E. Davis, X. Yu, L. Yang, O. K. 
Pickeral, L. Z. Rassenti, J. Powell, D. Botstein, J. C. Byrd, M. R. Grever, B. D. 
Cheson, N. Chiorazzi, W. H. Wilson, T. J. Kipps, P. O. Brown and L. M. Staudt 
(2001). "Relation of gene expression phenotype to immunoglobulin mutation 
genotype in B cell chronic lymphocytic leukemia." J Exp Med 194(11): 1639-1647. 
Rozman, C. and E. Montserrat (1995). "Chronic lymphocytic leukemia." N Engl J Med 
333(16): 1052-1057. 
Sano, H., S. Kane, E. Sano, C. P. Miinea, J. M. Asara, W. S. Lane, C. W. Garner and G. E. 
Lienhard (2003). "Insulin-stimulated phosphorylation of a Rab GTPase-activating 
protein regulates GLUT4 translocation." J Biol Chem 278(17): 14599-14602. 
Sasaki, T., J. Irie-Sasaki, R. G. Jones, A. J. Oliveira-dos-Santos, W. L. Stanford, B. Bolon, A. 
Wakeham, A. Itie, D. Bouchard, I. Kozieradzki, N. Joza, T. W. Mak, P. S. Ohashi, A. 
Suzuki and J. M. Penninger (2000). "Function of PI3Kgamma in thymocyte 
 
 
172 
 
development, T cell activation, and neutrophil migration." Science 287(5455): 1040-
1046. 
Sawyer, C., J. Sturge, D. C. Bennett, M. J. O'Hare, W. E. Allen, J. Bain, G. E. Jones and B. 
Vanhaesebroeck (2003). "Regulation of breast cancer cell chemotaxis by the 
phosphoinositide 3-kinase p110delta." Cancer Res 63(7): 1667-1675. 
Schroder, A. E., A. Greiner, C. Seyfert and C. Berek (1996). "Differentiation of B cells in the 
nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis." 
Proc Natl Acad Sci U S A 93(1): 221-225. 
Shaik, Z. P., E. K. Fifer and G. Nowak (2008). "Akt activation improves oxidative 
phosphorylation in renal proximal tubular cells following nephrotoxicant injury." Am 
J Physiol Renal Physiol 294(2): F423-432. 
Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J. K. Choi, 
R. Trotta, P. Wlodarski, D. Perrotti, T. O. Chan, M. A. Wasik, P. N. Tsichlis and B. 
Calabretta (1997). "Transformation of hematopoietic cells by BCR/ABL requires 
activation of a PI-3k/Akt-dependent pathway." EMBO J 16(20): 6151-6161. 
Spaargaren, M., E. A. Beuling, M. L. Rurup, H. P. Meijer, M. D. Klok, S. Middendorp, R. 
W. Hendriks and S. T. Pals (2003). "The B cell antigen receptor controls integrin 
activity through Btk and PLCgamma2." J Exp Med 198(10): 1539-1550. 
Srinivasan, L., Y. Sasaki, D. P. Calado, B. Zhang, J. H. Paik, R. A. DePinho, J. L. Kutok, J. 
F. Kearney, K. L. Otipoby and K. Rajewsky (2009). "PI3 kinase signals BCR-
dependent mature B cell survival." Cell 139(3): 573-586. 
Stamatopoulos, K. (2009). "CLL: promiscuity leads to risks." Blood 114(17): 3508-3509. 
Stephens, L. R., A. Eguinoa, H. Erdjument-Bromage, M. Lui, F. Cooke, J. Coadwell, A. S. 
Smrcka, M. Thelen, K. Cadwallader, P. Tempst and P. T. Hawkins (1997). "The G 
beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, 
p101." Cell 89(1): 105-114. 
Subramaniam, P. S., D. W. Whye, E. Efimenko, J. Chen, V. Tosello, K. De Keersmaecker, 
A. Kashishian, M. A. Thompson, M. Castillo, C. Cordon-Cardo, U. P. Dave, A. 
Ferrando, B. J. Lannutti and T. G. Diacovo (2012). "Targeting nonclassical 
oncogenes for therapy in T-ALL." Cancer Cell 21(4): 459-472. 
 
 
173 
 
Sujobert, P., V. Bardet, P. Cornillet-Lefebvre, J. S. Hayflick, N. Prie, F. Verdier, B. 
Vanhaesebroeck, O. Muller, F. Pesce, N. Ifrah, M. Hunault-Berger, C. Berthou, B. 
Villemagne, E. Jourdan, B. Audhuy, E. Solary, B. Witz, J. L. Harousseau, C. 
Himberlin, T. Lamy, B. Lioure, J. Y. Cahn, F. Dreyfus, P. Mayeux, C. Lacombe and 
D. Bouscary (2005). "Essential role for the p110delta isoform in phosphoinositide 3-
kinase activation and cell proliferation in acute myeloid leukemia." Blood 106(3): 
1063-1066. 
Tili, E., J. J. Michaille, Z. Luo, S. Volinia, L. Z. Rassenti, T. J. Kipps and C. M. Croce 
(2012). "The down-regulation of miR-125b in chronic lymphocytic leukemias leads 
to metabolic adaptation of cells to a transformed state." Blood 120(13): 2631-2638. 
Tomasetti, M., J. Neuzil and L. Dong (2014). "MicroRNAs as regulators of mitochondrial 
function: role in cancer suppression." Biochim Biophys Acta 1840(4): 1441-1453. 
Tonegawa, S. (1983). "Somatic generation of antibody diversity." Nature 302(5909): 575-
581. 
Toogood, P. L. (2008). "Mitochondrial drugs." Curr Opin Chem Biol 12(4): 457-463. 
Vander Heiden, M. G., L. C. Cantley and C. B. Thompson (2009). "Understanding the 
Warburg effect: the metabolic requirements of cell proliferation." Science 324(5930): 
1029-1033. 
Vanhaesebroeck, B., S. J. Leevers, K. Ahmadi, J. Timms, R. Katso, P. C. Driscoll, R. 
Woscholski, P. J. Parker and M. D. Waterfield (2001). "Synthesis and function of 3-
phosphorylated inositol lipids." Annu Rev Biochem 70: 535-602. 
Vanhaesebroeck, B., M. J. Welham, K. Kotani, R. Stein, P. H. Warne, M. J. Zvelebil, K. 
Higashi, S. Volinia, J. Downward and M. D. Waterfield (1997). "P110delta, a novel 
phosphoinositide 3-kinase in leukocytes." Proc Natl Acad Sci U S A 94(9): 4330-
4335. 
Vu, T. H., M. Sciacco, K. Tanji, C. Nichter, E. Bonilla, S. Chatkupt, P. Maertens, S. Shanske, 
J. Mendell, M. R. Koenigsberger, L. Sharer, E. A. Schon, S. DiMauro and D. C. 
DeVivo (1998). "Clinical manifestations of mitochondrial DNA depletion." 
Neurology 50(6): 1783-1790. 
Vuillier, F., G. Dumas, C. Magnac, M. C. Prevost, A. I. Lalanne, P. Oppezzo, E. Melanitou, 
G. Dighiero and B. Payelle-Brogard (2005). "Lower levels of surface B-cell-receptor 
 
 
174 
 
expression in chronic lymphocytic leukemia are associated with glycosylation and 
folding defects of the mu and CD79a chains." Blood 105(7): 2933-2940. 
Warburg, O. (1956). "On the origin of cancer cells." Science 123(3191): 309-314. 
Ward, P. S. and C. B. Thompson (2012). "Metabolic reprogramming: a cancer hallmark even 
warburg did not anticipate." Cancer Cell 21(3): 297-308. 
Wegrzyn, J., R. Potla, Y. J. Chwae, N. B. Sepuri, Q. Zhang, T. Koeck, M. Derecka, K. 
Szczepanek, M. Szelag, A. Gornicka, A. Moh, S. Moghaddas, Q. Chen, S. Bobbili, J. 
Cichy, J. Dulak, D. P. Baker, A. Wolfman, D. Stuehr, M. O. Hassan, X. Y. Fu, N. 
Avadhani, J. I. Drake, P. Fawcett, E. J. Lesnefsky and A. C. Larner (2009). "Function 
of mitochondrial Stat3 in cellular respiration." Science 323(5915): 793-797. 
Whiteman, E. L., H. Cho and M. J. Birnbaum (2002). "Role of Akt/protein kinase B in 
metabolism." Trends Endocrinol Metab 13(10): 444-451. 
Wierda, W. G., S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K. A. Do, J. Cortes, D. Thomas, 
G. Garcia-Manero, C. Koller, M. Beran, F. Giles, F. Ravandi, S. Lerner, H. 
Kantarjian and M. Keating (2007). "Prognostic nomogram and index for overall 
survival in previously untreated patients with chronic lymphocytic leukemia." Blood 
109(11): 4679-4685. 
Wiestner, A., A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis, S. E. Henrickson, H. Zhao, 
R. E. Ibbotson, J. A. Orchard, Z. Davis, M. Stetler-Stevenson, M. Raffeld, D. C. 
Arthur, G. E. Marti, W. H. Wilson, T. J. Hamblin, D. G. Oscier and L. M. Staudt 
(2003). "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with 
unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene 
expression profile." Blood 101(12): 4944-4951. 
Winkler, D. G., K. L. Faia, J. P. DiNitto, J. A. Ali, K. F. White, E. E. Brophy, M. M. Pink, J. 
L. Proctor, J. Lussier, C. M. Martin, J. G. Hoyt, B. Tillotson, E. L. Murphy, A. R. 
Lim, B. D. Thomas, J. R. Macdougall, P. Ren, Y. Liu, L. S. Li, K. A. Jessen, C. C. 
Fritz, J. L. Dunbar, J. R. Porter, C. Rommel, V. J. Palombella, P. S. Changelian and J. 
L. Kutok (2013). "PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates 
immune responses and suppresses activity in autoimmune and inflammatory disease 
models." Chem Biol 20(11): 1364-1374. 
 
 
175 
 
Wise, D. R. and C. B. Thompson (2010). "Glutamine addiction: a new therapeutic target in 
cancer." Trends Biochem Sci 35(8): 427-433. 
Woyach, J. A., A. J. Johnson and J. C. Byrd (2012). "The B-cell receptor signaling pathway 
as a therapeutic target in CLL." Blood 120(6): 1175-1184. 
Yancopoulos, G. D. and F. W. Alt (1986). "Regulation of the assembly and expression of 
variable-region genes." Annu Rev Immunol 4: 339-368. 
Yang, Z. Z., O. Tschopp, M. Hemmings-Mieszczak, J. Feng, D. Brodbeck, E. Perentes and 
B. A. Hemmings (2003). "Protein kinase B alpha/Akt1 regulates placental 
development and fetal growth." J Biol Chem 278(34): 32124-32131. 
Yuan, T. L., H. S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J. V. Frangioni and L. C. 
Cantley (2008). "Class 1A PI3K regulates vessel integrity during development and 
tumorigenesis." Proc Natl Acad Sci U S A 105(28): 9739-9744. 
Zhang, W., D. Trachootham, J. Liu, G. Chen, H. Pelicano, C. Garcia-Prieto, W. Lu, J. A. 
Burger, C. M. Croce, W. Plunkett, M. J. Keating and P. Huang (2012). "Stromal 
control of cystine metabolism promotes cancer cell survival in chronic lymphocytic 
leukaemia." Nat Cell Biol 14(3): 276-286. 
Zhao, J. J., H. Cheng, S. Jia, L. Wang, O. V. Gjoerup, A. Mikami and T. M. Roberts (2006). 
"The p110alpha isoform of PI3K is essential for proper growth factor signaling and 
oncogenic transformation." Proc Natl Acad Sci U S A 103(44): 16296-16300. 
Zhou, Y., E. O. Hileman, W. Plunkett, M. J. Keating and P. Huang (2003). "Free radical 
stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to 
ROS-generating anticancer agents." Blood 101(10): 4098-4104. 
                                                                    
 
 
 
 
 
  
 
 
176 
 
                                                                         Vita 
Hima V. Vangapandu was born in Visakhapatnam, Andhra Pradesh, India on March 
27
th
 to the parents of V. Rama Krishna and P. Jyothi as a single child. She grew up in 
Hyderabad and Visakhapatnam, Andhra Pradesh. She attended school at St. Joseph’s Girls’ 
High School, Visakhapatnam from 1998-2002. She completed her 11
th
 and 12
th
 grades from 
Sri Chaitanya Junior college from 2002-2004. Hima graduated with a degree in Bachelors of 
Technology from a college affiliated to Jawaharlal Nehru Technological University, 
Hyderabad in 2008. She came to United States of America in 2008, to pursue higher 
education. She received a Masters’ degree in Biomedical Sciences from University of South 
Carolina, School of Medicine at Columbia, South Carolina. In August, 2012, she enrolled in 
The University of Texas Graduate School of Biomedical Sciences at Houston and later joined 
the laboratory of Dr. Varsha Gandhi in the Department of Experimental Therapeutics, MD 
Anderson Cancer Center and affiliated with the Experimental Therapeutics Academic 
Program (ETAP). Hima conducted her Ph.D work under Gandhi’s advisory. And she will 
complete all the requirements of Doctor of Philosophy degree in March 2016. 
During Hima’s graduate training, she received multiple travel awards from both UT-
GSBS and ETAP to attend the annual meetings of American Association of Cancer Research 
(AACR), where she presented her work. She also received a research award from ETAP in 
2014. Hima received UT MD Anderson Alumni and Faculty Association Award in 
Translational Research in 2014. In addition, she also received Student Apple Award in 2015 
from ETAP for her volunteer activities towards the program. She received Floyd Haar, M.D., 
Endowed Memorial Research Award in Memory of Freda Haar of 2015-2016 through UT 
GSBS for her research in leukemia. 
 
 
177 
 
Publications 
Vangapandu, H. and Gandhi, V.  Chronic lymphocytic leukemia at genomic level.   In. 
Multitargeted Approach to Treatment of Cancer, Ed. Varsha Gandhi, Kapil Mehta, Rajesh 
Grover, Sen Pathak and Bharat B. Aggarwal, Springer Production; Heidelberg, Germany, 
2014. 
Stellrecht CM, Vangapandu HV, Le XF, Mao W, Shentu S. ATP directed agent, 8-chloro-
adenosine,  induces AMP activated protein kinase activity, leading to autophagic cell death in 
breast cancer cells. Journal of Hematology and Oncology, 7(23) 1756-8722, 2014. 
Jorgez CJ, Wilken N, Addai J, Newberg J, Pastsuzak A, Bournat J, Mukherjee S, 
Vangapandu HV, Sahin A, Rosenfeld JA, Lipshultz LI,  Lamb  DJ. Genomic and genetic 
variation in E2F transcription factor-1 in men with nonobstructive azoospermia Fertility and 
Sterility, 103(1):44-52.e12015. 
 
Jorgez CJ, Rosenfeld JA, Wilken NR; Vangapandu HV, Sahin A; Pham D, Carvalho CM, e 
Bandholz A, Miller A, Weaver DD, Burton B, Babu D, Bamforth JS, Wilks T, Flynn DP, 
Roeder E, Patel A, Cheung SW, Lupski JR, Lamb DJ. Genitourinary Defects Associated with  
Genomic Deletions in 2p15 Encompassing OTX1. PLoS One,2014. 9(9): p. e107028. 
 
Shull AY, Clendenning ML, Ghoshal-Gupta S, Farrell CL, Vangapandu HV, Dudas L, 
Wilkerson B, Buckhaults PJ 2013 Somatic Mutations, Allele Loss, and DNA Methylation of 
the Cub and Sushi Multiple Domains 1 (CSMD1) Gene Reveals Association with Early Age 
of Diagnosis in Colorectal Cancer Patients. PLoS ONE 8(3). 
 
Tannour-Louet M, Lewis SK, Louet JF, Stewart J, Addai JB, Sahin A, Vangapandu HV, 
Lewis AL, Dittmar K, Pautler RG, Zhang L, Smith RG, Lamb DJ (2013) Increased 
expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause 
resistance to vitamin D3-based therapies. FASEB J fj.13-236109. 
Vangapandu H and Ai W. Kruppel like factor (KLF4) a Transcription factor with diverse 
context dependent functions. Gene Ther Mol Biol Vol 13, 194-203, 2009. 
 
Permanent Address: 
50-121-29/21 
Balayya Sastri Layout, Seethammadhara, 
Visakhapatnam, Andhra Pradesh 
India, 530013 
